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Chemoprevention is a promising approach to decrease the incidence of lung cancer in
current and former smokers. Directly delivering drugs to the lung could lead to a high
concentration in the target organ with a lower dose compared to other means of
administration. The primary advantages of aerosol delivery in treating lung diseases include
improving the bioavailability of the drug in the lung, decreasing the medicine dose, rapid
action, and reducing the systemic toxicity as well as side effects. Spray techniques are widely
used for aerosol delivery. Two spray techniques were evaluated in this study for their
applications in lung cancer chemoprevention. One is the spray-drying process which was
used to study the inhibitory effects of chemopreventive agents in lung tumorigenesis using
the A/J mice model. The other is a twin-head electrospray (THES) to generate
chemopreventive agent particles. Six single agents and three combinational agents, both
natural and synthetic compounds, were investigated in the first part of this dissertation work.
Polyphenon E and Polyphenon E without EGCG, which are mixtures of tea catechins, were
ii

studied to investigate the prevention mechanism of the mixture. Resveratrol was delivered in
aerosol form to improve its efficacy, because it did not show any inhibitory effects in the
dietary form due to its low bioavailability in the lung. Gefitinib and erlotinib were delivered
via aerosols to decrease the dose to prevent severe skin toxicities associated with high
dosages. The effect of aerosolized budesonide was studied. It was further combined with
diet Polyphenon E, diet indole-3-carbinal, or oral pioglitazone in the animal study for the
inhibitory effects over lung carcinogenesis. Aerosol characterization and drug concentration
in different organs of mice, after exposure to the drug aerosols, were also carried out to
facilitate the data interpretation. In the second part of this work, a twin-head electrospray
system was developed to be used as an aerosol generator in animal studies of lung cancer
chemoprevention. The system consists of two electrospray heads: one producing positively
charged particles and the other for negatively charged ones. The coagulation between
oppositely charged droplets generated by the THES was verified in three ways. The size
evolution due to coagulation was studied for particles from 10 nm to 710 nm. The effect of
the initial charge level on the coagulation process was investigated using dual-capillary ES.
The residual charges on coagulated particles were measured. The particle transmission
efficiency through the THES system was also characterized. The effect of particle mixing on
the coagulation process was also investigated. The THES was then used to generate PLGAbased controlled release drug particles. Two drugs, budesonide and pioglitazone, were coated
with PLGA using dual-capillary heads in the THES. Particles in various sizes and different
drug-to-polymer ratios were prepared. The release profiles of prepared drug particles before
and after coagulation were compared to investigate the release characteristics of THESprepared drug particles. A promising application of the THES, as an electrospray inhaler,
was also proposed.
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Chapter 1
Introduction and Overview

1

1.1 Introduction
Pulmonary drug delivery is an attractive, noninvasive drug administration method
for many reasons. These include accessing very large absorption area in the lung,
avoiding metabolism in the liver, decreasing the required dosage, and minimizing
systemic effects (Gagnadoux et al. 2008). Inhalation is the preferred route of delivering
drugs for the treatment and prevention of lung diseases, especially asthma, chronic
obstructive pulmonary disease (COPD), and lung cancer (Hohenegger 2010). Through
inhalation, drug particles are delivered directly to the target organ, which can greatly
reduce the required dose compared with systemic delivery, offer a more rapid response,
and minimize the systemic toxicity and side effects. Also, inhalation treatment provides
an alternate route to introduce drugs systemically, especially for those drugs that can be
absorbed efficiently from the lung, such as insulin.
The effectiveness of the inhalation therapy highly depends on the particle
deposition efficiency in the target site. The target deposition site varies with the disease.
For example, for the prevention of lung cancer, the drug particles need to be spread all
over the lung, including alveoli, while for the treatment of lung cancer, the drug
particles are preferably target-delivered to lung tumor cells. For the treatment of COPD
and asthma, the goal is to deliver most of the drug aerosols to a patient’s
bronchopulmonary tree and lower airways. The deposition efficiency is affected by
many factors, including the particle size distribution, inhalation pattern (e.g., flow rate,
volume, and breath-holding time), airway geometry, and properties of the inhaled
particles as well as the carrier. The particle size distribution is controlled by the aerosol
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generator. There are many techniques to generate drug particles for pulmonary drug
delivery, with spray technique being an important one.
Chemoprevention is believed to be a promising approach to control cancer at
various sites (Sporn and Suh 2002). Although significant improvement has been
achieved in the prevention of breast cancer (Chang 1998), no successful lung cancer
chemoprevention is available. Aerosol delivery of chemopreventive agents for lung
cancer attracted more and more attention, especially after the failure of clinical trials
using retinoids (Spinella and Dmitrovsky 2000). Animal studies showed that two major
issues believed to be responsible for the failure, low bioavailability at the target site and
high systemic toxicity, could be solved by using aerosol delivery. An important step in
research regarding lung cancer chemoprevention is to select effective chemopreventive
agents with low systemic toxicity or side effects using animal models. Thus, to use
aerosolized drugs in animal studies provides direct and important guidance for future
research.
The overall objective of this dissertation is to advance our current knowledge on
using spray techniques in lung cancer chemoprevention. Accordingly, it has two major
parts: (1) investigation of chemopreventive agents using aerosol delivery in mice model
and (2) design and evaluation of a twin-head electrospray system which could
potentially be used in lung cancer chemoprevention study. The motivations for each
part are explained in the following sections.

3

1.2 Part I: Aerosol Delivery and Evaluation of Agents
for Lung Cancer Chemoprevention
The aerosol route has many advantages compared to traditional routes of
administration, such as oral, intravenous and intraperitoneal. Experiments using
aerosolized chemopreventive agents had been carried out by different groups (Anderson
et al. 2008; Kohlhaufl et al. 2002; Wattenberg et al. 2000; Wattenberg et al. 1997).
However, most animal inhalation studies used devices which generate super-micrometer
particles, mainly due to the lack of suitable generators for animal studies. All drugs need
to be first tested in animal models before moving to human clinical trials. Besides
particle size, deposition efficiency is also related to the geometry of the respiration
pathway, which is much smaller in animals like mice or rats than in humans. Figure 1.1
shows the deposition efficiency in the respiratory system as a function of particle size in
mice and human. The deposition is related to both particle diameter and the target site.
For lung cancer chemoprevention, the agents need to be delivered to deep lung region
including alveolus. As shown in Figure 1.1, the highest deposition efficiency in alveoli
was particles less than 0.1 µm. For mice, the smallest particle size tested in the
experiment was 0.27 µm, which had the highest deposition in alveoli than larger
particles. Meanwhile, 0.27 µm particles have a higher deposition in the alveoli of mice
compared to human, indicating that small particles are more suitable in studies using
mice. Instead of using devices designed to generate super-micrometer particles, new
devices are needed in animal studies to generate particles with diameters in submicrometer and nanometer ranges with stable performance.
4
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Figure 1.0.1 Particle deposition efficiency as a function of particle size in various sites of the respiratory
system of CF1 mice (a) (Raabe et al. 1988) and human lung (b) (ICRP 1994).
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The main goal of lung cancer chemoprevention is to identify the effective agents.
The studies on molecular and cell levels provide the information on the mechanisms,
which are the first step in identifying the effective agents. Next, the drugs need to be
investigated using animal models. Most of the animal studies use traditional route of
administration. However, the same drug may show a different efficacy when it is
delivered differently. In aerosol delivery, drug particles are directly introduced to the
target site without going through the first-pass metabolism. It is an effective method for
those drugs that have low bioavailability in the lung when introduced orally. However, it
may not work for those drugs whose active form is the metabolites. The drugs which
may potentially be used in aerosolized form need to be first studied in animal models.
A major cause of lung cancer is long term exposure to cigarette smoke. Due to the
complexity of the composition of the cigarette smoke, it is unlikely to prevent lung
cancer by only inhibiting one pathway. Thus, using more than one agent at the same
time has a larger opportunity to successfully prevent the incidence of lung cancer.
Different agents for the combination study can be administrated in different routes. The
combinational effects also need to be investigated in animal models.
The major objectives for the first half of the dissertation are:
1.

To design a mice dosing system for the evaluation of chemopreventive agents
using aerosol delivery.

2.

To study the chemopreventive effects of single aerosolized agents using A/J
mice model.

3.

To study the combination effects of agents administrated by aerosol and oral
delivery using A/J mice model.
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1.3 Part II: Design and Evaluation of a Twin-head
Electrospray (THES) System
Electrospray is capable of generating highly charged monodisperse particles in a
wide range of particle sizes. The highly charged particles are most likely deposited if the
charge level is not reduced. The common techniques to reduce the charges are corona
discharge, radioactive materials, and soft X-ray (Chen et al. 1995; Ebeling et al. 2000;
Hogan et al. 2004). When two electrosprays are operated at the same time, with one
spray generating positive charged particles and the other generating negative ones,
collisions between oppositely charged particles occur when the two aerosol flows meet.
The collision serves as a charge neutralization process. Also, the collision can be used
for various applications.
The idea of using two sprays to generate countercharged droplets was first
proposed in 1965 to study the collision of two charged droplets (Schneider et al. 1965).
It was later used to encapsulate solid particles with liquid droplets using electrostatic
attractions (Langer and Yamate 1969). Several studies using the twin-head electrospray
had been carried out after that. The twin-head electrospray was designed and the
application in powder production was evaluated (Borra et al. 1999; Camelot et al. 1999).
Based on the application, the experiments only focused on supermicrometer particles.
No systematic characterization about the operation conditions and the coagulation
process was carried out. A direct observation of the interaction between the countercharged droplets was done by Almekinders et al.(Almekinders and Jones 1999). Two
multi-jet electrohydrodynamic atomizers were used to generate counter charged droplets,
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which were attracted by electrostatic force. No characterizations were carried out
regarding the particles formed after the charge-enhanced coagulation. The interactions
between fibers and particles generated by countercharged electrospinning and
electrospray were studied (Morozov and Vsevolodov 2007; Park et al. 2008) Morozov et
al. used eletrospinning to generate polymer fibers, and electrospray to generate ions to
neutralize the charged fiber indirectly. No interactions between oppositely charged
particles were observed in the system designed by Park et al.
Although twin-head ES has been designed and studied previously, no systematic
characterization of the system and the droplets coagulation process was done. Further,
most of the particles generated by the previous twin-head ES systems were
supermicrometer particles. All the previous studies only used single capillary ES. Dualcapillary ES has many advantages over single capillary ES, especially on the synthesis of
controlled release drug particles. The coagulation between droplets generated by two
spray heads with dual-capillary provides more variations in the generation of drugloaded polymer particles for controlled drug delivery.
The major objectives of the second half of the dissertation are:
1. To design a twin-head electrospray system.
2. To systematically evaluate the performance of the twin-head ES.
3. To synthesize and characterize controlled-release drug particles using the twinhead ES system.
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1.4 Dissertation Structure
In addressing the two major components, the whole dissertation contains nine
chapters. The first part, including chapters 2, 3, 4 and 5, focuses on aerosol delivery and
evaluation of lung cancer chemopreventive agents in animal models. The second part,
including chapters 6, 7, and 8, focuses on the design and evaluation of the twin-head
electrospray. Brief descriptions of each chapter are as follows.
In chapter 1, a general introduction in which the background, the motivations and
objectives of this study are given.
PART I:
Chapter 2 first introduces the background of lung cancer chemoprevention and the
standard approaches in evaluating the chemopreventive agents. The advantages of
aerosol delivery are summarized. Previous studies using aerosol delivery in lung cancer
chemoprevention studies are overviewed. The combination treatments in lung cancer
chemoprevention are reviewed.
In chapter 3, a nose-only mice dosing system was developed. The protocols of
animal experiment used in this study are introduced. All the chemopreventive agents
tested in this study are summarized.
Chapter 4 gives the results of the evaluation of aerosolized single agents for their
inhibitory effects on lung tumorigenesis using A/J mice model. First, Polyphenon E and
Polyphenon E without EGCG were compared, with the objective of determine the role
of EGCG, which is the main component of Polyphenon E, in the chemopreventive
effects of the mixture form (Polyphenon E). Another natural agent, resveratrol, was
also studied as a chemopreventive agent for lung cancer by aerosol delivery. Three
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synthetic agents, gefitinib, erlotinib and budesonide, all of which are approved by FDA
for use in humans, were investigated for their efficacy in inhibiting lung carcinogenesis
separately.
In chapter 5, the combination treatments of aerosolized budesonide and oral
Polyphenon E, indole-3-carbinol, and pioglitazone were studied for lung cancer
chemoprevention. The inhibitory effects of single agents as well as the combination
groups are compared.
PART II:
In chapter 6, a general introduction on electrospray, electrostatic coagulation and the
adhesive forces between particles are given. Previous studies regarding twin-head
electrospray system are summarized. A potential application of twin-head ES as an
inhaler is discussed.
In chapter 7, a twin-head electrospray system was designed. The performance was
evaluated. First, the coagulation between counter charged particles were verified by
particle size distribution, particle morphology, and fluorescence tracers. The particle size
distributions before and after coagulation were compared. The initial particle size
ranged from 10 nm to over 700 nm. The effects of initial charge levels on the size
distribution evolution were studied by using dual-capillary ES in each spray head. The
residual charge of particles exiting the system after coagulation was studied by an
electrostatic precipitator. The ratios of neutral, positively and negatively charged
particles were compared for three particle sizes. A second coagulation chamber with the
two spray heads facing each other was also designed and its performance was evaluated
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and compared with the 90 degree chamber. At last, the particle transmission efficiency
through the system was characterized by fluorescence analysis.
In chapter 8, the twin-head ES system was used to generate drug-loaded polymer
particles. The particle size distribution and morphology with or without coagulation was
characterized. The in vitro release profile was characterized by high performance liquid
chromatography. Two drugs, budesonide and pioglitazone, were used for this study. The
release profiles of particles generated by one spray head were compared to that of
particles generated by both spray heads with different solution and liquid feed flow rate.
A biexponential kinetic model was used to facilitate the comparison. The possibility of
using the THES system as an inhaler was discussed.
In chapter 9, the accomplishments of this dissertation are summarized, as well as
the issues and challenges that deserve future research efforts.
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Chapter 2
Review of Lung Cancer
Chemoprevention
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2.1 Chemoprevention of Lung Cancer
Cancer is a major public health problem in many countries of the world, accounting
for 23.2% of death in the United States in 2010 (Jemal et al. 2010). Although scientists
have made great achievements on both the basic understandings of the nature of cancer
and the clinical treatments of certain types of cancer, the death rates from some
common cancers still have not decreased (Sporn and Suh 2000). Lung cancer is the
most common form of cancer in the world and the leading site of cancer-related death
in both men and women (Jemal et al. 2010). The current therapies of lung cancer are
surgery, radiation and chemotherapy. Despite improvements in traditional therapies, the
5-year survival rate is still low. About 90% of lung cancer patients die from their disease
(Minna et al. 2002). Instead of trying to cure lung cancer, another approach, named
chemoprevention, controls lung carcinogenesis (Hecht et al. 2009).
Chemoprevention is defined as the use of natural or synthetic agents to reverse,
prevent, or delay carcinogenic progression to invasive cancer. Chemoprevention
approaches target the carcinogenic process at early and potentially reversible stages,
focusing on the inhibition of one or many elements in the stepwise progression toward
cancer (Minna et al. 2002; Soria et al. 2003). Chemoprevention is considered to be an
important approach to decrease the incidence of lung cancer in current and former
smokers. It has been applied with some early success to individuals at high risk for
breast, prostate, and colon cancer, but chemoprevention for lung cancer is not currently
available.
An important objective of lung cancer chemoprevention research is to identify
active agents. Two major criteria of a successful agent are effectiveness and tolerable
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toxicity. In chemoprevention study, it is important to verify the efficacy and safety of
the tested agents in cell culture and animal models before clinical trials. The most
common animal model in evaluating chemopreventive agents for lung cancer is the
carcinogen-treated A/J mice model. The A/J mouse is susceptible to both
spontaneously-occurring and carcinogen-induced lung tumors. The tumors induced by
carcinogens in A/J mice are similar to human lung adenocarcinoma in morphological,
histological and molecular features. More than 50 chemicals have been tested for the
chemopreventive efficacy in the A/J mouse (Hecht et al. 2009).
Chemoprevention can be considered at three different major strategy levels: primary,
secondary and tertiary (Cohen and Khuri 2002; Soria et al. 2003). Primary prevention
intends to delay the development of cancer or hinder its progression in healthy
individuals who are at high risk, such as current and former smokers. Besides
chemoprevention drugs, approaches such as smoking prevention and cessation
treatments

are

also

considered

as

primary

chemoprevention.

Secondary

chemoprevention aims at persons with evidence of early disease, but without the
symptoms of cancer. Tertiary prevention targets patients who had previous cancers,
trying to prevent the development of second primary tumors, to prevent the recurrence,
and to decrease the morbidity of established disease. Since the stages of tumor
progression of each level are quite different, chemopreventive agents with different
action mechanisms are used at each level. As a result, researchers developed different
protocols in mice models.
Based on the three chemoprevention strategies, three protocols are commonly used
in the A/J mice model: complete, post-initiation and tumor progression (Figure 2.1)
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(Wang et al. 2006). In the complete chemoprevention protocol, the treatment begins
one to two weeks before carcinogen initiation and continues until the termination
(usually 20-24 weeks), which corresponds to the primary prevention in healthy
individuals. This model is usually used to examine agents that either block carcinogen
initiation or suppress tumor growth. The post-initiation chemoprevention protocol
begins intervention two to three weeks after carcinogenic initiation and continues
thereafter. The whole protocol usually lasts for 20-24 weeks. Postinitiation mimics the
situation in ex-smokers. It can determine the tumor suppressing effects after the tumor
initiation, which mainly corresponds to the secondary chemoprevention. The tumor
progression chemoprevention protocol begins treatment 12-20 weeks after carcinogen
initiation and continues until approximately 40 weeks post-carcinogen initiation. This
protocol determines the inhibitory effects of preventive agents on the progression from
adenomas to carcinomas.

Figure 2.1 Three commonly used chemoprevention protocols in A/J mice model. (a) complete protocol;
(b) post-initiation protocol; (c) tumor progression protocol. The arrow indicates carcinogen initiation; the
dot indicates the beginning of intervention

There are four commonly used carcinogens in mouse study to induce lung tumors:
benzo[a]pyrene (B(a)P), 4‑(methylnitrosamino)‑1‑(3‑pyridyl)‑1‑butanone (NNK),
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ethyl carbamate (urethane) and vinyl carbamate (VC). B(a)P and NNK present in
cigarette smoke and are highly carcinogenic. The tumors induced by B(a)P and NNK at
about 20 weeks after initiation are all adenomas. Urethane is a constituent of some
cigarette smoke. VC, which is a carcinogenic metabolite of urethane, has not been
analyzed in cigarette smoke or in smokers as a metabolite. Generally, urethane and VC
could induce more tumors than B(a)P and NNK even with a smaller dosage. Besides,
adenocarcinoma appears earlier when urethane or vinyl carbamate are used as the
carcinogen (Gunning et al. 2000).

2.2 Administrations by Aerosol
Typical administrations used in animal models include oral, intravenous,
intraperitoneal, and aerosol routes (Francis et al. 1994). In order to reach a good
inhibitory effect, higher doses of chemopreventive agents are often required, which may
cause systemic toxicity and adverse effects. Targeting chemopreventive agents to specific
areas within the body can result in better efficacy and lower toxicity (Lippman et al.
1998).
Inhaling medications are widely accepted as the optimal route of administration in
treating lung diseases. Directly delivering drugs to the lung could lead to a high
concentration in the target organ with a lower dose compared with other means of
administration. Aerosol delivery for therapy of lung cancer in humans has been
reported to be effective without adverse effects (Tatsumura et al. 1993; Verschraegen et
al. 2004).

16

The pioneer work using aerosolized agent for lung cancer chemoprevention was
done by Wattenberg et al. (Estensen et al. 2004; Wattenberg and Estensen 1997;
Wattenberg et al. 2000; Wattenberg et al. 1997). Budesonide, which is currently used in
the treatment of asthma through inhalation, was investigated for its chemopreventive
effects on lung carcinogenesis by aerosol delivery. Aerosolized budesonide at low dose
inhibited all stages of progression from hyperplasia formation to cancer in B(a)P
induced mice lung carcinogenesis without systemic toxicity.
Retinoids are natural occurring or synthetic vitamin A metabolites and analogs
(Cohen and Khuri 2002; van Zandwijk 2005). Their effectiveness in human cancer
chemoprevention was associated with systemic vitamin A toxicities. Also, retinoids can
be easily bound to serum proteins or be cleared in gut and liver, which highly limited the
delivery of retinoids to lung tissues when they are orally administrated (Cohen and
Khuri 2005). The clinical studies regarding retinoids in the prevention of lung cancer
did not show enough efficacies (Toma et al. 1999). Through aerosol inhalation, retinoids
can be delivered locally at low dosage without compromising the antitumorigenic
responses (Spinella and Dmitrovsky 2000). Aerosol delivery of a liposomal formulation
of all-trans-retinoic acid to the lungs of mice effectively retained its biological activity
without observable adverse effects (Parthasarathy et al. 1999). Inhalation of isotretinoin,
which showed protective effects against second aerodigestive tumors in a randomized
clinical trial, could reduce tumor multiplicity at a relatively low dose without obvious
toxic signs (Dahl et al. 2000). A preliminary clinical study using aerosolized vitamin A
suggested that inhalation of retinyl esters could be a promising therapeutically approach
for chemoprevention of lung cancer (Kohlhaufl et al. 2002).
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2.3 Combination treatment
Cigarette smoking, both active and passive, is the main epidemiologically proven
cause of lung cancer (Staempfli and Anderson 2009). Cigarette smoke is a complex
mixture of carcinogens and toxicants. Lung cancer caused by long-term exposure to
cigarette smoke is unlikely to be prevented through intervention in a single pathway.
Combinations of drugs that act through different mechanisms may achieve greater
chemopreventive efficacy (Hecht et al. 2009).
The combination approach for cancer chemoprevention has many advantages. By
carefully selecting the combinational agents, a better preventive efficacy can be reached
with a lower dose of each agent. However, additive or synergistic toxicities of the agents
should also be investigated (Castonguay 1992).
The combination treatment in lung cancer chemoprevention has been investigated
using multiple agents in animal models. ElBayoumy et al. compared the efficacy of four
agents (1,4-phenylenebis(methylene)selenocyanate (p-XSC), phenethyl isothiocyanate
(PEITC), indole-3-carbinol (I3C), and d-limonene (d-L)) individually and in
combination using complete protocol in A/J mice (ElBayoumy et al. 1996). All single
agents and the combination group inhibited tumor multiplicity significantly. No statistic
difference in the inhibitory effects was observed between the mixture and single agents.
Dietary myo-inositol and dexamethasone were found to inhibit tobacco smoke-induced
lung tumors in A/J mice (Witschi et al. 1999). However, the average tumor number
induced by tobacco smoke was relatively low (2.1 for control group). Dietary myoinisitol was also combined with aerosolized budesonide or dietary N-acetyl-S-(N-2phenethylthiocarbamoyl)-L-cysteine (PEITC-NAC) (Hecht et al. 2002; Wattenberg et al.
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2000). The combination groups showed better efficacy than either single agents. Further,
the combination of PEITC-NAC, myo-inositol and I3C or 3,3'-diindolylmethane (DIM),
showed significant inhibition on tumor multiplicity (Kassie et al. 2010b). Dietary I3C
and silibinin were studied for combinatorial treatment with in A/J mice (Dagne et al.
2011). Enhanced inhibition of lung adenocarcinoma was observed in the combination
group with low doses without causing obvious loss of body weight. Green tea
polyphenols and atorvastatin were found to have synergistic inhibition on lung
tumorigenesis (Lu et al. 2008). Another study investigated the effects of dietary green
tea extract and aerosolized difluoromethylornithine (DFMO) during lung tumor
progression in A/J mice (Anderson et al. 2008). However, no additive or synergetic
effects were observed due to the lack of efficacy of aerosolized DFMO. Synthetic
triterpenoids (CDDO-Methyl ester or CDDO-Ethyl amide) and rexinoids (LG100268
or NRX194204) were combined for the prevention and treatment of lung cancer (Liby
et al. 2009). The combination groups showed significant inhibition on tumor load over
each single agents as well as the control group in both post-initiation and progression
protocol.
The results of animal studies confirmed that by selecting appropriate agents, the
combination treatment may achieve better inhibitory effects than single agents. The
successful animal experiments provide guidance and potential candidates for future
studies.
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Chapter 3
Experimental Setup and Protocols
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3.1 Animal Experiments
In this study, we used the post-initiation protocol in carcinogen-treated A/J mice to
test the efficacy of chemopreventive agents. Female A/J mice at 6 weeks of age were
obtained from Jackson Laboratories (Bar Harbor, ME). The use of animals was
approved by the Washington University’s Institutional Animal Care and Use Committee.
The mice were housed at a constant temperature and humidity and received a standard
diet and water.
At the age of 8 weeks, carcinogen was given to mice to initiate the tumor growth.
Either a single intraperitoneal (i.p.) dose of B(a)P (100 mg/kg body weight) in 0.2 ml of
tricaprylin, or two doses of VC by i.p. injection once a week for two consecutive weeks
(0.32 mg per injection in 0.2 mL sterile saline without adjusting pH) were used. Two
weeks after the first dose of carcinogen, the mice were randomly divided into control
and treatment groups with 12 or 16 mice per group to reach the enough sample size.
Each treatment group had a corresponding control group. The only difference between
the treatment group and its corresponding control group was that the treatment group
received chemopreventive agent while the control group was treated with the same
procedure but with only the vehicle containing no drug. Daily treatments were then
began, and continued till the end of the experiment (Figure 3.1). All solutions were
prepared just before use and stored on ice until use. Ethanol and dimethyl sulfoxide
were used to dissolve the chemopreventive agents used in the aerosol delivery.
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Figure 3.1 Treatment protocol

Three different administration methods were used. For aerosol delivery, the mice
were exposure to aerosols for 2 min, 8 min, or 15 min per day, 5 times per week. The
dose time varied with the tested drug. An air control group was included in the first
animal study. The mice in the air control group were placed in the chamber for 8
minutes without aerosol treatment to control for potential stress factors affecting
tumorigenesis. No difference was observed between the air control group and the
solvent control group, so no air control group was included in the later studies. The
inhalation exposures were conducted using a custom-built nose-only 12-mice exposure
chamber (Figure 3.2). The design of the chamber ensures that the mice place their
noses into the cone of each exposure port in the chamber. Mice were randomly placed
into exposure ports to minimize any bias inside the chamber.
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Figure 3.2 Nose-only mice exposure chamber used in the animal study (with mice loaded in the chamber)

For diet treatment, the drug was well mixed with AIN-76A purified powder diet
(Dyets, Inc., Bethlehem, PA) and 3% sugar with a KitchenAid (St. Joseph, MI) for one
hour. Diet was prepared twice per week. Fresh diet in the cages was changed daily. For
gavage treatment, the mice received gavage once per day, five days per week.
The body weights of the mice were measured every week for the duration of
treatments. Mice were sacrificed 20 or 22 weeks after exposure to carcinogen by CO2
asphyxiation. Lungs from each mouse were fixed in Tellyesniczky’s solution (Zhang et al.
2000) overnight, followed by 70% ethanol. The fixed lungs were evaluated under a
dissecting microscope to obtain fixed surface tumor count and individual tumor size.
Tumor volume (V) was calculated using tumor diameter (r) based on the following
formula: V (mm3) = 4πr3/3 (Zhang et al. 2000). The total tumor volume in each mouse
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was calculated by the sum of all tumors. Tumor load was determined by averaging the
total tumor volume of each mouse in each group.

3.2 Aerosol Procedure
Drug solution was atomized into droplets by a custom-made Collison Type atomizer.
The flow rate was 2.27 l/min. Aerosol flow was then passed through two diffusion
dryers containing silica gel to remove water from droplets and/or two scrubbers with
active carbon which was used to remove organic solvent. The resulting dry aerosol flow
with only desired chemicals was then introduced into the nose-only exposure chamber
from the top inlet. Effluent aerosol was discharged from an opening at the bottom of
the chamber. The schematic diagram is shown in Figure 3.3.
Scrubber

Mice Exposure Chamber

Diffusion Dryer

Compressed Air

Atomizer
Filter

Figure 3.3 Schematic diagram of aerosol delivery system used in animal study

The size distribution of the aerosol was determined by scanning mobility particle
sizer (SMPS) spectrometer, which includes an Electrostatic Classifier (TSI model 3080),
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a Differential Mobility Analyzer (DMA, TSI model 3081) and a Condensation Particle
Counter (CPC, TSI model 3025). Geometric median diameter (GMD), mass median
diameter (MMD), geometric standard deviation (GSD) and particle concentration were
obtained. Online samples were taken inside the chamber right at the place where mice
were supposed to inhale aerosols. Different sample points were used to monitor the
concentration uniformity inside the chamber.
The mass of inhaled drug was calculated as follows:

Minhaled = [C ]aerosol ⋅ RMV ⋅ t ,

(3.1)

where [C]aerosol is the aerosol concentration of drugs (mg/l), RMV is the respiratory
minute volume of the mouse (0.025 l/min, based on Guyton’s formula), and t is the
exposure time.
The deposition ratio of aerosol within the lung was estimated by the following
equation:

%Deposition =

M tissue
× 100% ,
M inhaled

(3.2)

where Mtissue (mg) is the mass of drug that deposited in lung.
The dose could be estimated by:
Dose =

M inhaled C aerosol × RMV × t
=
,
M body
M body

(3.3)

where M body is the body weight which was taken to be 0.020 kg. However, in reality,
the deposition ratio is always less than 1, so the actual dose is less than the estimate
value.
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3.3 Tissue Assay Method
Lung, liver, and spleen tissues were weighed, frozen in liquid nitrogen, and crushed
with a precooled hammer. The tissue homogenate was collected in a tube with 0.2 ml
DMSO. Then the samples were vortexed for 2 minutes and centrifuged at 13,000 rpm
for 15 minutes at 4 °C. Supernatants were tested by HPLC. The serum was extracted as
above for lung tissue homogenate.
Drug concentrations in tissue and serum samples were determined by HPLC. The
HP 1100 series HPLC system consisted of an autosampler, a binary pump, a
thermostatted column compartment, and a diode array detector (Agilent Tech, Santa
Clara, CA). The HPLC column was 4.6 × 75 mm Zorbax SB-C18 3.5 µm column. The
column temperature was maintained at room temperature (20 °C). The flow rate of the
mobile phase was 1 ml/min. The detection conditions are summarized in Table 3.1.
Polyphenon E and Polyphenon E without EGCG are mixtures. The largest peak of
Polyphenon E and Polyphenon E without EGCG was used for quantification,
respectively. EGCG peak was used for Polyphenon E and EC peak was used for
Polyphenon E without EGCG.
For certain drugs, a pre-experiment was carried out to determine the dosed mass in
the lung. Mice were exposed to the drug aerosols for 10 minutes. Following exposure,
the animals were sacrificed by cervical dislocation at designated time points with the end
of the exposure marked as time zero. Blood was obtained by retro-orbital sinus
sampling, and collected into plastic centrifuge tubes. The lung was severed at the carina,
the esophagus and trachea were removed. All samples were stored in liquid nitrogen
until assayed.
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Table 3.1 HPLC methods for drugs used in this study

Drug

Mobile

Mobile Solution A

Solution B

Volumetric

Detection

Ratio of

Wavelength

A:B

(nm)

Polyphenon E

0.1% Trifluoroacetic acid

Methanol

75:25

254

Budesonide

20 mM Sodium phosphate, pH=2

Acetonitrile

45:55

254

Gefitinib

50 mM ammonium acetate, pH=2.2

Acetonitrile

80:20

348

Erlotinib

0.1% Trifluoroacetic acid

Acetonitrile

65:35

348

Resveratrol

50 mM ammonium acetate, pH=2.2

Acetonitrile

70:30

308

Pioglitazone

20 mM Sodium phosphate, pH=2

Acetonitrile

70:30

269

Indole-3-Carbinol

H2O

Acetonitrile

40:60

280

3.4 Statistical Analysis
Tumor multiplicity and tumor load were analyzed by two sided Student’s t test using
Microsoft Excel 2007 (Microsoft, Redmond, WA) to determine differences in the
number and in the size of lung tumors per mouse between groups. In all t-tests, the
level of statistical significance was set at P < .05. For combination treatment, tumor
multiplicity and tumor load were analyzed by one-way analysis of variance (ANOVA)
followed by the Tukey’s multiple comparisons to determine differences in the number
and in the size of lung tumors per mouse between groups. The level of statistical
significance was set at p < 0.05.
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3.5 Summary of Chemopreventive Agents Evaluated
in This Study
Four sets of experiments were carried out. Eight drugs of different concentrations,
including natural and synthesis chemicals, individually or combined with others, were
tested for their inhibitory effects on lung tumorigenesis using A/J mice model and
postinitiation protocol. Table 3.2 summarized the chemopreventive agents and the
evaluation conditions. The chemical structures of the agents or their main component
are shown in Figure 3.4.
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Table 3.2

Chemopreventive agents evaluated using postinitiation protocol in A/J mice model

Agents

Administration

Concentration

Carcinogen

Complete Time

Polyphenon E

Aerosol

15 mg/ml

B(a)P

Jul. 2008

Polyphenon E
without EGCG

Aerosol

15 mg/ml

B(a)P

Jul. 2008

1 mg/ml
Budesonide

Aerosol

6 mg/ml

Jul. 2008
B(a)P

3 mg/ml

Jul. 2008
Nov. 2009

1 mg/ml
VC

Feb. 2009

B(a)P

Nov. 2009

B(a)P

Sep. 2010

VC

Feb. 2009

B(a)P

Nov. 2009

VC

Feb. 2009

B(a)P

Nov. 2009

B(a)P

Nov. 2009

B(a)P

Nov. 2009

B(a)P

Nov. 2009

5 mg/ml
Iressa

Aerosol

5 mg/ml
10 mg/ml
15 mg/ml
1 mg/ml

Tarceva

Aerosol

5 mg/ml
5 mg/ml
7.5 mg/ml

Resveratrol

Aerosol

15 mg/ml
15 mg/ml

Budesonide + Poly E

Budesonide + I3C
Budesonide +
Pioglitazone

Aerosol +

3 mg/ml +

Diet

1.5%

Aerosol +

3 mg/ml +

Diet

10 µmol/g

Aerosol +

3 mg/ml +

Gavage

10 mg/kg
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EGCG

Budesonide

Gefitinib

Erlotinib

Resveratrol

Indole-3-carbinol

Pioglitazone

Figure 3.4 The chemical structures of evaluated chemopreventive agents
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Chapter 4
Chemopreventive Effect of Aerosolized
Single Agent on Lung Tumorigenesis in
A/J Mice
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4.1 Polyphenon E and Polyphenon E without EGCG
The cancer preventive activity of tea polyphenols has received more attention in
recent years. The inhibitory activities of tea constituents against carcinogenesis at
different organ sites have been demonstrated in many animal models (Clark and You
2006; Ju et al. 2007). Polyphenon E is a well-defined pharmaceutical-grade mixture of
polyphenols that contain at least five different catechins: epicatechin (EC), epicatechin
gallate (ECG), epigallocatechin (EGC), gallocatechin gallate (GCG), and (–)epigallocatechin-3-gallate (EGCG), with EGCG being the most abundant (Chang et al.
2003; Clark and You 2006). EGCG was thought to be the most active component in
Polyphenon E (Clark and You 2006). However, our previous results showed that
aerosolized EGCG failed to show significant inhibition on both tumor multiplicity and
tumor load, while at the same concentration, aerosolized Polyphenon E inhibited lung
tumorigenesis significantly (Yan et al. 2007). This indicates that EGCG alone can not
show chemopreventive activity by aerosol administration, which means that either
EGCG is not the active compound in Polyphenon E, or EGCG will show its antitumor
activity only when other components in Polyphenon E are present. The capacity of
other tea catechins to prevent lung tumorigenesis needs to be further investigated to
understand the role of EGCG in chemoprevention of lung cancer. This work was
initiated to compare the inhibitory activities of Polyphenon E and Polyphenon E
without EGCG by aerosol administration.
Since 65 w.t.% (weight percent) of Polyphenon E is EGCG, the daily delivery time
for Polyphenon E without EGCG group was 2.8 min/day with the agent and 5.2
min/day with only air. The total exposure time of Polyphenon E without EGCG group
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was also 8 min/day, which was the same as other groups. Therefore, mice in treatment
groups were exposed to similar amount of tea catechins other than EGCG.

4.1.1 Composition

Analysis

for

Polyphenon

E

and

Polyphenon E without EGCG.
The chromatogram of Polyphenon E and Polyphenon E without EGCG are
comparatively shown in Figure 4.1. Eight different catechins were identified in
Polyphenon E, with EGCG being the most abundant. EGCG accounted for 65 w.t.%
of Polyphenon E, while no other catechins accounted for more than 10 w.t.%. The
concentrations of the various catechins in Polyphenon E without EGCG were:
epicatechin (EC), 44%; epigallocatechin (EGC), 28% and the other six catechins, 7%.
Small amount (1.4%) of EGCG was also detected in Polyphenon E without EGCG.
The composition of Polyphenon E and Polyphenon E without EGCG are given in
Table 4.1. Although the ratios among different catechins were different, the main
difference between Polyphenon E and Polyphenon E without EGCG was in the
amount of EGCG.
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Figure 4.1 Chromatogram of Polyphenon E and Polyphenon E without EGCG. Data provided by Mitsui
Norin Co., Ltd. (Japan)
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Table 4.1 Composition of Polyphenon E and Polyphenon E without EGCG 1

Abbreviation

Polyphenon E
(w.t.%)

Polyphenon E
without EGCG
(w.t.%)

-

0.7

0.8

(+–)-gallocatechin

(+–)-GC

0.2

1.7

(–)-epigallocatechin

(–)-EGC

3.8

28.2

(+–)-C

1.0

3.3

(–)-EGCG

65.0

1.4

(+–)-epicatechin

(+–)-EC

9.1

43.9

(–)-gallocatechin gallate

(–)-GCG

3.5

0.1

(–)-epicatechin gallate

(–)-ECG

6.6

0.3

(–)-CG

0.2

0.2

-

89.4

79.1

Caffeine

(+–)-catechin
(–)-epigallocatechin gallate

(–)-catechin gallate
Total catechins

4.1.2 Aerosol Characteristics
The typical size distributions of Polyphenon E and Polyphenon E without EGCG
inside chamber are given in Figure 4. Polyphenon E and Polyphenon E without EGCG
yielded similar particle size distribution with geometric median diameter (GMD) of 0.13
µm and geometric standard deviation (GSD) of 1.6. The mass median diameter (MMD)
of Polyphenon E and Polyphenon E without EGCG was around 0.3 µm. Two sample
points were chosen inside the exposure chamber to measure the size distribution. No
difference in GMD, MMD and GSD was found among measurements at each sample
point.

1

Data provided by Mitsui Norin Co., Ltd. (Japan).
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(a)

(b)
Figure 4.2 Size distributions of Polyphenon E (a) and Polyphenon E without EGCG (b) in exposure
chamber. The mean size of (a) and (b) was 0.13 µm, with the geometric standard derivation around 1.65.
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4.1.3 Deposition Dose
In Figure 4.3, the concentrations of EGCG in Polyphenon E and EC in
Polyphenon E without EGCG in the lung were given as a function of time following
aerosol exposure. The concentration of EGCG or EC immediately following the
exposure was taken as time 0. Because the catechins in Polyphenon E other than
EGCG are in really small mass ratio (less than 10 %) and the dose mass of aerosol was
much lower than that achieved by other administrations such as oral, the concentrations
of other catechins in Polyphenon E were lower than the detection limit. For
Polyphenon E without EGCG, EC was detected and used for quantification. Since
EGCG is 65% of Polyphenon E in mass and EC is 44% of Polyphenon E without
EGCG in mass, the concentrations of Polyphenon E and Polyphenon E without
EGCG were estimated. The concentration of Polyphenon E was 0.042 µg/mg in lung
at time 0, and decreased with time slowly. After 50 minutes, the concentration was 0.023
µg/mg. The half-life of elimination of Polyphenon E from the lung, t1/2,lung, was
estimated to be 48 minutes. The concentration of Polyphenon E without EGCG
showed similar trend as Polyphenon E. The dosed mass and delivery ratio were
summarized in Table 4.3. The concentration of all the tea catechins in Polyphenon E
and Polyphenon E without EGCG in the serum was much lower (less than 0.04 µg/ml)
for both cases.
Using an average body weight of 0.020 kg, the inhaled dose of was calculated to be
4.19 mg/kg for Polyphenon E and 1.83 mg/kg for Polyphenon E without EGCG. The
dose level was much lower than oral administration previously reported (Yan et al.
2006b). The deposited mass in lung was calculated from assayed lung concentration,
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given as deposited mass versus body weight. The deposition ratios of Polyphenon E and
Polyphenon E without EGCG group were 5.2% and 5.4%, respectively (Table 4.3).
Pharmocokinetic parameters of EGCG in Polyphenon E and EC in Polyphenon E
without EGCG are given in Table 4.2. The following parameters were estimated as
described earlier (Liao et al. 2004b): maximum lung concentration (Cmax); the mean area
under the lung concentration-time curve (AUC); the area arising from the last measured
time point to infinity (AUC∞); the mean resident time (MRT∞) and the lung half-life (t1/2).
The residence time of EC in Polyphenon E without EGCG was shorter than that of
EGCG in Polyphenon E, which showed that EGCG has a longer half-life than EC
when EGCG was in mixture form.

Drug Concentration in Lung (ug/mg)

0.04
EGCG in Polyphenon E
EC in Polyphenon E without EGCG
0.03

0.02

0.01

0.00
0

10

20

30

40

50

Time, min

Figure 4.3 Concentration of EGCG in Polyphenon E (circle) and EC in Polyphenon E without EGCG
(triangle) in the lung following aerosol inhalation. The concentration of EGCG in Polyphenon E and EC
in Polyphenon E without EGCG in mice lung decreased with time slowly. Bar: SD.
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Table 4.2 Pharamacokinetic parameters of EGCG in Polyphenon E and EC in Polyphenon E without
EGCG for aerosol administration (Data shown in Mean ± SD)

EGCG in

EC in Polyphenon E

Polyphenon E

without EGCG

Cmax (µg/g)

27.3 ± 2.6

20.2 ± 2.2

AUC (µg/g  h)

16.2 ± 1.9

9.8 ± 1.3

AUC∞ (µg/g  h2)

28.0 ± 2.5

14.1 ± 1.2

MRT∞ (h)

1.15 ± 0.11

0.64 ± 0.07

t1/2 (min)

48.1 ± 7.2

34.7 ± 5.2

Parameters

4.1.4 Chemoprevention Effects
Mice were treated by aerosol for 18 weeks after the injection of B(a)P. During the
experiment, all mice showed great tolerance to treatment with either Polyphenon E or
Polyphenon E without EGCG. No significant difference in body weight was observed
(Figure 4.4).
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Polyphenon E without EGCG
Polyphenon E
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Figure 4.4 Body weight monitoring during the treatment duration. The body weights of mice were
measured every week. During the whole treatment duration, the body weights of mice increased slowly,
no signs of systemic toxicities and adverse effects were found.
Table 4.3 Effects of aerosolized Polyphenon E and Polyphenon E without EGCG on lung tumorigenesis
in female A/J mice (Data shown in Mean ± SE)

Deposited
Group

mass
(µg/kg)

Deposi-

Final Body

Tumor

Inhibi

tion (%)

Weight (g)

Multiplicity

-tion

Tumor
Load
(mm3)

Inhibit
-ion

Air Control

-

-

22.6 ± 1.9

5.69 ± 0.83

-

1.78 ± 0.33

-

Solvent Control

-

-

22.3 ± 1.8

5.88 ± 0.55

-

1.74 ± 0.21

-

80 ± 22

5.4 ± 1.6

23.2 ± 1.8

4.73 ± 0.70

20.0%

1.36 ± 0.31

21.8%

222 ± 51

5.2 ± 1.3

23.1 ± 1.7

2.79 ± 0.64

52.5%

0.66 ± 0.24

62.1%

Polyphenon E
without EGCG
Polyphenon E
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Effects of aerosolized Polyphenon E and Polyphenon E without EGCG on lung
tumorigenesis in female A/J mice are summarized in Table 4.3. B(a)P induced an
average of 5.69 ± 0.83 (n=16) tumors per mouse in air control group and 5.88 ± 0.33
(n=16) tumors per mouse in solvent control group. Results in tumor multiplicity and
tumor load showed no significant difference in Air control group and Solvent control
group. Mice treated with Polyphenon E showed a significant decrease in both tumor
multiplicity [53%; 2.79 ± 0.64 (n=14)] and tumor load [62%; 0.66 ± 0.24] when
compared to the solvent control group (P < 0.001), while Polyphenon E without
EGCG treatment exhibited statistically non-significant reduction in tumor multiplicity
[20%; 4.73 ± 0.70 (n=15)] and tumor load [22%; 1.36 ± 0.31].
Green tea has been shown to be able to inhibit the development of lung cancer in
several animal models (Cao et al. 1996; Liao et al. 2004a; Mimoto et al. 2000; Yang et al.
1998b; Zhang et al. 2000). Polyphenon E, which is a mixture of polyphenols containing
at least five tea catechins, is believed to be the effective agent. Among tea catechins,
EGCG, which is believed to have the highest antioxidant activity, is the most abundant
catechin in Polyphenon E. However, our previous results showed that Polyphenon E
could decrease tumor load by 59%, while at the same concentration, EGCG did not
show any significant inhibition on tumor multiplicity and tumor load (Yan et al. 2007).
Results also showed that inhalation of EGCG did not modulate tobacco smoke-induced
tumorigenesis (Witschi et al. 2004). Herein, by aerosol administration, Polyphenon E
without EGCG was compared to Polyphenon E on their chemopreventive efficacies
under the same condition. The results showed that Polyphenon E inhibited lung
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tumorigenesis, which agreed to our previous results, while Polyphenon E without
EGCG failed to inhibit lung tumor growth.
In this study, the aerosolized Polyphenon E inhibited tumor multiplicity by 53% and
tumor load by 62%, respectively (Table 4.3). The results show that by aerosol delivery,
Polyphenon E could both cause the regression of the tumorigenesis once the tumor
progression was initiated by carcinogen, and inhibition of tumor growth during tumor
progression. This indicates that Polyphenon E is preventive at all stages of
carcinogenesis, which agrees with previous results (Wang et al. 1992). However, at the
same concentration as catechins besides EGCG in Polyphenon E, Polyphenon E
without EGCG did not show statistically significant effects in both the tumor
multiplicity (20%) and tumor load (22%) (Table 4.3).
Based on HPLC analysis, the main difference between the chemical composition of
Polyphenon E and Polyphenon E without EGCG was the content of EGCG. 65% of
Polyphenon E was EGCG, while in Polyphenon E without EGCG, there was only 1.4%
EGCG left, compared to 44% of EC and 28% of EGC (Table 4.1). Although there
were differences in the ratios among other tea catechins in Polyphenon E and
Polyphenon E without EGCG, the difference became minor when compared to the
difference in the amount of EGCG. The difference in tumor multiplicities between
Polyphenon E group and Polyphenon E without EGCG group was attributed to the
presence of EGCG.
It is believed that EGCG is the main active compound in tea catechins. However, in
our previous study, aerosol administration of EGCG alone at the same concentration
for 18 weeks in a similar way as this study did not show significant effects in the tumor

42

load (Yan et al. 2007). Combined previous results without this study, EGCG in purified
form and Polyphenon E without EGCG both showed no significant effect on lung
tumorigenesis, while Polyphenon E inhibited tumor multiplicities by 53%. This indicates
that EGCG or other tea catechins alone are not as active as the combined form,
Polyphenon E, in lung tumor inhibition. Both EGCG and other tea catechins need to
be present in order to show inhibitory effect on lung cancer. One possible reason might
be that the presence of other tea catechins may affect the absorption (Yang et al. 1998a),
biologic activity, or other properties of EGCG. Because tea catechins have similar
chemical structure, they compete for any resources they need, such as binding sites, and
thus the metabolic conversion of EGCG is retarded and the residence time of EGCG
increases when compares to the case in which pure EGCG was administrated.
Comparison of pharmacokinetic properties of both decaffeinated green tea (DGT) and
purified EGCG in rat administrated by intravenous injection showed that other
components in DGT could affect the plasma concentration and elimination of EGCG
(Chen et al. 1997). In our study, the half-life of EGCG in Polyphenon E in lung after
aerosol administration was longer than that of EC in Polyphenon E without EGCG
(Table 4.2). Detailed information on EGCG and Polyphenon E administrated by
aerosol is not available so far. More studies are expected in the future.

4.1.5 Aerosol Generation
Compared to other methods of administration, aerosol inhalation could reach
higher efficacy at the primary target sites in the lung with relatively low dose level (Liao
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et al. 2004b). In this study, an improved aerosol delivery system was used to give a stable
size distribution with smaller particle mean size and standard deviation.
Particle size is always a key factor which affects lung deposition of an aerosol. In
general, for humans, aerosols with a MMAD less than 3 µm have a higher chance of
reaching the lower airways and being deposited in the alveoli (Labiris and Dolovich
2003). Because of the smaller size of respiration tract, the optimal particle size for mice
inhalation study is much smaller. Study showed that for CF1 mice, 0.27 µm particles
reached a higher deposition ratio in lung (45.4%) than larger particles (dp > 1.09 µm,
deposition ratio less than 9.7%) (Raabe et al. 1988). Most of previous studies on
aerosolized chemopreventive agents used different types of nebulizer to generate
aerosol. Although nebulizer has a high mass throughput, it usually generates particles in
a relatively wide size range with large geometric standard deviations (Dahl et al. 2000;
Liao et al. 2004b; Yan et al. 2007). In this study, we used a custom-built atomizer, which
gave a much narrower particle size distribution. The MMAD of Polyphenon E and
Polyphenon E without EGCG were both around 0.3 µm, which was more favorable in
mice inhalation study. Besides, both Polyphenon E group and Polyphenon E without
EGCG group used the same concentration (15 mg/ml), which assured that the MMAD
were similar for both cases.
In this study, diffusion dryer and scrubber were used to remove water and ethanol
from droplets formed by atomizer before aerosol flow entering the exposure chamber,
which guaranteed that mice were exposed to only the desired agents and air. Each
diffusion dryer contained two concentric cylinders formed by an inner wire screen
cylinder and an acrylic outer cylinder. The annular volume between cylinders was filled
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with silica gel. As aerosol flowed through the inner cylinder, water vapor diffused
through the wire screen and into the silica gel. Scrubber worked similarly with diffusion
dryer, except that scrubber had four inner wire screen cylinder to enhance removal
efficiency. In diffusion dryer, particle loss was minimized because the particles did not
come into contact with the silica gel or active carbon. Compared to diffusion dryer, the
evaporation-condense method, which was commonly used in previous studies (Liao et
al. 2004b; Yan et al. 2007), introduced extra particle loss because of thermophoresis
(Zheng 2002), which reduced the deposition ratio in lung.
The in-situ size distribution measurement showed that the inhalation system
provided aerosol with stable size distribution. In this study, the SMPS system was used
to provide the high-resolution size distribution in the exposure chamber. Through the
sample hole at the bottom of the chamber, two sample points were selected. Each
sample point was at the height where mice nose would be. Thus, the exact size
distribution information of the aerosol in the chamber could be collected. No
significant difference in size distributions indicates that the aerosol inside exposure
chamber was uniform and stable. All mice were exposed to particles with the same size
distribution. Furthermore, mice had been put into the chamber randomly throughout
the treatment. So, mice in the same group could be considered to receive similar
treatment.

4.2 Resveratrol
Using naturally occurring compounds as potential cancer chemopreventive agents in
human populations is a promising approach. Researchers have observed that a lower
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risk of lung cancer among consumers of wine compared with consumers of other
alcohol beverages, which may be partly attributed to the high resveratrol content,
particularly in red wine (Athar et al. 2007). Resveratrol, a polyphenol found in numerous
plant species, including mulberries, peanuts, and grapes, has been shown to have antiinflammatory, antioxidant, antitumor, neuroprotective, and immunomodulatory
activities. As a chemoprevention agent, resveratrol has been shown to inhibit tumor
initiation, promotion, and progression (Jang et al. 1997). Although evidence regarding
gene expression has been found in cell studies, dietary resveratrol failed to show
inhibitory effect on B(a)P induced tumorigenesis in A/J mice (Berge et al. 2004; Hecht
et al. 1999). No resveratrol or resveratrol conjugates were detectable by HPLC in the
lung tissue of animals receiving a resveratrol-supplemented diet, which means
resveratrol given in the diet might not be able to reach the lung tissue in sufficient
concentrations, or in a biologically active form. Aerosol administration could deliver
resveratrol directly to the lung despite the poor bioavailability of resveratrol, which
makes it possible to utilize resveratrol as a chemopreventive agent for lung cancer.
In this study, aerosolized resveratrol was investigated in female A/J mice model and
post-initiation protocol. Two sets of experiments were carried out, with different
carcinogens, B(a)P and VC. Two concentrations of reveratrol, 7.5 mg/ml and 15 mg/ml,
corresponding to estimated doses at 4.15 mg/kg and 8.30 mg/kg, were compared in the
first set of experiment using VC as carcinogen.
The average body weight of all groups are shown in Figure 4.5. In general, the body
weight of mice receiving resveratrol was close to the control groups. There was no
statically significant difference. Resveratrol was well tollerented under the given dose.
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The concentrations of resveratrol in the lung and serum of the B(a)P treated
groups were obtained using the method described in section 3.2. The concentration in
the lung was 0.56 ± 0.42 µg/g lung. Low concentration of resveratrol was also detected
in the serum samples. The average concentration was 0.075 ± 0.005 µg/ml.
The inhibitory effects of aerosolized resveratrol are given in Figure 4.6. Aerosolized
resveratrol showed no effects on tumor multiplicity in VC-treated groups. Significant
inhibition on tumor load was achieved. The decrease in tumor load was 26.3% (P<0.05)
and 36.0% (P<0.01). The inhibitory effects increase with the increase of dose. For
B(a)P treated groups, only the high dose was tested. The average tumor multiplicity and
tumor load were decreased by 37.1% (P<0.01) and 72.0% (P<0.05), respectively.
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Figure 4.5 Body weight during the treatment duration
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Figure 4.6 Chemopreventive effects of resveratrol in femail A/J mice model. (a)VC was used as
carcinogen; (b) B(a)P was used as carcinogen. *, P < 0.05; **, P < 0.01; bar, SE
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The mechanisms of the anti-tumor effects of resveratrol have been well studies in
cell models (Shankar et al. 2007; Ulrich et al. 2005; Whyte et al. 2007). However,
previous studies using diet resveratrol did not show effects on lung tumorigenesis
(Berge et al. 2004; Hecht et al. 1999). Animal studies and limited human studies showed
that resveratrol was mainly accumulated in liver and kidney following its ingestion
(Wenzel and Somoza 2005). And it has been observed that resveratrol has a very short
half life resulting in low bioavailability. In this study, resveratrol was directly introduced
into the lung through inhalation. The presence of resveratrol in the lung was confirmed
by HPLC analysis. The tumor load was decreased by aerosolized resveratrol at both
doses in B(a)P or VC treated mice. The results indicate that aerosol delivery is a
promising approach to delivery the drug to the lung for lung cancer chemoprevention,
especially for those drugs with low bioavailability.

4.3 Gefitinib (ZD1839, Iressa)
Gefitinib (ZD1839, Iressa) is orally active inhibitors of the intracellular tyrosinekinase domain of the epidermal growth factor receptor (EGFR). EGFR is a tyrosine
kinase (TK) receptor of the ErbB family that is activated in a variety of cancers, which
makes it a promising target for anticancer therapy. Selective blockade of the EGFR via
newly developed agents has been an exciting area of research and can be an effective
therapeutic approach, specifically in non-small-cell lung cancer (NSCLC) (Hida et al.
2009).
Gefitinib is the first molecularly targeted agent to be registered for advanced
NSCLC. In preclinical studies of cell lines and human tumor xenografts, gefitinib
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produced growth inhibition in a variety of solid tumor types, including lung cancer.
Four phase I clinical trials showed that gefitinib had durable clinical benefit, and it was
well tolerated. In two phase II trials in Japan, Europe and United States, the overall
response rate was 10% to 18%. Higher response rate and longer survival were achieved
in Asian patients and never-smokers. Based upon these data, gefitinib received approval
in May 2003 in the United States as third-line monotherapy treatment of patients with
this disease. (Pao and Miller 2005) Gefitinib is now approved in 36 countries worldwide
as a first-, second-, or third-line treatment option of NSCLC (Hida et al. 2009).
The possibility of using gefitinib as a chemopreventive agent was studied using the
female A/J mice model (Yan et al. 2006a). Gefitinib, which is administrated by diet,
significantly inhibited both tumor multiplicity and tumor load. However, higher doses
(larger than 200 mg/kg) caused light alopecia, especially at the region near the eyelid, in
some treated mice. The dose level could be reduced by administrating gefitinib by
aerosol.

4.3.1 Aerosol Characteristics
Figure 4.7 shows the size distribution of gefitinib which were obtained using
scanning mobility particle sizer (SMPS). In our study, the diameter of gefitinib particles
ranged from 0.02 µm to 0.6 µm, with over 95% of the particles smaller than 0.3 µm,
which is more favorable for aerosolized drug delivery in mouse model (Raabe et al.
1988). The calculated dose was 0.55 mg/kg, 2.77 mg/kg, 5.53 mg/kg, and 8.30 mg/kg
for gefitinib concentration of 1 mg/ml, 5 mg/ml, 10 mg/ml, and 15 mg/ml,
respectively. The recommended dose for human is 250 mg/day, corresponding to 4.17
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mg/kg using a 60 kg body weight. Note that the calculated dose for aerosol delivery is
much higher than the real dose. When estimating the dose, one assumption is that all
the particles being inhaled deposit in the lung, which is hardly the case. The deposition
ratio varies with particle size. No 100% deposition can be achieved for the particle sizes
covered in the given size distribution.
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Figure 4.7 The size distribution of Gefitinib particles (5 mg/ml solution) used in the mice experiment.

4.3.2 Pharmacokinetics of Gefitinib
A pre-experiment was first carried out to determine the pharmacokinetics of
gefitinib in the lung. Gefitinib was dissolved in 1:1 Dimethyl Sulfoxide/Ethanol
solutions at a concentration of 5 mg/ml. Mice were exposed to gefitinib particles for 15
minutes. Following exposure, the animals were sacrificed at designated time points with
the end of the exposure marked as time zero. Blood and lung samples were obtained,
assayed and analyzed using HPLC.

51

In Figure 4.8, the concentrations of gefitinib in the lung were given as a function of
time following aerosol exposure. The pharmacokinetic parameters are shown in Table
4.4. The maximum concentration was achieved at time 0. The concentration in lung
decreased with time. The half-life of gefitinib in the lung was about 90 min. Gefitinib
was not detected in blood until the last time point, which was 1 hour after exposure.
The results indicated that by aerosol route, gefitinib was mainly accumulated in the lung
1 hour after delivery. Hence, the systemic effects of gefitinib could be highly reduced by
aerosol delivery.
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Figure 4.8 Concentration of Gefitinib in the lung following 15 min aerosol inhalation. Bar, SD.
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Table 4.4Pharamacokinetic parameters of gefitinib for aerosol administration (Data shown in Mean ± SD)

Parameters

Gefitinib

Cmax (µg/g)

1.81 ± 0.38

AUC (µg/g  h)

2.37 ± 0.83

AUMC∞ (µg/g  h2)

2.14 ± 1.11

MRT∞ (h)

0.90 ± 0.52

t1/2 (min)

1.33 ± 0.60

4.3.3 Experimental Design
The treatment protocol was shown in Figure 5(a). Female A/J mice at 8 weeks of
age were used in this experiment. Three sets of experiments were carried out. Two
carcinogens, B(a)P and VC were compared. Two weeks after the i.p. injection of
carcinogen, mice were randomly divided into control and treatment groups with 12
mice per group: (1) VC solvent control group (DMSO: Ethanol = 1:1); (2) Gefitinib-VC
1 mg/ml; (3) Gefitinib-VC 5 mg/ml; (4) B(a)P solvent control group 1 (DMSO:
Ethanol = 1:1); (5) Gefitinib-B(a)P 5 mg/ml; (6) B(a)P solvent control group 2 (DMSO:
Ethanol = 1:1); (7) Gefitinib-B(a)P 10 mg/ml; (8) Gefitinib-B(a)P 15 mg/ml.
All the mice were exposed to aerosols for 15 min/day and 5 days/week. The
treatment began two week after the carcinogen injection and continued for 18 (VC
treated groups) or 20 weeks (B(a)P treated groups (Figure 4.9).
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Figure 4.9 Experiment protocol

4.3.4 Chemopreventive Effects
There were no significant body weight differences between gefitinib treated groups
and their corresponding control groups for all the experiments (Figure 4.10), indicating
that at the given concentrations, aerosolized gefitinib was well-tolerated.
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Figure 4.10 The average body weight of mice during the treatment: (a) VC treated groups; (b) B(a)P
treated groups.

The results of tumor number and tumor load in all the groups were shown in
Figure 4.11 (a), (b), (c), and (d). VC induced an average of 43.3 ± 1.5 (n=12) tumors per
mouse in the solvent control group. The average tumor load was 21.6 ± 5.6 mm3.
Gefitinib showed no inhibitory effects on tumor number. However, the tumor load was
decreased with the increase of gefitinib concentration. The 1 mg/ml gefitinib decreased
the tumor load by 26% (p<0.05), and the 5 mg/ml gefitinib decreased tumor load by 33%
(p<0.05). B(a)P induced an average of 5.0 ± 0.63 (n=12) tumors per mouse in the
solvent control group 1 and 4.1 ± 0.62 (n=12) tumors per mouse in solvent control
group 2. The average tumor load in B(a)P solvent control group 1 and 2 were 0.30 ±
0.07 mm3 and 0.78 ± 0.17 mm3, respectively. Similar to the VC groups, aerosolized
gefitinib (5 mg/ml, 10 mg/ml and 15 mg/ml) did not show significant inhibitory effects
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on tumor multiplicity, while the decrease in tumor load were 39%, 46%, and 56%,
respectively, when compared with the corresponding solvent control group.
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Figure 4.11 (a) Tumor number of VC-treated groups. (b) Tumor load of VC-treated groups. (c) Tumor
multiplicity and tumor load of the first set of B(a)P treated groups. (d) Tumor multiplicity and tumor load
of the second set of B(a)P treated groups. Bar, SE. *, P<0.05.

In this study, both B(a)P and VC were used to induce lung carcinogenesis. B(a)P
mainly induces lung adenomas, while VC mainly induces lung adenocacinomas and
carcinomas (Gunning et al. 2000). As shown in Figure 5, aerosolized gefitinib decreased
the tumor load in both B(a)P and VC treated groups, which indicates that although
gefitinib could not cause tumor regression once the tumor progression was initiated by
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carcinogens, it can significantly inhibit the growth of adenomas, adenocacinomas and
carcinomas. The HPLC results confirmed that gefitinib was mainly concentrated in the
lung. Furthermore, there was no alopecia observed on any of the aerosolized gefitinibtreated mice, while when gefitinib was administrated orally, alopecia was observed at
the region near eyelid (Yan et al. 2006a). By using aerosol delivery, the desired dose
could be highly reduced comparing with oral route. In the mean time, the systemic
toxicity could be minimized by directly introducing the drug to the target organ. Thus,
aerosol delivery of gefitinib could be a promising approach in lung cancer
chemoprevention.

4.4 Erlotinib (OSI-774, Tarceva)
Erlotinib, which is also an orally available reversible ATP-competitive inhibitor of
the wild-type EGFR TK, showed positive response in clinical trials. A randomized,
placebo-controlled Phase III trial (BR.21) conducted by National Cancer Institute of
Canada Clinical Trials Group, in which the overall survival was 6.7 months for erlotinib
versus 4.7 months for placebo (Shepherd et al. 2005), directly led to the approval of
erlotinib by the US Food and Drug Administration in 2004 for treatment of patients
with locally advanced or metastatic NSCLC after failure of at least one previous
chemotherapy regimen (Pao and Miller 2005). More clinical trials using erlotinib for the
treatment of early stage, locally advanced and metastatic NSCLC have carried out. The
results have been well summarized (Gridelli et al. 2010; Iyer and Bharthuar 2010).
Pharmacoeconomic analysis indicated that in patients with advanced NSCLC, second-
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or third-line treatment with erlotinib is clinically effective in improving survival (LysengWilliamson 2010).
The mechanisms of erlotinib are similar to gefitinib. Erlotinib competes with
adenosine triphosphate (ATP) for the ATP-binding sites localized on the EGFR
intracellular domain and inhibits autophosphorylation by EGFR-tyrosine kinase, which
results in blockage of downstream EGFR signal transduction pathways, cell cycle arrest
and inhibition of angiogenesis ((Iyer and Bharthuar 2010)).
The major side effects of erlotinib are skin rash and diarrhea, similar to gefitinib.
The recommended daily dose for human is 150 mg/day. The possibility of using
erlotinib as a chemopreventive agent was studied using the female A/J mouse model.

4.4.1 Aerosol Characteristics
First, the aerosol characteristics of erlotinib generated by the aerosol delivery system
were determined by SMPS system. The size distribution of erlotinib particles generated
by the atomizer using 5 mg/ml erlotinib solution is shown in Figure 4.12.
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Figure 4.12 Size distribution of 5 mg/ml Erlotinib
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The geometric median diameter (GMD) was 0.118 µm, and the geometric standard
deviation (GSD) was 1.6. The aerosol mass concentration Caerosol was 132 µg/liter.
Similarly, for 1 mg/ml erlotinib solution, the GMD and Caerosol decreased with the
solution concentration. The GMD was 0.07 µm, and the aerosol mass concentration

Caerosol was 26.4 µg/liter. The custom-made Collison type atomizer could provide stable
aerosol size distribution, which ensured that the mice received the same dose everyday
throughout the experiment. As shown in Figure 4.12, the diameters of erlotinib
particles generated by the system ranged from 0.02 µm to 0.6 µm. 90% of the particles
were 0.03 to 0.4 µm in diameter, which was in the favorable ranges for mice inhalation
study (Raabe et al. 1988).

4.4.2 Parmacokinetics of erlotinib
A pre-experiment was carried out to determine the pharmacokinetics of erlotinib in
the lung. Mice were exposed to erlotinib (5 mg/ml solution) for 15 min. In Figure 4.13,
the concentrations of erlotinib in the lung were given as a function of time following
aerosol exposure. Pharmocokinetic parameters of aerosolized erlotinib were calculated
based on Figure 4.13. The following parameters were estimated as described earlier
(Liao et al. 2004b): maximum lung concentration (Cmax); the mean area under the lung
concentration-time curve (AUC); the area under first moment curve (AUMC∞); the
mean resident time (MRT∞) and the lung half-life (t1/2). The data are given in Table 4.5.
The half-life of erlotinib in the lung was about 29 min, while the mean resident time
was 42 min. Low concentration in the serum (0.11 µg/ml) was detected 1 hour after
exposure. The results indicate that after aerosol delivery, erlotinib mainly stayed in the
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lung for the first hour after being inhaled. Compared with gefitinib, erlotinib had a
shorter MRT∞ and t1/2 in the lung.
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Figure 4.13 Concentration of erlotinib in the lung following aerosol inhalation Bar, SD.
Table 4.5 Pharamacokinetic parameters of erlotinib for aerosol administration. (Data shown in Mean ±
SD)

Parameters

Tarceva

Cmax (µg/g)

4.59 ± 0.70

AUC (µg/g  h)

2.92 ± 0.52

AUMC∞ (µg/g  h2)

2.06 ± 0.23

MRT∞ (h)

0.71 ± 0.21

t1/2 (min)

28.88 ± 1.31

4.4.3 Chemoprevention Effects
Mice were treated by aerosol for 18 or 20 weeks after carcinogen injection. During
the experiment, all mice showed good tolerance to treatment with erlotinib. No
significant difference in body weight was observed (Figure 4.14).
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Figure 4.14 Body weight monitoring during the treatment duration.

The results of tumor multiplicity and tumor load for each group are shown in
Figure 4.15. VC induced an average of 43.3 ± 1.5 (n=12) tumors per mouse in the
solvent control group. The average tumor load was 21.6 ± 5.6 mm3. The tumor number
in groups treated by 1 mg/ml erlotinib and 5 mg/ml erlotinib were 40.6 ± 2.5 and 45.3
± 3.0, respectively. No inhibitions on tumor multiplicity were achieved by aerosolized
erlotinib. The tumor load was decreased with the increase of erlotinib concentration.
The decrease in tumor load was 24.5% (P<0.05) and 35.7% (P<0.01). Similar results
were observed for B(a)P treated groups. The mice received erlotinib at a solution
concentration of 5 mg/ml had an average tumor number of 4.73 ± 0.3, while the
control group had an average of 5.0 ± 0.6 tumors per mouse. No decrease in tumor
number was achieved. For tumor load, erlotinib inhibited by 63.8% (P<0.05) compared
to control group.
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Figure 4.15 Chemopreventive effects of Erlotinib in femail A/J mice model. (a)VC was used as
carcinogen; (b) B(a)P was used as carcinogen. *, P<0.05; **, P<0.01; bar, SE.

Erlotinib has been investigated in all stages of NSCLC, including early stage, locally
advanced, metastatic stage, and recurrent NSCLC. The results of clinical trials suggest
that erlotinib has beneficial effects in treating certain types of NSCLC patients, the
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main characteristic of whom are never- or light smokers, having adenocarcinoma and
bronchioloalveolar carcinoma, female gender, and Asians. Many reviews have
summarized the current status regarding erlotinib recently (Gridelli et al. 2010; Iyer and
Bharthuar 2010; Laack et al. 2010). Herein, the chemopreventive effects of erlotinib had
been investigated using female A/J mice model and post-initiation protocol. Two
carcinogens were used separately to induce lung tumorigenesis. Erlotinib had shown on
effects on tumor multiplicity. The average tumor numbers were similar with the
corresponding control groups. However, significant inhibition on tumor load, which
increased with the dose, was observed for all erlotinib treated groups. The results
indicated that although erlotinib could not cause the regression of the tumorigenesis
once the tumor was initiated by carcinogens, it can inhibit tumor growth during tumor
progression for both adenomas and adenocarcinomas. The effectiveness of EGFR
inhibitors, such as gefitinib and erlotinib, associates with acute toxicity, especially the
skin rash, in clinical trials. The occurrence of skin reactions is considered as a potential
surrogate marker for anti-EGFR drug efficacy (Gridelli et al. 2010). However, such
toxicity is not acceptable if erlotinib is used as a chemopreventive agent. By aerosol
delivery, the necessary dose could be reduced without sacrificing the effects. Our studies
showed that the tumor growth was inhibited with no obvious side effects observed. So,
aerosol delivered erlotinib can be a good candidate for lung cancer chemoprevention.

4.5 Budesonide
Budesonide is a glucocorticoid steroid for the treatment of asthma, the treatment of
non-infectious rhinitis, and the treatment and prevention of nasal polyposis. Animal
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studies showed that synthetic glucocorticoids have lung cancer chemopreventive
efficacy (Wang et al. 2003; Wattenberg et al. 1997; Yao et al. 2004). Budesonide was first
shown to have inhibitory effects on B(a)P induced pulmonary adenoma formation in
the female A/J mouse model through administrations by both diet and aerosol in 1997
(Wattenberg and Estensen 1997; Wattenberg et al. 1997). In order to further minimize
the systemic effects and potential side effects, Wattenberg et al. examined aerosol
administration of budesonide with low doses. The inhibitory effect decreased with
lower dose level (Wattenberg et al. 2000). By using different mouse models, Wang et al.
showed that budesonide has both chemopreventive and chemotherapy effects on lung
tumors in mice with different germline mutations and that the degree of efficacy
depends on genotypes of mice (Wang et al. 2003). Gene expression array analysis
indicated that the chemopreventive effects of budesonide in the mouse lung
tumorigenesis assay involved increased and decreased expression of a wide variety of
genes in multiple signaling pathways (Yao et al. 2004).
In our study, the chemopreventive effects of aerosolized budesonide were examined
using female A/J mice. Two concentrations, 1 mg/ml and 6 mg/ml were compared.
The corresponding dose of budesonide was estimated to be about 72.8 µg/kg body
weight for 1 mg/ml solution and 437µg/kg body weight for 6 mg/ml solution.
The average body weights of each group during treatment are given in Figure 4.16.
The low concentration of budesonide had no effects on body weight. The body weight
was close to that of control group for the treatment duration. However, the body
weight of mice receiving high concentration budesonide decreased significantly since
the second week of treatment. The average body weight was about 11% lower than the
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control group. Similar results were observed by Wattenberg et al. (Wattenberg et al.
1997). The decrease in body weight indicated that even though budesonide was
introduced directly to the lung through inhalation, at higher concentration, budesonide
still caused systemic effect. The dose should be kept lower than this for future studies.
The results of tumor multiplicity and tumor load for each group are shown in
Figure 4.17. Both tumor multiplicity and tumor load were decreased by aerosolized
budesonide. The inhibitory effects increase with the increase of budesonide
concentration. The decrease in tumor number was 35.4% (P<0.01) and 41.5% (P<0.01)
for budesonide concentration of 1 mg/ml and 6 mg/ml, respectively. The decrease in
tumor load was 40.7% (P < 0.05) for low dose and 72.4% (P < 0.001) for high dose.
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Figure 4.16 Body weight monitored during treatment
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Figure 4.17 Inhibitory effects of aerosolized budesonide on tumor number (left) and tumor load (right). *,
P<0.05; **, P<0.01; ***, P<0.001. Bar, SE.

4.6 Summary
Six aerosolized chemopreventive agents were tested for their inhibitory effects on
lung tumorigenesis using female A/J mice and post-initiation protocol. This study
showed that Polyphenon E was an effective chemopreventive agent on inducing tumor
regression and inhibiting tumor growth, while Polyphenon E without EGCG was
ineffective. EGCG is thought be the most active component in Polyphenon E, but it
has to be with other tea catechins to show chemopreventive activity on lung
tumorigenesis in aerosolized form. Resveratrol, which showed no effects on lung
tumorigenesis previously when it was given in diet, inhibit tumor growth significantly.
HPLC analysis confirmed the existence of resveratrol in the lung. Two EGFR inhibitors,
gefitinib and erlotinib, inhibited the growth of tumors initiated by either B(a)P or VC.
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No skin toxicity, which was commonly associated with the effectiveness in both animal
study and human clinical trials, was observed throughout the treatment. Budesonide
inhibited both tumor multiplicity and tumor load. The inhibitory effects increased with
the dose. However, higher dose cause severe decrease in body weight. Lower dose was
recommended for future testing.
In summary, the delivery by aerosol of chemopreventive agents has been
demonstrated to be a novel method for providing the powerful efficacies in
chemoprevention of lung tumorigenesis. Aerosol delivery can decrease the dose while
remaining the efficacy, minimize the toxicity, and improve the bioavailability in the lung.
The inhalation system used in this study is capable of providing aerosol with stable size
distribution which was suitable for chemoprevention study using mice. The aerosol
delivery is an effective approach of chemoprevention, which could be considered for
further studies in animal models as well as clinical trials.
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Chapter 5
Chemoprevention of lung carcinogenesis
by the combination of aerosolized and
oral delivered agents in A/J mice

68

5.1 Introduction
Target populations for lung cancer chemoprevention include those who are at high
risk of developing lung cancer, e.g. current and former smokers. Cigarette smoke is a
complex mixture of carcinogens and toxicants. Thus, lung cancer caused by years of
smoking is unlikely to be prevented through intervention in a single pathway.
Combinations of drugs that act through different mechanisms may achieve greater
chemopreventive efficacy (Hecht et al. 2009).
As introduced in section 4.5, budesonide, which is a glucocorticoid steroid for the
treatment of asthma, has inhibitory effects on B(a)P induced pulmonary adenoma
formation in the female A/J mouse model through administrations by both diet and
aerosol in 1997 (Wattenberg and Estensen 1997; Wattenberg et al. 1997). Our
experiments also confirmed this. By introducing a second chemopreventive agent, myoinosital, in diet, in addition to aerosol administration of budesonide, a better efficacy
was achieved compared with single agent treatment (Wattenberg et al. 2000). In order to
further investigate the inhibitory effects by combining budesonide with other effective
chemoprevention agents, we carried out more experiments, including the combination
of aerosolized budesonide with diet Polyphenon E, diet Indole-3-carbinol, and gavage
pioglitazone, respectively.
As introduced in section 4.1, Polyphenon E is a well-defined green tea extract
containing at least five tea catechins, with (–)-epigallocatechin-3-gallate (EGCG) being
the most abundant (Chang et al. 2003; Clark and You 2006). Polyphenon E has been
shown to have inhibitory effects on lung carcinogenesis in animal models (Clark and
You 2006; Yan et al. 2006b). It is believed that EGCG, which can bind to various
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proteins, is the most active compound in polyphenon E although the direct targets of
EGCG have not been identified yet.
Indole-3-carbinol (I3C) is a glucobrassicin derivative found at high concentration in
cruciferous vegetables. As a nutritional supplement, I3C has been considered as a
promising preventive and treatment agent for breast and other types of cancers
(Bradlow 2008; Grubbs et al. 1995; Jin et al. 1999; Manson et al. 1998; Plate and
Gallaher 2006; Souli et al. 2008; Srivastava and Shukla 1998; Tanaka et al. 1992; Yu et al.
2006). I3C may cause induction of phase I and phase II enzymes, inhibition of
proliferation and induction of apoptosis in tumor cells, and modulation of estrogen
metabolism (IARC 2004). In lung cancer chemoprevention, the dose-dependent and
post-carcinogen tumor-inhibitory activities of I3C was examined lately using A/J mice
model (Kassie et al. 2008b). Diet administration of I3C at 10 µmol/g or higher showed
over 50% inhibition efficiency. I3C had been combined with other drugs for the
treatment of lung tumorigenesis (Dagne et al. 2011; Kassie et al. 2010b). The inhibition
on tumor multiplicity of the combination groups was higher than single agents.
The peroxisome proliferator-activated receptors γ (PPARγ) is a member of the
nuclear hormone receptor superfamily of ligand-activated transcription factors. It has a
critical role in the regulation of multiple cellular processes including lipid metabolism
and differentiation (Lehrke and Lazar 2005; Michalik et al. 2004; Nemenoff 2007).
PPARγ expression was increased in non-small cell lung cancer (NSCLC) and PPARγ
expression correlated with lung cancer histologic type and grade (Theocharis et al. 2002).
PPARγ is a molecular target for thiazolidinediones (TZDs), such as troglitazone,
rosiglitazone, and pioglitazone. Pioglitazone and rosiglitazone are synthetic PPARγ
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ligands used clinically to treat type II diabetes. Recent epidemiological studies indicated
a significant decrease in lung cancer risk in patients receiving TZDs to treat diabetes,
suggesting that TZDs may have chemopreventive effects on lung cancer (Nemenoff
2007). The mechanisms of the inhibitory effects of TZDs on NSCLC were reviewed
recently (Keshamouni et al. 2004). Troglitazone has been shown to inhibit the growth
of NSCLC cells in vitro and in vivo (Keshamouni et al. 2004; Satoh et al. 2002).
Pioglitazone has a favorable safety profile compared to other TZDs in regards to
cardiovascular side effects (Shah and Mudaliar 2010). This is a strong rationale for
testing pioglitazone versus rosiglitazone or troglitazone (Gegick and Altheimer 2001;
Stafylas et al. 2009). Pioglitazone induced apoptosis and inhibited tumor growth in
xenograft models of lung cancer (Keshamouni et al. 2004). In a lung adenocarcinoma
model using mice, Wang et al. found that oral dose of pioglitazone inhibited tumor load
by 50% or higher (Wang et al. 2010).
The four drugs have shown good inhibitory effects in lung cancer individually using
animal models without causing systemic toxicity or weight loss, which indicates they are
good candidates for chemoprevention study. Here, the chemopreventive effects of the
combination of Polyphenon E, I3C, and pioglitazone with aerosolized budesonide for
the inhibition of B(a)P induced lung tumorigenesis in A/J mice was studied and
compared with single agents.

5.2 Experimental Design
The experimental design is summarized in Table 5.1. There were 12 groups, total
140 mice included in this study. Each treatment group had a corresponding control
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group. The only difference between the treatment group and the control groups was
that no drug was used in the control groups.
Table 5.1 Experimental design of the combination treatment

#

Groups

Dose

Administration

1

Diet Control

AIN-76A diet

Diet

2

Gavage Control

3

Solvent Control

50% DMSO / EtOH

Aerosol

Solvent +

50% DMSO / EtOH +

Aerosol

Diet Control

AIN-76A diet

Diet

Solvent +

50% DMSO / EtOH +

Aerosol

Gavage Control

Solvent for Gavage

Gavage

6

Budesonide

2.25 mg/ml in DMSO/EtOH

Aerosol, 2 min

7

Polyphenon E

1.5 % in AIN-76A diet

Diet

8

Pioglitazone

10 mg/kg body weight

Gavage

10 µmol/g in AIN-76A diet

Diet

Budesonide +

2.25 mg/ml budesonide in DMSO/EtOH

Aerosol 2 min

Poly E

+ 1.5% PolyE in AIN-76A diet

+ Diet

Budesonide +

2.25 mg/ml budesonide in DMSO/EtOH

Aerosol 2 min

Pioglitazone

+ 10 mg pioglitazone/kg body weight

+ Gavage

Budesonide +

2.25 mg/ml budesonide in DMSO/EtOH

Aerosol 2 min+

I3C

+ 10 µmol/g I3C in AIN-76A diet

Diet

polyethylene glycol : 0.5 g/L carboxymethylcellulose in PBS = 1:1

Gavage

4

5

9

10

11

12

Indole-3carbinol (I3C)

Figure 5.1 shows the experiment protocol. The post-initiation A/J mice model was
used. All treatment began 2 weeks after the i.p. injection of B(a)P. All solvent control
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groups and all groups receiving budesonide were subjected the aerosol delivery
treatment for 2 minutes per day, 5 days per week. All gavage control groups and
pioglitazone groups received oral gavage 5 days per week. All diet treatment groups
received AIN-76 diet with drugs and 3% sugar. The total treatment duration continued
for 20 weeks. All mice were sacrificed 22 weeks from the B(a)P injection.
B(a)P (100 mg/kg)
Termination

Start of treatments

Aerosol Treatment (solvent control, budesonide), 5 times/week, 2 min/day.
Gavage Treatment (gavage control, pioglitazone), 5 times/week.
Diet Treatment (AIN-76A) (diet control, polyphenon E, indole-3-carbinol)
0 week

2 weeks

22 weeks

Figure 5.1 Treatment Protocol

5.3 Results
5.3.1 Aerosol Characteristics
We first determined the aerosol characteristics of budesonide generated by our
aerosol delivery system. The custom-made Collison type atomizer could provide stable
aerosol size distribution, which ensured that the mice received the same dose everyday
throughout the experiment. The size distribution of budesonide particles generated by
the atomizer is shown in Figure 5.2. The geometric median diameter (GMD) was 0.078
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µm, and the geometric standard deviation (GSD) was 1.7. The mass median diameter
(MMD) was 0.12 µm. The aerosol mass concentration Caerosol was 83.7 µg/liter.
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Figure 5.2 Size distribution of budesonide particles in exposure chamber. The diameter of budesonide
particles ranged from 0.01 µm to 0.4 µm, which was in the favorable ranges for mice inhalation study
(Raabe et al. 1988).

5.3.2 Dose for All Drugs
Tissue distributions of drugs were also examined. At the end of the study, 4 mice
from each group were randomly selected and the left lobe of the lung was homogenized
to analyze agent concentration. Serum, liver and spleen tissue were obtained for the
same purpose. Tissue concentrations of each agent are summarized in Table 5.2. The
concentration of budesonide was 2.7 µg/g of lung. Budesonide was not detected in
serum, liver or spleen tissue via HPLC. Assuming that there were no budesonide
accumulated in other unanalyzed organs, the total concentration of budesonide in mice
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was thus estimated to be 20.25 µg/kg body weight. In contrast to aerosolized
budesonide, orally administered polyphenon E and pioglitazone, were detected in all
analyzed tissues. Serum concentrations were significantly higher than concentrations in
lung tissue. The difference in drug distribution between aerosol and oral delivery
indicated that aerosol delivery achieved an elevated lung tissue concentration while
minimizing systemic drug levels.
Table 5.2 Accumulated concentrations of chemopreventive agents after 20 weeks treatment

Concentrations in
Groups

Drug

Administration

Lung (µg/g)

Blood
(µg/ml)

Liver (µg/g)

Spleen
(µg/g)

Budesonide

Budesonide

Aerosol

2.66 ± 0.17

ND2

ND

ND

Polyphenon E

Polyphenon E

Diet

12.57 ± 3.86

31.58 ± 9.15

44.84 ± 3.94

42.88 ± 2.91

Pioglitazone

Pioglitazone

Gavage

2.51 ± 0.41

5.24 ± 2.60

1.50 ± 0.18

3.25 ± 0.45

Budesonide &

Budesonide

Aerosol

2.67 ± 0.32

ND

ND

ND

Polyphenon E

Polyphenon E

Diet

10.73 ± 2.84

31.91 ± 4.42

46.38 ± 3.60

36.67 ± 4.47

Budesonide &

Budesonide

Aerosol

2.73 ± 0.35

ND

ND

ND

Pioglitazone

Pioglitazone

Gavage

1.44 ± 0.17

4.03 ± 2.01

1.62 ± 0.21

4.40 ± 0.53

However, no I3C was detected for all the samples. It was reported that I3C was
rapidly absorbed, distributed, and eliminated within one hour after oral administration
(Anderton et al. 2004). In our case, I3C was mixed in the daily diet. No directly dose
was introduced right before sacrifice. As a result, no I3C was detected by HPLC. I3C,
which is susceptible to oligomerization under acidic conditions, is converted into several

2

ND, Not detected.
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condensation products after ingestion. It has been suggested that the observed
biological activity may be attributable mainly to the acid condensation products, in
particular, 3,3’-diindolylmethane (DIM), which has shown promising cancer
chemopreventive properties in vitro and in vivo (Bhatnagar et al. 2009; Kim et al. 2010;
Rahman et al. 2009). However, the sample collection process we used here was not
capable of extracting DIM from tissues.

5.3.3 Chemopreventive Effects of Aerosolized Budesonide
Mice were treated with aerosolized budesonide for 20 weeks. The initial dose of
budesonide was estimated to be about 209 µg/kg body weight. The body weight in all
budesonide-treated groups decreased slowly during the first 7 weeks of treatment. The
average body weight in budesonide-treated groups was about 8% less than the
corresponding control group by the end of 7th week. As a result, we decreased the dose
of budesonide by 25% (about 157 µg/kg body weight) for the duration of treatment.
After the dose adjustment, body weight increased in budesonide treated mice, indicating
that the budesonide was well tolerated at this dose. There were no significant body
weight differences between budesonide treated groups and their corresponding control
groups at the end of the experiment.
In the solvent control group, B(a)P induced an average of 5.0 ± 0.63 (n=12) tumors
per mouse. The average tumor load in control group was 0.30 ± 0.07 mm3. Aerosolized
budesonide alone significantly decreased both tumor multiplicity [56.7%; 2.17 ± 0.47
(n=12)] and tumor load (78.4%; 0.07 ± 0.02 mm3) when compared to the control group,
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shown in Figure 5.3. The tumor incidence was 100% for solvent control group, and 83.3%
for budesonide group.
0.4
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(a)

(b)
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3

Tumor Load (mm )

Tumor Number (#)

0.3
4

3

0.2

**

2
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0.0
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Budesonide

Solvent Ctrl

Budesonide

Figure 5.3 Effects of budesonide on lung tumorigenesis in female A/J mice. (a) Tumor number; (b)
Tumor load. ** P<0.01, Bar: SE

5.3.4 Combination of Budesonide and Polyphenon E
Polyphenon E has been reported to be effective in lung cancer chemoprevention
(Wattenberg et al. 1997; Yan et al. 2006b). Since it targets different proteins and
pathways compared with budesonide, we thus tested the combination effect of
aerosolized budesonide and diet polyphenon E using A/J mice model. Single dose of
B(a)P at the concentration of 100 mg/kg was used to induce lung tumors. Two weeks
after carcinogen injection, budesonide was given by aerosol while Polyphenon E (15
g/kg diet) was given in diet for 20 weeks. As shown in Table 5.3, Polyphenon E did not
show inhibitory effects on tumor number, while it decreased tumor size by 82.9%. The
combination of budesonide and Polyphenon E further decreased the tumor load by
77

88.8%, while no improvement was observed in tumor multiplicity when compared to
the case of budesonide only. Tumor incidence was 90% for budesonide and
Polyphenon E group, while it was 100% for all other groups shown in Table 5.3.
Table 5.3 Effects of combined budesonide and polyphenon E on lung tumorigenesis in female A/J mice

Final Body

Tumor

Weight (g)3

Multiplicity4

Diet Control

27.3 ± 4.2

14.67 ± 1.62

-

3.90 ± 1.37

-

Polyphenon E

23.9 ± 1.8

10.75 ± 1.16

26.7%

0.67 ± 0.15

82.9%6

23.3 ± 1.5

8.64 ± 1.03

-

1.28 ± 0.38

-

18.3 ± 1.3

3.60 ± 0.54

58.3%7

0.09 ± 0.04

88.8%8

Group

Solvent & Diet
Control
Budesonide &
Polyphenon E

Inhibition

Tumor Load
(mm3)5

Inhibition

5.3.5 Combination of Budesonide and Indole-3-carbinol
Indole-3-carbinol was given at the concentration of 10 µmol/g by diet two weeks
after carcinogen initiation. For this combination group, the mice were also subjected to
aerosolized budesonide in addition to receiving I3C in diet. As shown in Table 5.4, after
20 weeks’ treatment, I3C alone decreased tumor number by 35.8% and tumor load by
83.2% compared with the diet control group. By combining aerosolized budesonide and
diet I3C, the tumor load was further decreased by 85%, while there was no
improvement in tumor number.
3

Data shown as Mean ± SD, similar for Table 5.4 and 5.5
Data shown as Mean ± SE, similar for Table 5.4 and 5.5
5 Data shown as Mean ± SE, similar for Table 5.4 and 5.5
6 P<0.01 versus diet control group
7 P<0.001 versus diet & solvent control group
8 P<0.01 versus diet & solvent control group
4
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Table 5.4 Effects of combined budesonide and I3C on lung tumorigenesis in female A/J mice

Final Body

Tumor

Weight (g)

Multiplicity

Diet Control

27.3 ± 4.2

14.67 ± 1.62

-

3.90 ± 1.37

-

I3C

26.1 ± 3.3

9.42 ± 1.12

35.8%

0.66 ± 0.16

83.2%9

23.3 ± 1.5

8.64 ± 1.03

-

1.28 ± 0.38

-

20.3 ± 2.5

5.00 ± 0.85

42.1%

0.12 ± 0.04

84.9%10

Group

Solvent &
Diet Control
Budesonide
& I3C

Inhibition

Tumor Load
(mm3)

Inhibition

5.3.6 Combination of Budesonide and Pioglitazone
Pioglitazone was given by oral gavage at the concentration of 10 mg/kg body
weight. When compared to the gavage control group, no inhibitory effects on tumor
number were observed while the tumor size was significantly decreased by 63%.
Pioglitazone was also studied for its chemoprevention effects when combined with
aerosolized budesonide. We observed a 90% inhibition in tumor load compared to the
corresponding control group. 87% of all the tumors observed in the combination group
were smaller than 0.5 mm in diameter, compared to 42% in budesonide treated group
and 51% in pioglitazone treated group. The combination of pioglitazone and
budesonide did not significantly affect tumor multiplicity compared to budesonide alone.
The results are summarized in Table 5.5.

9 P<0.01

versus diet control group
versus diet & solvent control group

10 P<0.01
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Table 5.5 Effects of combined budesonide and pioglitazone on lung tumorigenesis in female A/J mice

Group

Final Body

Tumor

Inhibition

Tumor Load
(mm3)

Inhibition

% tumors

Weight (g)

Multiplicity

Gavage Control

20.9 ± 1.9

4.33 ± 0.62

-

0.36 ± 0.13

-

23.1%

Pioglitazone

23.0 ± 2.5

4.08 ± 0.61

5.8%

0.13 ± 0.03

63.3%11

50.8%

20.1 ± 2.5

4.70 ± 0.69

-

0.26 ± 0.07

-

39.2%

19.2 ± 1.7

2.09 ± 0.44

55.5%12

0.03 ± 0.01

89.6%13

87.0%

Solvent &
Gavage Control
Budesonide &
Pioglitazone

< 0.5 mm

5.4 Discussion
Chemoprevention using combinations of agents targeting different pathways may
offer significant advantages compared with single agents by increasing efficacy. In
addition, this approach may allow the use of lower doses with the potential to reduce
adverse side effects. Budesonide inhibits all stages of lung tumorigenesis induced by
B(a)P in the A/J mouse model (Wattenberg and Estensen 1997; Wattenberg et al. 1997)
and is a good candidate for combinational studies (Alyaqoub et al. 2007; Wattenberg et
al. 2000). Three agents (i.e., Polyphenon E, indole-3-carbinol, and pioglitazone), which
were shown to have inhibitory effects on lung carcinogenesis under different
mechanisms, were selected as combination agents with aerosolized budesonide. Using a
post-initiation protocol, we determined the effect of combination treatment on lung
adenoma prevention in A/J mice.

11

P<0.05 versus gavage control
P<0.05 versus solvent & gavage control, P<0.01 versus pioglitazone group
13 P<0.05 versus solvent & gavage control, P<0.01 versus pioglitazone group
12
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In this study, budesonide was introduced through aerosol delivery using an aerosol
generation and exposure system which could ensure that mice received constant dose of
drug throughout the experiment (Fu et al. 2009). Since mice have much smaller
respiratory tract than human, the optimal particle size for mice inhalation studies is less
than 0.3 µm (Raabe et al. 1988). In our study, the diameter of budesonide particles
ranged from 0.01 µm to 0.4 µm, with the mass median diameter at 0.12 µm (Figure 5.2),
which is more favorable for aerosolized drug delivery in mouse model compared with
previous studies in which nebulizers was used for generating aerosolized agents (Dahl et
al. 2000; Liao et al. 2004b).
After 20 weeks treatment, aerosolized budesonide alone inhibited tumor multiplicity
by 57% and tumor load by 78%, similar to what has been observed previously
(Wattenberg et al. 1997). As expected, aerosol delivery achieved high budesonide
concentrations in lung tissue but undetectable amounts in other tissues tested. Thus, by
delivering agent particles directly to the mouse lung, the systemic dose could be
significantly reduced without affecting efficacy. This in turn should reduce the risk of
side effects and minimize systemic toxicity. Since chemoprevention targets healthy
people with a high risk of developing lung cancer, efficacy and safety are two key
criteria for the selection of chemopreventive agents. Compared to other means of
administration, aerosol delivery has distinct advantages in satisfying the above two
criteria.
Polyphenon E, which is a mixture of polyphenols containing at least five tea
catechins, has been shown to be able to inhibit the development of cancer at different
target sites in several animal models. For lung cancer chemoprevention, Polyphenon E
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shows good inhibitory effects (Fu et al. 2009; Yan et al. 2006b; Zhang et al. 2010),
suggesting that Polyphenon E is a good candidate for lung cancer chemoprevention. In
this study, by adding 15 g/kg Polyphenon E in diet, the tumor load was decreased by 83%
when compared with the control group. The inhibition on tumor load was further
increased to 89% when combining budesonide with Polyphenon E. No significant
effect on the tumor multiplicity was observed when comparing Polyphenon E alone
group with the control group. Similarly, for the combinational group, the inhibition on
tumor number was at the same level with the budesonide only group. Our previous
study showed that aerosolized polyphenon E could inhibit tumor growth without
showing significant decrease in body weight (Fu et al. 2009). Thus, introducing both
agents by aerosol in the combinational study at the same time could be an alternative
approach to further decease the agent dose level while minimizing the side effects.
Indole-3-carbinol is well-accepted as a nutritional supplement. Kassie et al. studied
the inhibition of I3C on VC-induced lung adenocarcinoma as well as 4(methylnitrosamino)-1-(3-pyridyl)-1-butanone

(NNK)

plus

B(a)P-induced

lung

tumorigenesis in A/J mice model (Kassie et al. 2010a; Kassie et al. 2008b). In their study,
by receiving I3C in diet for more than 10 µmol/g beginning at 50% of carcinogen
treatment, the mice had at least 50% less tumor number compared with the control
group. However, using postinitiation protocol and VC as carcinogen, the effective dose
of I3C was 70 µmol/g diet. In our study, for the I3C treatment group, the mice received
10 µmol/g I3C in diet for 20 weeks starting 2 weeks after the carcinogen treatment. The
tumor load was significantly decreased by 83%, while the inhibition on the tumor
number was around 36%, indicating that, at the test dose, I3C could not effectively
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cause the regression of tumorigenesis using this protocol. As a result, the tumor
number of combination group was not further reduced when compared with the result
of individual agent treatment group. The tumor load was decreased by 85% for the
combinational group, while the decrease was 83% for the I3C treatment group and 78%
for the budesonide treatment group. The mechanisms through which I3C or
budesonide suppress tumorigenesis have been extensively investigated in cell culture
models as well as in animal models (Kassie et al. 2008a; Kassie et al. 2010a; Tao et al.
2002; Wu et al. 2005; Yao et al. 2004). Different targeting pathways for I3C and
budesonide suggest that combination of these two agents might achieve better
inhibitory effects, which is consistent with our experimental results.
Pioglitazone is a synthetic PPARγ ligand which has been approved by the Food and
Drug Administration (FDA) for the treatment of type II diabetes. PPARγ agonists have
anticancer effects on cell lines by binding with PPARγ receptor which then forms an
active heterodimer with the retinoid X receptors (Ondrey 2009). Pioglitazone acts via
distinct mechanisms (Han and Roman 2006; Hazra et al. 2007; Keshamouni et al. 2005)
and was selected as a combination agent with aerosolized budesonide. After 20 week
administration of pioglitazone by oral gavage, the number of tumors in the pioglitazone
treatment group was not affected. In contrast, tumor load was decreased by 63%. When
combined with budesonide, pioglitazone did not enhance the inhibition of tumor
multiplicity compared to the budesonide treated group. However, tumor load in the
combination group was decreased by ~90% compared to its corresponding control
group. Approximately 87% of total tumors were smaller than 0.5 mm in diameter in the
combination group, compared to 51% in pioglitazone group and 42% in budesonide
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group. Large tumors are significantly inhibited in combination group compared to either
single agent. Budesonide and pioglitazone have different mechanisms in inhibiting lung
cancer (Nemenoff 2007; Nemenoff et al. 2008; Yao et al. 2004). The combination
effects of budesonide and pioglitazone were shown to be independent and additive on
cell growth by using a linear model, which indicated that the two agents functioned
individually in inhibiting lung tumorigenesis and the overall inhibition was increased due
to the additive effect (Fu et al. 2011b).
The drugs tested here for their efficacy on lung cancer chemoprevention, are either
approved by the FDA to be used on human (i.e., budesonide and pioglitazone), or
natural agents that are extracted from food (i.e., Polyphenon E and I3C). In this study,
the two FDA approved drugs were introduced in the same ways as they have been using
to treat certain diseases- budesonide was introduced through inhalation, while
pioglitazone was given orally. The two natural drugs were introduced orally, the same
way as how people take them in daily life. Our results showed that by combining those
two drugs, the tumor number and tumor load was further reduced by 56% and 90%,
respectively. The combination of aerosolized budesonide and oral pioglitazone might be
a good candidate for clinical trials.
In this study, we used post-initiation protocol, i.e., all the treatment began after the
tumor being initiated by carcinogen. Under this protocol, all three chemopreventive
agents (i.e., I3C, pioglitazone, Polyphenon E) examined for their combination with
budesonide showed significant inhibitory effects on the tumor size but less effect on the
tumor number compared with the groups of testing them as single agent. Similarly, all
the combinational groups failed to further decrease the tumor number when compared
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to the budesonide alone treatment group. The inhibitions on the tumor load were
higher for all combinational groups than that of any individual treatment group.
However, the difference was not statistically significant between the combination
treatment and the budesonide group, mainly due to the strong inhibitory effect by
budesonide alone. The decrease in tumor load by budesonide only was already 78%. To
further test the combinational effects, the dose of budesonide should be decreased.

5.5 Summary
In this study, the combinative effects of aerosolized budesonide with oral
Polyphenon E, indole-3-carbinol, or pioglitazone were investigated using female A/J
mice. Aerosolized budesonide inhibited lung adenoma formation. Compared with
solvent control group, budesonide decreased the tumor multiplicity and the tumor load
by 56.7% and 78.4%, respectively. Furthermore, aerosol delivery can achieve high
concentration in the target organ with low chemopreventive agent dose compared to
other administration routes. Used as a single agent, Polyphenon E, I3C and pioglitazone
all showed significant inhibition on tumor load. The decrease in tumor load was 82.9%
by Polyphenon E, 83.2% by I3C, and 63.3% by pioglitazone. No effects on tumor
multiplicity were achieved. By combining aerosolized budesonide with Polyphenon E,
indole-3-carbinol or pioglitazone, respectively, the tumor load of test mice could be
significantly reduced. Budesonide with polyphenon E decreased tumor multiplicity by
58.3% and tumor load by 88.8%. For budesonide with I3C, the decrease in tumor
multiplicity was 42.1%, while the decrease in tumor load was 84.9%. Budesonide and
pioglitazone showed the most decrease on tumor load among the three combination
85

treatment cases. The decreased in tumor load was 89.6%, while in tumor multiplicity it
was 55.5%. The three agents used for the combination treatment with budesonide did
not decrease tumor number. As a result, the combination groups all showed similar
inhibitory effects on tumor multiplicity as budesonide alone case. Since the three agents
can significantly inhibit tumor growth, the inhibition on tumor load after combined with
budesonide was even greater. Among all three combination groups, pioglitazone
combined with budesonide showed the greatest inhibitions on tumor load, which makes
them a promising candidate for further investigation. Our result shows that the
combination of agents targeting different pathways could be a promising approach in
lung cancer chemoprevention.
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Chapter 6
Review of Twin-head Electrospray
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6.1 Introduction
Electrohydrodynamic spraying (Electrospray, ES) is a method to generate
monodisperse particles with diameters in the range of nanometers to micrometers. The
main advantages of electrospray include:
(1) The particles generated by electrospray when it is operated in the stable cone-jet
mode are in narrow size range.
(2) The particles are highly charged with the same polarity, which highly decreases
the particle agglomerations due to mutual repulsion.
(3) The particles are airborne after generation. Based on the applications, they can
be either remained in airborne or collected for further process.
(4) Both liquid solution and suspension can be sprayed.
(5) By using dual-capillary or tri-capillary, the particles can be modified to form
multiple layers or contain multi-functional groups.
Coagulation is the most important interparticle phenomenon for aerosols. It has
been studied both theoretically and experimentally since 1917 when Smoluchowski
developed the theory for the collision frequency function for Brownian coagulation.
The coagulation can be increased when there are attractive electrical forces between
particles. With the high charge levels achieved by electrospraying, charge-enhanced
coagulation has been utilized for various applications using systems containing two
electrospray heads.
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6.2 Electrostatic Coagulation
Coagulation of charged aerosols in the absence of electrostatic dispersion is
described in a discrete form by (Zebel 1958):
∞ ∞
d N i p 1 ∞ i −1 p − q , q p − q q
= ∑∑ β i − j , j N i − j N j − ∑∑ β i p, ,jq N i p N qj
dt
2 q = −∞ j =1
q = −∞ j =1
,

(6.1)

where N is the number concentration of the particles made of i primary particles
having p charges, i or j is the number of primary particles, p or q is the number of
elementary charge units per particle, t is the time, and β is the coagulation coefficient.
The first term on the right-hand side accounts for the formation of particles of size i
and charge p due to collisions of particles of size i - j and number of charges p - q and
particles of size j and number of charges q, respectively. The second term describes the
loss of particles of size i and charge p by coagulation with any other particle in the
system.
The collision rate of particles carrying charges of opposite polarities is highly
enhanced compared to the case of neutral particles coagulation. Zebel and Fuchs
derived the coagulation coefficient of electrically charged (including both unipolar
charged and bipolar charged) particles by Coulomb force (Fuchs 1964).

β i p, ,jq =

βi , j
Wi ,pj,q

,

(6.2)

where β i p, ,jq is the coagulation coefficient of neutral particles and W i ,pj,q is the Fuchs
stability function. For collisions of particles with opposite sign,
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W i ,pj,q =

exp( κ ) − 1
2 pqe 2
,κ =
κ
( d pi + d pj )εk B T

,

(6.3)

where dpi and dpj are the diameters of the colliding particles, e is the element charge,
kB is Boltzmann constant, ε is the dielectric constant of the medium, and T is the
temperature. For particles of the opposite sign, κ is negative, W i ,pj,q is positive and less
than unity. So β i p, ,jq is larger than β i , j , indicating that the collisions occur more rapidly
than in the case of neutral particles.

6.3 Adhesive Forces between Coagulated Particles
The interaction forces between two coagulated particles include the electrostatic
force, the van der Waals force, and the forces arising from the surface tension of liquid
films (Hinds 1999a). The above forces depend on both particle properties, such as the
material, shape, surface roughness, size, and the contact velocity; and environmental
conditions, such as the relative humidity and temperature.
Droplets generated by electrospray are highly charged with the same polarity. The
aggregation among the droplets is negligible due to the mutual repulsion. This is one of
the advantages of ES in aerosol generation. In the twin-head electrospray system,
oppositely charged droplets generated by two electrosprays carried an extremely large
number of positive or negative charges. The electrostatic attraction was the main force
to drag droplets together. The attractive Coulomb force can be estimated from the
following equation:
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FE =

kE qq'
,
x q2

(6.4)

where k E is Coulomb constant, q and q’ are the number of charges on each of the
two droplets, and xq is the distance between the two particles.
The van der Waals forces are effective when two particles are very close to each
other. The random movements of electrons surrounding the nucleus of electrically
neutral atoms on the surface of particles induces dipoles, which creates an opposite
polarity on the surface of another particle when the two were a few molecular diameters
apart. The resultant attractive force between two particles can be estimated by the
following equation:

Fw =

AD
,
12x 2

(6.5)

where A is the Hamaker constant, which depends on the material; D is
2R1R 2 /(R1 + R 2 ) , with R1 and R2 to be the radius of the two particles; and x is the

separation distance that depends on the surface roughness of the particle and the
contact surface.
When there are liquid molecules on the surface of particles, an attractive force is
created by the surface tension of the liquid in the capillary space at the point of contact.
Also, the curved liquid surface causes a Laplace pressure, which attracts particles toward
each other. The force is related to the surface tension of the liquid, the diameter of the
particle, the surface roughness, and the contact angles.
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6.4 Review of Designs and Applications of THES
This concept of using two sprays to generate countercharged droplets was first
proposed in 1965 to study the collision of two charged droplets (Schneider et al. 1965).
Electrostatic atomization was used to generate droplets with diameters around 180 µm.
Two charged droplets were introduced into a Faraday cage, where the charge and
velocity were measured before the collision. A 4 × 5 camera was used to photograph
the trajectories of the two opposite charged droplets. The experimental apparatus is
shown in Figure 6.1. Their experiments confirmed that the collision rate of oppositely
charged droplets was much higher than that of droplets carrying like charges. However,
the experimental apparatus could only measure extremely large droplets.
Capillary Tube Connected with Pulse
Generator
Charging Electrode
Deflection Plates
Deflection Plates
Charging Electrode
Faraday
Cage

Capillary Tube Connected with Pulse
Generator

Figure 6.1 Experimental apparatus for studying the collision between two charged droplets. (Schneider et
al. 1965)

Langer et al. studied the encapsulation process between charged liquid droplets and
solid particles (Langer and Yamate 1969). They also used electrostatic atomization to
generate droplets with diameter larger than 1 µm. Despite the loss of charged droplets
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on the grounded plate before they entered the encapsulation chamber, a high percentage
of encapsulation was observed for droplets larger than 10 µm.
+ D.C.High Voltage

- D.C.High Voltage

Burettes

Glass Container
Encapsulation Space
Sample Slide

Figure 6.2 Electrostatic aerosol encapsulator for aerosols larger than 1 µm.(Langer and Yamate 1969)

The possibility of using bipolar coagulation of particles generated by two sprays in
powder industry was studied (Borra et al. 1999; Camelot et al. 1999) using the
experimental setup shown in Figure 6.3. Each of the two electrosprays generated
droplets containing one reaction precursor. The coagulation of two precursor droplets
created a good mixing of chemical compounds on a microscale. The droplets produced
by bipolar coagulation can serve as microreactors to form powders with desired
composition. Based on their applications in powder production, super micrometer
droplets are favorable. Moreover, this research was mainly focused on the micromixing
and microreactor. Limited information on the system characterization and evaluation of
the coagulation process was provided.
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+ D.C.High Voltage

N2

- D.C.High Voltage
Precursor 2

Precursor 1
Reactor

Electrostatic
Precipitator
APS
OVEN
Filter
CPC

Figure 6.3 Experimental apparatus using two electrospray in powder synthesis. (Borra et al. 1999; Camelot
et al. 1999)

The interactions between fibers and particles generated by countercharged
electrospinning and electrospray were studied by Park et al (Park et al. 2008) (Figure 6.4).
They observed that the stream of fibers changed their moving direction towards the
oppositely charged droplets due to the changes in electrostatic forces. However, the
encountering phenomena between oppositely charged particles generated by the same
system were hardly observed.
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Reservior B

Reservior A
Electrospinning

+ D.C.High Voltage

Electrospray

- D.C.High Voltage
Nozzle A

Nozzle B

Ground Plate (Cu)

Figure 6.4 Experimental setup to study the interaction between counter charged fibers and particles. (Park
et al. 2008)

Similar approach was used to manufacture nanomat using electrospinning and
electrospray (Morozov and Vsevolodov 2007). Here, electrospinning was used to
generate polymer fibers, while electrospray was used generate ions using a volatile
solvent to neutralize the charges carried on fibers. The schematic diagram are given in
Figure 6.5. In their system, the fibers were not neutralized immediately after they
deposited. Instead, opposite charges accumulated on both side of the nanomat. As a
result, the nanofibers collapsed into a film due to electrostatic attraction.
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Electrospinning

Electrospray

+ D.C.High Voltage

- D.C.High Voltage

Nanomat Formation

Figure 6.5 Schematics of a device used for the manufacturing of free and mesh-supported nanofilters
and nanomats. (Morozov and Vsevolodov 2007)

A direct observation of the interaction between the counter-charged droplets
generated by two electrosprays was done by Almekinders et al.(Almekinders and Jones
1999). They designed a multi-jet electrohydrodynamic atomizer. By operating two EHD
atomizers using high voltage with different polarities, the two aerosols were attracted by
electrostatic force. However, they claimed that “The positive and negative charged
droplets become spatially distributed such that inter-droplet Coulomb forces are leveled
out and no droplet coalescence takes place.” There were no characterizations about the
particle size before and after the mixing.

6.5 Potential Application as ES Inhaler
A potential application of the twin-head electrospray system in pulmonary drug
delivery is the electrospray inhaler. There are many commercial aerosol generators for
drug inhalation, such as jet nebulizers, pressurized meter-dose inhalers and dry powder
inhalers, most of which generate polydisperse aerosols with drug particles or droplets. It
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is believed that monodisperse particles are better for target site delivery. The idea of
using electrospray for target drug inhalation was first recognized by Tang and Gomez
(Tang and Gomez 1994). Battelle Memorial Institute developed a portable electrospray
inhaler (Figure 6.6)(Zimlich et al. 1999). A phase I clinical trial and in vitro studies
showed that the dose efficiency was much higher than commercial inhalers (Gomez
2002).

Gravitational
Feeding
CO2

Mass Flow
Controller
Capillary

Air Flow
V1

Orifice Plate

V2

High Voltage
Power Supply

Electrometer

Figure 6.6 Prototype electrospray aerosol delivery system. (Gomez 2002)

Since the charges carried by particles might cause particle loss in the oropharyngeal
region due to image force, they must be neutralized before delivery. In general the
charge level of ES-produced particles can be reduced by passing them through an
environment where bipolar ions were produced via corona discharge, soft X-ray, or
radioactive materials (Chen et al. 1995; Ebeling et al. 2000; Hogan et al. 2004). Using a
radioactive source is an effective and reliable way to electrically neutralize charged
particles (Liu and Pui 1974). However, it is not practical due to safety regulations and
similar case for soft X-ray, too. So, a corona discharge was used to neutralize the highly
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charged monodisperse droplets. Corona discharge has been widely used in electrospray
systems (Borra et al. 2004; Ijsebaert et al. 2001; Lu and Koropchak 2004; Tang and
Gomez 1994; Tang and Gomez 1995). However, one main drawback of corona
discharging is the generation of ozone during the process, which played a key role in the
failure of the clinical trial with human volunteers. Ozone is a highly toxic air pollutant,
which was shown to be carcinogenic with long-term exposure in animals (Herbert et al.
1996; Menzel 1984). An alternative choice of neutralization method, which should be
safe and convenient to use, is required to replace the corona discharge in the
electrospray inhaler. In a twin-head electrospray system, monodisperse droplets carrying
both positive and negative charges are generated separately. Since we can control the
charge levels on both positive and negative charged particles, the particles could reach
approximately zero net charge after mixing the two aerosol flows. The coagulation
between opposite charged particles can also serve as a neutralization process. No
further neutralization is required. By using two electrosprays, the mass output can also
be increased. So, the twin-head electrospray could be used as an electrospray inhaler
after careful design and evaluation.
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Chapter 7
Design and Characterization of a Twinhead Electrospray (THES) System
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7.1 Design of the Twin-head Electrospray System
A schematic diagram of the designed twin-head electrospray system is shown in
Figure 7.1. The system contained two identical electrospray heads and a neutralization
chamber. In each electrospray head, both single capillary and dual-capillary could be
used. The inner diameter of the outer capillary was fixed at 0.046 inches. The outer
diameter of the inner capillary was fixed at 1/32 inches, while the inner diameter could
be chosen from a variety of choices. The distance between the spray nozzle and the
counter electrode, which was a metal ring inserted into the top surface of the
neutralization chamber, was adjustable. The electrical field was created by applying high
voltage on the metal spray nozzle while grounding the metal orifice. A plexiglass outer
case, which was used to hold the spray head, served as the insulation part. Air flow was
introduced into each spray head chamber from the inlet tube, which was connected at
90º to the outer case and located above the spray nozzle. The 16 columniform openings
on the metal plate allowed the aerosol flow to be uniformly distributed surrounding the
spray nozzle. Then, the air flow carrying the highly charged droplets entered the
neutralization chamber. One LED light was glued into the case of each spray head for
illumination, while a glass window was installed on the other side of each case. A
microscope was used to monitor the spray condition through the small window.
Two coagulation chambers were designed. The first one was named as 90 degree
chamber, as shown in Figure 7.1(a) and (b). The two electrospray heads were fixed at
two perpendicular surfaces on the coagulation chamber respectively, with the spray
nozzle pointing towards the center of the chamber. The coagulation chamber could
hold up to four neutralizers (Po210, Nuclespot P-2042, NRD LLC, NY), with two on the
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top level and two on the bottom level. When four neutralizers were used, the charge
level carried by droplets could be highly reduced to reach the Boltzmann equilibrium
charge distribution. Using fewer neutralizers would allow the charge-enhanced
coagulation to take place inside the chamber. The second chamber was a 180 degree
chamber. The two spray heads were installed on the side surfaces of the chamber, with
the spray nozzles facing each other. Two aerosol flows from each spray head mixed in
the center of the coagulation chamber and then exited from the bottom opening. This
180 degree chamber can hold two neutralizers. The effects of the design of chamber,
mainly the angles between two aerosol flows, on the coagulation process are discussed
later.

(a)
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(b)
Neutralizer Holder

Connected
spray head
Connected
spray head

to

to
Aerosol Outlet

Neutralizer Holder

(c)
Figure 7.1 Design of the twin-head electrospray system. (a) photo of the system; (b) the 90 degree
chamber and the spray nozzles; (c) the 180 degree coagulation chamber.
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7.2 Experimental Setup and Methods
7.2.1 Experimental Setup
Given in
Figure 7.2 is the experimental setup for the size distribution characterization. The 90
degree chamber was used for most of the studies, except for section 7.3.5. Sucrose
(ACS reagent, ≥99.0%, Sigma-Aldrich) was dissolved in isopropanol (IPA) /aqueous
(4:1 in v/v) solution at the desired concentration. Ammonium acetate (ACS reagent,
≥99.99%, Sigma-Aldrich) was added into the solution to adjust the conductivity. The
single capillary with an i.d. of 0.008 inches was used in this part. The liquid feeding flow
rate was controlled by a syringe pump (PHD 22/2000, Harvard Apparatus, MA).
Particle-free compressed air was introduced into each spray head at 2.5 lpm. The
residence time of particles inside the neutralization chamber was then calculated to be
0.24 s. During operation, a positive or negative high voltage was applied at the spray
head via a high voltage DC power supply (Bertan, Series 230, Spellman High Voltage
Electronics Corp., NY). The sprays were in the stable cone-jet mode for all the
measurements. When all four neutralizers were presented in the chamber, droplets could
be neutralized immediately after entering the coagulation chamber to reach the
Boltzmann equilibrium charge distribution. The electrostatic coagulation of aerosols
having the Boltzmann equilibrium charge distribution was negligible compared with
Brownian coagulation (Adachi et al. 1981). So, four neutralizers were used to
characterize the size distribution of particles generated by either single head electrospray
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or twin-head electrospray without electrostatic coagulation. The size distribution of
aerosols passing through the chamber was then measured by the scanning mobility
particle sizer (SMPS). To characterize the coagulation between highly charged particles,
no neutralizers were used inside the neutralization chamber. An electrostatic precipitator
was used to remove all charged particles, only particles that collided with other particles
carrying the same charge number with opposite polarity could penetrate through the
precipitator. A 25 mm filter holder with glass fiber filter media (Lydall
Filtration/Seperation, Inc., NH) was connected to the outlet of the precipitator to
collect the neutral particles. So, the percentage of neutral and charged particles can be
characterized using fluorescence analysis.

Syringe Pump

Syringe Pump

Positive H.V.

Negative H.V.

Compressed Air

Compressed Air

Electrostatic Precipitator
H.V.
Filter Holder
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Electrostatic Classifier

UCPC

(TSI 3080)

(TSI 3025A)

Figure 7.2 Experimental setup for the size distribution measurement

7.2.2 Particle Characterizations
The morphology of particles was characterized by SEM (Nova NanoSEM 2300,
FEI).
A Zeiss Axioskop A1m fluorescence microscope was used to identify the
composition of the particles after coagulation. Green fluorescent images were created
using a GFP filter (31019 GFP FLTR SET), with excitation at 425/40 nm and detection
at 505/40 nm. For the red channel, a TRITC filter (CZ915 RHODAMINE SET), with
546/10 nm excitation, and 590 long-pass detection was used. Uranine (Sigma-Aldrich)
and rhodamine 6G (Sigma-Aldrich) were dissolved in the sucrose solution separately to
label the particles. During the operation, one spray head was used to spray uranine
solution, while the other sprays rhodamine solution. No neutralizers were installed for
this characterization to ensure electrostatic coagulation. The particles exiting the
chamber were collected on a microslide for imaging.
To verify the composition of coagulated particles, an experiment was carried out
using two drug solutions, 0.1% EGCG/ethanol and 0.1% budesonide/ethanol. Each
solution was sprayed using one of the spray head. The size distribution was measured
using SMPS. After identifying the peak diameter of coagulated particles, a long DMA
(model 3081, TSI, MN) was used to classify the particles so that only particles with the
same electrical mobility as particles of the peak diameter could penetrate through the
DMA. An electrostatic precipitator was used to collect the particles exiting from the
DMA. After collection, the particles were re-dissolved in ethanol. Drug concentrations
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were characterized using high efficiency liquid chromatography (HPLC). The HP 1100
series HPLC system was used. The same analyzing methods described in chapter 3.3
were used.

7.2.3 Fluorescence Analysis
Fluorescence analysis was used to characterize the percentage of neutral and
charged particles that exited the THES chamber as well as the particle loss at various
locations of the ES system. Uranine was the fluorescent tracer for the quantitative
analysis of deposited particles. The electrospray solution was prepared by dissolving 0.1%
(v/v) sucrose and 1 g/l uranine in an isopropanol/water mixture. A filter was connected
to the exit of the coagulation chamber to collect particles that passage through the
chamber.
After each run, particles deposited at various locations in the ES system were
recovered by wiping the surface with cotton swabs wetted in a wash solution, which was
an aqueous solution of 0.001 N ammonium hydroxide. The uranine on the cotton
swabs was then dissolved in 25 ml of wash solution. The mass of the uranine collected
on the filter was measured by immersing the entire filter medium in 25 ml of the wash
solution. The uranine deposited on the wall of the tubing connecting the ES system
with the HEPA filter was also recovered by cotton swabs, which were then immersed in
the same wash solution as the filter. The concentration of uranine in the various wash
solutions was measured by a calibrated fluorometer (GloMax®-Multi Jr Single Tube
Multimode Reader, Promega Corporation, CA). For each experimental run, we further
checked the mass conservation of uranine by comparing the amount of uranine
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recovered from various locations in the generator with the total amount of uranine
sprayed. In general the difference between the sprayed and recovered amounts was
within 5% of the total sprayed.

7.3 Results and Discussion
7.3.1 Demonstration of Coagulation in THES
To study the coagulation process in the THES system, single capillary ES was used
for both spray heads. Sucrose solutions of 0.1% (v/v) and a conductivity of 115 µS/cm
were prepared. To simply the problem, the two sprays were operated at the same
condition except for the polarity of the high voltage. As a result, the particles generated
in each spray heads had the same size distribution and average number of charges of
either positive or negative polarity. After being emitted from the cone-jet, droplets were
carried into the coagulation chamber by filtered air at a flow rate of 2.5 lpm. The two
aerosol flow met after entering the coagulation chamber. The coagulation chamber
could hold up to four neutralizers at different locations. The charge-enhanced
coagulation could be controlled by the number and location of the neutralizers.
First, the operations of each spray head were characterized. The size distributions
of particles generated by each spray head, as well as by both spray heads, with four
neutralizers installed are compared in Figure 7.3.
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Figure 7.3 The size distributions of particles generated using (a) one spray head using positive voltage; (b)
the other spray head using negative voltage; (c) both a and b together. All the cases used 4 neutralizers in
the coagulation chamber.

The three size distributions shown in Figure 7.3 were similar in shape. The mean
sizes were 151.3 nm for positive spray, 150.7 nm for negative spray, and 153.7 nm when
both spray heads were used. The geometric standard deviations (GSD) were all 1.11.
The particle size generated by electrospray is affected by both the operation and the
physical properties of the solution. In our experiments, the same solution was used in
both sprays, and the operations were set to be the same. The only difference was that
positive high voltage was applied to one spray head, while negative high voltage was
applied to the other one. As shown in Figure 7.3 (a) and (b), the size distributions of
both cases were similar. When the two spray heads were operated together, droplets
carrying either positive or negative charges were generated and introduced into the
coagulation chamber at the same time. The droplets were exposed to the bipolar ions as
soon as they entered the coagulation chamber. The charges carried on the droplets were
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neutralized by the radioactive material to reach Boltzmann equilibrium charge
distribution. The electrostatic coagulation of aerosols having the Boltzmann equilibrium
charge distribution is negligible compared with Brownian coagulation (Adachi et al.
1981). As a result, the size distribution was similar to that generated by either positive or
negative spray, indicating that the coagulation process, both Brownian coagulation and
electrostatic coagulation, among droplets generated by the THES was negligible when
the charge level were reduced to Boltzmann equilibrium charge distribution. For the rest
of the experiments, the size distribution using twin-head ES obtained with four
neutralizers was considered as the initial size distribution, and was used for the
comparison of the size distributions after charge-enhanced coagulation.
The size distributions of particles generated using both spray heads, with four
neutralizers, two neutralizers on the bottom level, or without neutralizers in the
coagulation chamber, are shown in Figure 7.4.
7e+5

2.0e+6

7e+6

(b)

(a)

(c)
6e+5

6e+6
1.5e+6

5e+5

dN/dlogDp (#/cm3)

5e+6

4e+5

4e+6
1.0e+6

3e+5

3e+6

2e+6

2e+5

5.0e+5

1e+5

1e+6

0.0

0
50

100

200

Dp (nm)

0
50

100

200

Dp (nm)

50

100

200

Dp (nm)

Figure 7.4 The size distributions of particles generated by two spray heads in THES. (a) 4 neutralizers
were used; (b) 2 neutralizers were used at the bottom level; (c) no neutralizers were used.
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When four neutralizers were used, as discussed before, the coagulation process was
negligible. The size distribution remained good monodispersity. By removing the two
neutralizers at the top level of the coagulation chamber, the size distribution was
broadened, while the peak shifted towards larger sizes, as shown in Figure 7.4(b).
However, there was a shoulder on the left-hand side of the peak, corresponding to the
original particles that did not coagulate with others. If no neutralizers were used (Figure
7.4(c)), the peak diameter was about the same as the case with two neutralizers, but the
shape of the peak was not the same. Figure 7.4(c) had more particles on the right-hand
side of the peak, and fewer particles on the left-hand side. The shoulder in Figure 7.4(b)
was not seen in Figure 7.4(c).
When there were no neutralizers at the top level of the coagulation chamber, no
bipolar ions presented when the two aerosol flows met. The charges carried on the
droplets increased the collisions among droplets. The final particle size increased due to
coagulation. Meanwhile, the charge number of the particles after coagulation also
decreased to a relatively lower level. As droplets entered the bottom level of the
chamber, two neutralizers were used to further neutralize the charges. Further
coagulation was again negligible. The shoulder on the left-hand side of the peak
represented the particles that passed through the chamber without colliding with other
particles. However, when no neutralizers were in the coagulation chamber, the only way
to reduce the charges on the droplets was through coagulation. For those droplets that
did not collide with others, the high charge level increased their chances of getting loss
due to deposition. Also, when no neutralizers presented, charge-enhanced coagulation
was not terminated due to the lower charge level achieved by exposing particles to
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bipolar ions. As a result, more droplets had the chance to coagulate compared with the
other two cases. The overall effect ended up with fewer small particles and more large
particles in the size distribution.
To verify that the increase in particle size was because the coagulation between
positive and negative charged droplets generated by the two identical spray heads
separately, an experiment using two drugs was carried out. Budesonide and
epigallocatechin-3-gallate (EGCG) were dissolved in ethanol at a concentration of 0.1%.
The conductivities and liquid feed rate were the same, so that the particles generated by
the two spray heads were similar. The two drug solutions were sprayed using the THES
at the same time. The size distributions before and after coagulation are shown in Figure
7.5(a) and (b). The initial distribution had a peak value of 57.3 nm and GSD of 1.14.
After coagulation, a second peak with a larger particle size (peak at 73.7 nm) showed up.
The 74 nm particles were classified using a long DMA, collected using an electrostatic
precipitator, and re-dissolved in ethanol. The drug concentrations were then analyzed
using HPLC. The volume percentages of each drug in the collected particles are given
in Figure 7.5(c). 48.4% of the total mass was EGCG, while 51.6% was budesonide. The
volume ratio of the two drugs was almost 1:1, indicating that the large particle was a
combination of two drug particles of similar size.
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Figure 7.5 Verification of coagulation using budesonide and EGCG. (a) Size distribution of budesonide
and EGCG before coagulation (four neutralizers were used); (b) Size distribution of budesonide and
EGCG after coagulation (two neutralizers were installed at the bottom level); (c) The total volume of
budesonide and EGCG in the collected particles with a diameter of 74 nm. Bar, SD.

The SEM image of coagulated sucrose particles is given in Figure 7.6(a). All the
collected particles were spherical in shape after coagulation. One possible explanation
would be that the solvent was not totally evaporated when the collision happened. Two
droplets merged into one after the collision, which ended up with a spherical particle
after solvent evaporated.
The particles in the fluorescence image were also spherical Figure 7.6 (b), (c) and (d).
Both green and red particles could be observed separately under corresponding filter.
By overlaying the two images, most of the particles overlapped. The particles which
could be observed under both filters contained both fluorescent tracers, indicating that
the particles were formed due to the collision between oppositely charged particles.
However, there were a few particles which only appeared under one filter, which were
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primary particles that did not collide with others. Most of the particles were lost inside
the chamber if the charge level was not reduced by collisions. So compared with
coagulated particles, the primary particles were much less concentrated in number.

(a)

(b)
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(c)

(d)
Figure 7.6 SEM and fluorescence images of coagulated particles. (a) SEM image of sucrose particles after
coagulation; (b) fluorescence image of green channel (uranine); (c) fluorescence image of red channel
(Rhodamine 6G); (d) fluorescence image of two channels together
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7.3.2 Size Evolution Due to Coagulation
Experiments had been carried out to study the changes in particle size after
coagulation. Sucrose was dissolved in isopropanol (IPA) /aqueous (4:1 in v/v) solution
at concentrations of 1% and 0.1%. Ammonium acetate was added into the solution to
adjust the conductivity. A capillary with an o.d. of 1/32 inches and an i.d. of 0.008
inches was used for both spray heads. All the sprays were in the stable cone-jet mode
for the experiment. The spray condition and spray current were monitored throughout
the experiment.
For a given liquid solution, the size of particles generated by single capillary
electrospray can be varied by changing the conductivity and the concentration of the
solution, and the liquid feed flow rate (Chen and Pui 1997; Ganan-Calvo 1997; Hartman
et al. 2000). In our experiment, two sucrose concentrations were prepared with different
conductivities. The solution feed flow rate varied from 0.15 µl/min to 1 µl/min. The
initial size before coagulation ranged from 17 nm to 710 nm. For all the tested
conditions, the spray was controlled at the cone-jet mode, in which monodisperse
particles were generated. The scaling laws of single capillary ES has been well
investigated and summarized (Cloupeau and Prunetfoch 1994; de la Mora 2007; Jaworek
and Krupa 1999; Marginean et al. 2007). It has been shown that for a single capillary ES
operated in cone-jet mode, the diameter of generated particle and the spray current
follow the following equations (Chen et al. 1995; de Juan and de la Mora 1997):

Q
Dp ∝  
K 

1/ 3

,

(7.1)

I ∝ ( QK )1/ 2 ,

(7.2)
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where Dp is the diameter of generated particles, Q is the feed flow rate of the
solution, and K is the conductivity of the solution.
The relationship between Dp and Q/K for sucrose solutions at 1% and 0.1% are
shown in Figure 7.7. The spray current I are plotted in Figure 7.8 as a function of
(QK)1/2. Both Dp and I showed good linear relationship with the corresponding function
of Q and K, indicating that the spray was in the cone-jet mode.
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Figure 7.7 Particle diameter as a function of liquid feed flow rate and conductivity. (a) 1% sucrose
solution; (b) 0.1% sucrose solution. Bar, SD.
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The size distributions before and after coagulation were measured by SMPS. The
size distributions before coagulation were measured with four neutralizers in the
coagulation chamber, while the distribution after coagulation was taken when no
neutralizers were used. When no neutralizers were used, the droplets remained in high
charge level until they collided with other highly charged droplets or deposited on the
wall. When there was no charge reduction process, over 95% of the particles were lost
inside the chamber (Fu et al. 2011a). In the THES, the coagulation was enhanced due to
electrical force. In the meantime, when the two droplets collided, the net charge on the
newly formed large droplet was much lower than that of each original one. As a result,
the droplets after coagulation had more chance to passage through the chamber than
droplets that did not collide with others. The size distribution after coagulation was
mainly composed of particles that had lower charge levels due to the collisions. The
representative size distributions before and after coagulation are shown in Figure 7.9.

117

1.2e+6

1.0e+7
(a)

(b)

dN/dlogDp (#/cm3)

8.0e+5
6.0e+6
6.0e+5
4.0e+6
4.0e+5
2.0e+6

dN/dlogDp (#/cm3)

1.0e+6

8.0e+6

2.0e+5

0.0

0.0
10

25

50 75100 150

300

10

Particle Diameter (nm)

25

50 75100 150

300

Particle Diameter (nm)

Figure 7.9 Size distributions generated by THES with (a) or without (b) electrostatic coagulation.

For the example shown in Figure 7.9, the primary particle size before coagulation
was 109 nm, with a GSD of 1.15. After coagulation, the diameters of particles shifted
towards larger size with a broader shape. The peak was around 151 nm and the GSD is
1.33. Note that there was also a peak of satellites with much smaller sizes (peak around
10 nm) in Figure 7.9(a). The satellites, which were also charged, were formed during the
jet breakup process (Chen et al. 1995). When the two aerosol flows entered the
coagulation chamber, not only the primary droplets, but also the satellites collided due
to electrostatic attraction. As shown in Figure 7.9, the peak of original satellites was
around 10 nm, while the peak of coagulated satellites was around 13 nm.
The particle diameters before and after coagulation are shown in a log-log plot
Figure 7.10. The particle diameter after coagulation can be calculated under the
following assumptions: 1) the particles were formed due to two spherical particles of
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the same size, and 2) the particles formed after coagulation were also spherical in shape.
Thus, the diameter of coagulated particle was:
d pc = 3 2 ⋅ d p ,

(7.3)

where dp was the original diameter of particles before coagulation. The theoretical
relationship was also plotted in Figure 7.10.
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Figure 7.10 Particle diameters before (Dp1) and after (Dp2) coagulation. Bar, SD.

The increase in particle diameter due to coagulation in general followed the
theoretical calculation in equation (7.3) throughout the tested diameter range from a few
nanometers to sub-micrometers. For both primary particles and satellites, the peak
diameters were 26% larger than the diameter before coagulation, doubling the particle
volume.
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The shape of the size distributions after coagulation was broader than the original
ones. The distributions were composed of particles which were formed due to
coagulation among droplets with different sizes. Although the original particles
generated by ES had a narrow size range, the coagulation process was not guaranteed to
only happen to particles of the same size or carrying the same number of charges. Also,
there might be collisions of more than two particles with different charge levels. Efforts
have been made to fit the size distributions with several peaks corresponding to
particles formed by coagulation between different numbers of original particles.
However, the fitting results could not explain well the reality because the resolution of
the measured size distribution was not high enough to separate those peaks.
The initial charge level of droplets generated by electrospray is very difficult to be
measured directly. In this study, we estimated the average number of charges using the
total number of particles and the spray current. Assuming that the all the particles
generated by electrospray had the same diameter, the total number of particles can be
calculated by mass conservation. The spray current was measured using a resistance and
a multimeter (Model 2000 6½-Digit Multimeter, Keithley Instruments, Inc., OH). The
Rayleigh limit of corresponding droplets was also calculated as follows:

q R = ̟ (8γε 0. d 3 )

1/ 2

(7.4)

,

where γ is the surface tension of the liquid, ε0 is the vacuum permittivity, and d is the
droplet diameter.
The average numbers of charge of the droplets generated by electrospray, as well as
the Rayleigh limits, are shown in Figure 7.11. The number of charges ranged from a few
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hundreds to tens of thousands, depending on the droplet diameters. Note that the
charges on the droplets were all below Rayleigh limits.
Although the charges and particle size both covered wide ranges, the electrostatic
coagulation was observed for all the tested cases. As shown in Figure 7.10, the peak
diameters after coagulation all followed the calculation based on two-particle collision,
disregarding the original charge level and particle size.
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Figure 7.11 The average numbers of charge of the droplets generated by electrospray. Bar, SD.

7.3.3

Effect of Charge Level

One limitation of single capillary ES is that the diameter of the generated particles
and the number of charges carried on each particle cannot be separately controlled.
Both the diameter and the charge level are related to the liquid feed flow rate and the
solution conductivity. Changing either of them will result in changes in both the size
and the charge. Dual-capillary ES was proposed to overcome this limitation. In dual121

capillary ES, by varying the conductivity of the outer solution while keeping everything
else the same, particles with the same diameter can be generated to carry different
number of charges. In this study, dual-capillary ES were used for both spray heads to
study the charge effects on the coagulation process in the THES system.
The inner solution was PEG (Mw=3350)/ethanol solution at concentrations of 1%
(v/v), with a conductivity of 35 µS/cm. The outer solution was ethanol with different
conductivities, i.e. 35 µS/cm, 78 µS/cm, 180 µS/cm, and 340 µS/cm. Two feed flow
rates, 0.5 µl/min and 1 µl/min were used for inner solution, while three feed flow rates,
1.5 µl/min, 2 µl/min, and 3 µl/min were used to introduce outer solution.
The initial average number of charge on the droplets was estimated in the same way
as discussed previously. In general, for the same liquid feed flow rate, by increasing the
conductivities of outer solution, the average number of charge increased. One example,
with 1 µl/min of 1% PEG as the inner solution, and 3 µl/min of outer solution with
various conductivities, is given in Figure 7.12.
The size distributions before and after coagulation were obtained using SMPS. Four
neutralizers were used to neutralize the electric charge so that the distribution without
coagulation could be measured. The size distributions were similar for the four cases
with different conductivities of outer liquid. When the neutralizers were removed,
coagulation happened, which increased the particle size and broadened the size
distribution. The distributions are shown in Figure 7.13.
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Figure 7.12 The average number of charge on the droplets generated by ES as a function of the
conductivities of outer liquid. The inner liquid was 1% PEG at feed flow rate of 1 µl/min. The outer
liquid was 3 µl/min ethanol, with different conductivities. Bar, SD.
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Figure 7.13 Size distributions before (a) and after coagulations (b,c,d,e) generated using dual-capillary
THES. The inner liquid was 1% PEG/ethanol solution at a conductivity of 35 µS/cm. The outer liquid
was ethanol, with conductivities of 35 µS/cm (b), 78 µS/cm (c), 180 µS/cm (d), and 340 µS/cm (e).
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When the conductivities of outer solutions increased, the number of charges
carried on the droplets also increased. However, the final particle size distributions were
very alike. The peak diameter was all 156 nm. The GSD slightly increased with the
charge level. Similar to single capillary ES cases, the increase in peak diameter
corresponded to the collision between two droplets with the same diameter. The results
showed that the initial charge level did not have influence on the size distribution after
coagulation, especially the peak diameter. The increase in particle size after coagulation
indicated that the incidence of collisions between two oppositely charged droplets was
independent with the initial particle size and charge level in the electrospray system.
Note that even though the spray current varied with operations, the number of charge
on ES-generated particles was very high, as shown in Figure 7.11 and Figure 7.12. The
attractions between oppositely and highly charged particles ensured the collisions.
However, the size distributions could not provide the information on the percentage of
particles that collided with others. Also, although the size distribution seems broader as
the spray current increases, the resolution of the size distribution was not high enough
to give the evidence whether the broadness was because of multi-body collision instead
of two-body collision, or because of the collision between particles with different sizes.
Even though the size distribution of particles generated by electrospray was much
narrower than those given by other aerosol generation techniques, the particle sizes still
varied in a small range. Besides, the charge distribution was broader than the size
distribution. The variation in particle size and charge make it complicated to
characterize the coagulation process in detail. Advanced techniques with high
resolutions may help resolve this problem.
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7.3.4 Residual charge
The ES generated particles are highly charged. As shown in Figure 7.11, for
different working conditions, the average number of charges varied from a few
hundreds to tens of thousands. The charge distribution of the main droplets is about
2.5 times broader than the size distribution (de Juan and de la Mora 1997). The
collisions between oppositely charged particles in the THES system were not necessarily
happen to particles with exactly the same charges. As a result, the particles after
coagulation might still carry a small amount of charge. But the charge levels were
greatly decreased.
To study the fraction of neutral, negative charged, and positive charged particles
that exited the THES system, a precipitator with two parallel plates was designed.
During operation, one plate was connected to high voltage while the other plate was
grounded. The aerosol flow was introduced into the space between the two plates. A
simple calibration was carried out to characterize the performance of the precipitator.
By using monodisperse sodium chloride particles which were generated using atomizer
and classified using DMA, the penetration through the precipitator under different
operation conditions could be calculated. Due to the parallel configuration, the
diffusion loss of small size particles was limited. The penetration of neutral particle
with diameter of 15 nm and above was over 99.0%. For singly charged particles, at an
air flow rate of 1.5 lpm, 99.9% of 100 nm particles deposited in the precipitator when
the applied high voltage was 8 kV.
Fluorescence measurement was used to quantify the charge fraction. Uranine was
dissolved in the sucrose solution at a concentration of 1 g/l. When the high voltage was
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on, positive and negative charged particles were separated and deposited on
corresponding plates. Neutral particles could survive the precipitator and would be
collected on a filter (Lydall Filtration/Separation, Inc., NH). After each experiment run,
the uranine was recovered using an aqueous solution of 0.001 N ammonium hydroxide.
The concentration of uranine in the various wash solutions was measured by a
fluorometer (GloMax®-Multi Jr Single Tube Multimode Reader, Promega Corporation,
CA).
For our experiments, the goal of using precipitator was to collect all the charged
particles inside the precipitator so that only neutral particles could passage it. The
voltage applied on one of the precipitation plate was set at 12 kV, which was the
maximum value it could handle. Aerosol flow was directly introduced into the plate
precipitator after exiting the THES at desired flow rate. Three cases were tested. The
peak diameters after coagulation were 85 nm, 128 nm, and 346 nm, respectively. The
average numbers of charge before coagulation were estimated to be 7334, 11269, and
21068, respectively. Based on the calibration, the air flow rate of the precipitator was 1
lpm for collecting 85 nm and 128 nm particles, and 0.3 lpm for collecting 346 nm
particles.
The results are compared in Figure 7.14. The peak diameters after coagulation were
listed in the figure. The initial charge level also increased with the increase in particle
size. After coagulation, in general, the ratios of positively and negatively charged
particles were close to each other, indicating that the aerosols exited from the THES
were close to zero net charge even when there was no extra neutralization used. The
ratios of neutral particles decreased with the increase in particle size and number of
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charge. For 85 nm particles (after coagulation, initial size 70 nm), 28% of total particles
exited from the ES chamber were neutral. For large particle size (346 nm after
coagulation), the ratio of neutral particle was less than 5%. The average charges on
original particles before coagulation were 3 times higher for 346 nm particles than 85
nm particles. The large variations in the charge number decreased the chance of
collisions between two particles with the same number of charge.
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Figure 7.14 The persentage of neutral, positive charged, and negative charged particles that exited from
the THES after coagulation. Bar, SD.

7.3.5 180 Degree Coagulation Chamber
Another version of the coagulation chamber was designed with the two spray heads
facing each other. The volume of the 180 degree chamber was slightly smaller than the
90 degree chamber. It can only hold two neutralizers. When neutralizers were used, the
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aerosols were exposed to bipolar ions after they entered the chamber so that
electrostatic coagulation could be negligible. If aluminum dummies were installed in
stead of radioactive material, the coagulation process was enhanced by electric
attractions between oppositely charged particles. The 180 degree chamber was
compared with the 90 degree chamber for the effects on coagulation.
Another major difference of the 180 degree chamber was the size of the orifice. By
fluorescence analysis, an interesting observation was the particle deposition inside the
THES chamber. For all the tested cases, heavy deposition on the grounded stainless
steel orifice plate of each spray head was observed. Highly charged particles needed to
penetrate through the orifice, enter the coagulation chamber to collide with other
particles or be neutralized by radioactive materials. According to our previous study (Fu
et al. 2011a), an orifice of small diameter caused more particle loss compared to larger
orifice. For the 90 degree chamber, the orifice was only 0.25” in diameter. To increase
the orifice can reduce the particle loss. In the 180 degree chamber, the orifice was
enlarged to 0.75”, which was the same diameter as the inner diameter of the spray
chamber. No obstruction presented between the spray head and the coagulation
chamber.
The size distributions using the 180 degree chamber with or without two
neutralizers in the chamber were shown in Figure 7.15. The spray solution was 1%
sucrose solution, with a conductivity of 178 µS/cm, and feed flow rate of 0.3 µl/min.
The same operation conditions of Figure 7.9 were used for this case. Figure 7.15(a)
shows that distribution with neutralizers present when the two flows containing
oppositely charged particles mixed, no charge-enhanced coagulation was observed. The
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distribution of the primary peak was similar to the one in Figure 7.9(a), indicating that
the modification of the orifice did not affect the operation of ES. However, by
increasing the orifice, the number of satellites that passage the chamber increased,
which agreed with our previous observation (Fu et al. 2011a). When there were no
neutralizers in the chamber, particle size increased due to coagulation process. An
ionizer (P-2031, Po210, NRD LLC., NY) was connected to the outlet of the spray
chamber to further neutralize the particles, corresponding to the case of the degree
chamber with two neutralizers installed at the bottom level. The size distribution is
given in Figure 7.15(b). The distribution had two major peaks: one had the same peak
diameter as that in Figure 7.15(a), corresponding to the droplets that exited the chamber
without colliding with other droplets; the larger one had the same peak diameter as that
in Figure 7.9(b), which was formed by coagulated droplets. The primary droplets that
did not collide with others had more chance to deposit during transportation before
entering the DMA for size measurement. By connecting the ionizer to the outlet of the
chamber, those particles were preserved. By fitting the size distribution with two
lognormal distributions (Figure 7.16), the ratio of coagulated particles and primary
particles that pass through the ES system could be roughly estimated. The fitting results
are summarized in Table 7.1. The coagulated particles accounted for 70.6% of the total
peak area. However, some of the primary droplets that did not collide with others got
lost inside the coagulation chamber. So the exact percentage of coagulated particles
should be lower than 70.6%.

130

2.0e+7

2.5e+6
(a)

1.8e+7

(b)
2.0e+6

1.4e+7
1.2e+7

1.5e+6

1.0e+7
8.0e+6

1.0e+6

6.0e+6
4.0e+6

5.0e+5

2.0e+6
0.0

0.0
10

25

50 75100 150 250

10

Particle Diameter (nm)

25

50 75100 150 250

Particle Diameter (nm)

Figure 7.15 Size distribution of particles generated by THES using the 180 degree chamber. (a) Size
distribution when two neutralizers were used. (b) Size distribution when no neutralizers were used in the
chamber. Note that for (b), an ionizer was connected with the aerosol exit of the chamber to neutralize
the aerosols.
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Figure 7.16 Curve fitting results of main peak shown in Figure 7.15(b).
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Table 7.1 Curve fitting results (Data shown in Mean±SD)

N0

Dp

GSD

1.4228e+06 ±

103.585476 ±

1.128799 ±

84467.3229

1.27962019

0.008623

1.9262e+06 ±

144.453532 ±

1.163854 ±

50704.3288

1.65624827

0.008712

Peak 1

% of Area

R2

29.6339310
0.98566045

Peak 2

70.3660690

To study the effects of the residence time, a metal tube with 1” in diameter and 3’ in
length was connected to the outlet of the coagulation chamber. No radioactive material
was used in this experiment. The size distributions are given in Figure 7.17. The spray
solution was 1% sucrose solution, with conductivity of 178 uS/cm, and feed flow rate
of 0.25 µl/min. The size distribution before coagulation (Figure 7.17(a)) had a primary
peak at 98.2 nm, with a GSD of 1.19. With no neutralizers installed, the particles exiting
the chamber were directly introduced to SMPS. As shown in Figure 7.17(b), the peak
diameter increased to 121.9 nm, and the GSD was increased to 1.37. To further increase
the residence time, the tube was connected and two air flow rates, 5 lpm and 2 lpm were
used. The residence times were 5.6 s for 5 lpm flow and 13.9 s for 2 lpm flow. The peak
diameter was not affected by the residence time, while the distributions were slightly
broader when compared with the case with no tube. The GSD was 1.40 for both flow
rates (Figure 7.17(c), (d)). However, the peak of primary particles was not observed for
all cases when no neutralizers were used. The particles that were highly charged were
lost during transportation between the coagulation chamber and the SMPS. The
residence time inside the coagulation chamber was 0.17 s at 5 lpm flow rate. The
unaltered particle size distribution under different residence times indicating that the
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characterization time of coagulation between highly charged particles was much smaller
than the residence time in the chamber.
The characteristic time of charge-enhanced coagulation can be estimated based on
the following assumptions: (1) the particles were all of the same size carrying the same
number of elementary charge; (2) the number concentration of positively and negatively
charged particles was the same; (3) the coagulation happened between two primary
particles, the collision between particles that already collided with others was negligible;
(4) the coagulation coefficient β remained constant.
For simple monodisperse coagulation with a constant value of β, the number
concentration N at time t can be calculated as (Hinds 1999b):
N (t ) =

N0
,
1 + N 0 βt

(7.5)

Based on the assumptions, the number concentration would decrease to N0/2 after
the electrostatic coagulation. Hence, the characteristic time can be calculated as:

t=

1
,
N0β

(7.6)

For particles in the continuum regime, the coagulation coefficient is

β0 =

4kB TC c
,
3η

(7.7)

where η is the viscosity of the medium (which is air in this study).
For particles in free molecular regime, the collision coefficient can be calculated as:
 6k B Td p
β 0 = 4
 ρp







1/ 2

,

(7.8)
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where ρp is the density of particle.
The collision coefficient of charge-enhanced coagulation can be calculated using
equation 6.2 and 6.3.
1.8e+7

1.4e+6
(a)

(b)

1.6e+7

1.2e+6

1.4e+7

1.0e+7

8.0e+5

8.0e+6

6.0e+5

6.0e+6

dN/dlogDp (#/cm3)

dN/dlogDp (#/cm3)

1.0e+6
1.2e+7

4.0e+5
4.0e+6
2.0e+5

2.0e+6
0.0

0.0
10

25

50 75100150 250

10

Particle Diameter (nm)

25

50 75100150 250

Particle Diameter (nm)

1.2e+6

2.5e+6
(c)

(d)
2.0e+6

8.0e+5
1.5e+6
6.0e+5
1.0e+6
4.0e+5

dN/dlogDp (#/cm3)

dN/dlogDp (#/cm3)

1.0e+6

5.0e+5

2.0e+5

0.0

0.0
10

25

50 75100150 250

10

Particle Diameter (nm)

25

50 75100150 250

Particle Diameter (nm)

Figure 7.17 Size distributions of particles generated using THES with 180 degree chamber. (a) before
coagulation; (b) after coagulation, exiting the chamber; (c) after coagulation, with 3’ tube, 5 lpm; (d) after
coagulation, with 3’ tube, 2 lpm.

The characteristic time of charge-enhanced coagulation happened in the THES for
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several typical cases are shown in Table 7.2. Droplets generated by electrospray were
highly charged. At such high number of charges, the coagulation happened within very
short period of time. As given in Table 7.2, the characteristic time was much less than
the residence time in the coagulation chamber. As a result, further increasing the
residence time will not show effects on the size distribution after coagulation, as shown
in Figure 7.17.
Table 7.2 The characteristic time of charge-enhanced coagulation happened in the THES

Particle

Droplet

Initial Number

Diameter

Diameter

(nm)

(nm)

22.5

225

1224

1.21e8

4.20e-5

88.2

409

3198

5.57e9

8.43e-5

300

1392

25695

6.28e8

7.01e-5

429.4

1993

63507

1.21e8

4.81e-5

# of Charge

Concentration
(#/cm3)

Characteristic Time
(s)

The evaporation rate of droplets can be estimated as follows (Hinds 1999c):
t=

Rρ p d p 2
p
p 
8 Dv M  d − ∞ 
 Td T∞ 

for dp > 1.0 µm

where R is the gas constant (8.314 m3 Pa K-1 mol-1), ρp is the density of the droplet, dp
is the diameter of the droplet, Dv is the diffusion coefficient of the vapor molecule, M is
the molar mass of the solvent, pd is the partial pressure of vapor at the surface of the
droplet, p∞ is the partial pressure of vapor in the gas surrounding the droplet, but away
from the immediate surface, Td is the temperature of the droplet, and T∞ is the
temperature away from the droplet surface.
The droplet lifetime for ethanol and water were calculated by Hinds (Hinds 1999c).
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It was shown that for droplets larger than 1 µm, the lifetime was in the order of 10-4 s
or larger for ethanol and water. Since the vapor pressure of IPA is very close to that of
ethanol, it is reasonable to estimate that the lifetime of the droplets larger than 1 µm
generated in the THES was in the order of 10-4 s. As given in Table 7.2, the
characteristic time of charge-enhanced coagulation for droplets larger than 1 µm was in
the order of 10-5 s, which is faster than the evaporation time. As a result, the collision
happened between two droplets instead of solid particles. The two droplets merged into
one large droplet after collision. As shown in SEM image, the particles after coagulation
were spherical in shape. By using more volatile solvent, when the evaporation rate is
faster than the coagulation rate, the coagulation may happen between particles.

7.3.6 Loss in the System
The particle transmission efficiency through the two coagulation chambers was
characterized using fluorescence analysis. HEPA filter was connected to the outlet of
the chamber to collect all the penetrated particles. In this study, one spray head was used
to spray uranine/sucrose solution, while the other spray head sprayed IPA with a
conductivity of 70 µS/cm. The transmission efficiency with and without neutralizers
were compared. In order to compare with the 180 degree chamber, only two
neutralizers were installed on the top level of the coagulation chamber for the 90 degree
chamber. Only one spray head was operated to spray uranine when neutralizers were
used. When no neutralizers were installed, both spray heads were operated together. In
this case, the highly charged IPA droplets were source of ions to neutralize the uranine
particles. The feed flow rate of IPA was varied to provide different ion concentrations.
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The ratio of the spray current of IPA and uranine was used as an indicator of the
difference in ion concentration. The higher the current ratio, the more ions compared
to particle concentrations. The particle transmission efficiencies are compared in Figure
7.18.
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Figure 7.18 Particle transmission efficiency through the THES system. Bar, SD.

For the 90 degree chamber, one spray current ratio was compared to the case with
the same particle generation condition, and two neutralizers on the top level. By using
radioactive materials to reduce the charge level, which is the most commonly used
technology in laboratory research (Liu and Pui 1974), 52.3% of the particles penetrated
the system. When the ion with opposite polarity was generated by another spray head at
a high concentration, the penetration was 44.2%. The coagulation process can achieve
84.5% effect of the neutralization by radioactive materials. Due to the small orifice
diameter, the particle deposition on the orifice was the major source of loss inside the
THES system. The size of the orifice had been greatly increased in the 180 degree
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coagulation chamber. As a result, for the case with two neutralizers, the particle
transmission efficiency through the system was 79.0%, which was much higher than the
same case with the 90 degree chamber. The transmission efficiencies of using IPA spray
instead of neutralizers were slightly lower than the case with neutralizers. For the four
ion concentrations, the transmission efficiencies were over 60.0%, which were still
higher than the cases with 90 degree chamber. By decreasing the ion concentrations, the
particle loss inside the chamber was slightly increased, indicating the decrease in
collisions between uranine and IPA droplets. For the 180 degree chamber, the spray
chamber was wide open due to the large orifice. So the particles could be attracted to
the orifice or even the spray chamber of IPA spray. When the spray current of IPA
increased, although the overall particle transmission efficiency increased, the deposition
on the IPA spray chamber also increased. This loss could be decreased by using the 90
degree configuration. A 90 degree chamber with large orifice might achieve even higher
particle transmission efficiency.

7.4 Summary
A twin-head electrospray system was designed with two configurations of the
coagulation chamber. The performance was evaluated under different operational
conditions. The spray head operated in the cone-jet mode could generate monodisperse
aerosols. By using two or more neutralizers, the charge-enhanced coagulations between
oppositely charged droplets were negligible. When no neutralizers were included at the
mixing region of the two aerosol flows, coagulation happened. The coagulation process
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was confirmed by the size distribution, fluorescence microscope, and chemical
composition analysis using HPLC.
The size change due to coagulation was characterized for particle size ranging from
10 nm to 710 nm, including both primary particles and satellites. The peak diameter of
particles after coagulation was about 1.3 times larger than the size before the
coagulation, indicating that the large particles were formed due to the collision of two
oppositely charged primary droplets. The initial droplet size and the charge level did not
affect the size distributions after coagulation. By using the 180 degree chamber, similar
size distributions of coagulated particles were observed. The number of charges on
particles was highly reduced due to the coagulation. Only a small portion of coagulated
particles are neutral. At least two-thirds of the particles remained carrying charges after
coagulation.
The particle transmission efficiency was characterized for both spray chambers. By
using two neutralizers, the transmission efficiency was 52.3% for the 90 degree chamber
and 79.0% for the 180 degree chamber. Compared with the cases with two neutralizers,
the transmission efficiency of the experiments without neutralizers was slightly smaller:
44.2% for the 90 degree chamber and over 60.0% for the 180 degree chamber. The
design of twin-head electrospray, which utilized the coagulation between oppositely
charged particles to reduce the charge level, could achieve almost equivalent particle
transmission efficiency with that achieved by using radioactive sources to neutralize the
charge.
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Chapter 8
PLGA-Based Controlled Drug Delivery
System Generated by a Twin-Head
Electrospray
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8.1 Introduction
Drug delivery systems have evolved from traditional methods to controlled release
delivery systems. Compared to traditional delivery system (TDS), controlled release drug
delivery system (CRS) can increase drug effectiveness by maintaining the drug
concentration in target organs at a desired level while decreasing the side effects caused
by drug concentration close to the toxic threshold which is often encountered in TDS
(Freiberg and Zhu 2004; Kumar and Kumar 2001; Kumar et al. 2002; Uhrich et al.
1999).
Biodegradable polymers are widely used in CRS to control the release rate and
protect the drug prior release. A novel method to synthesis drug/polymer system is
electrohydrodynamic atomization (Electrospray, ES). ES contains a capillary through
which sprayed liquid is introduced. During operation, high voltage is applied to the
capillary. When the electrical force is balanced with the surface tension, a stable cone-jet,
which can generate monodisperse droplets, will form at the tip of the capillary.
Electrospray has many advantages in generating drug loaded particles. It has been
shown that ES can generate particles with the diameters ranging from nanometers to
micrometers (Chen et al. 1995). The particle size can be easily controlled by varying the
solution concentration, liquid feed flow rate, and liquid conductivity without degrading
the particles’ chemical or biological properties (Chen and Pui 1997; Ganan-Calvo 1997;
Hartman et al. 2000). No high shear force is required. ES-generated particles are nearly
monodisperse, which can provide uniform release rate. High encapsulation efficiency
can be achieved by well controlling the spray conditions (Lee et al. 2010; Mei and Chen
2007). Single capillary ES was first used to generate drug-loaded particles (Hong et al.
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2008; Kumbar et al. 2007; Valo et al. 2009; Xie and Wang 2007; Xu and Hanna 2006).
Later, dual-capillary and tri-capillary were developed and studied for their applications in
controlled drug delivery (Lee et al. 2011; Lee et al. 2010; Xie et al. 2008). Compared to
the emulsion method, which is the most commonly used and well-studied method in
drug encapsulation, by using two or three coaxial capillaries, the encapsulation process
was not limited by the hydrophilic properties of the polymer and the drug.
Controlled drug delivery can not only control drug release profile, but also control
the drug concentration in a specific site. The most effective way in achieving this goal is
to directly deliver the drug to the target site. One good example would be pulmonary
drug delivery. ES-generated particles are airborne, which means that they can be directly
used in pulmonary drug delivery (Ijsebaert et al. 2001; Tang and Gomez 1994).
The twin-head electrospray (THES) system contained two identical electrospray
heads which can be operated using either a single capillary or a dual-capillary. The
THES system provides a way to first generate drug particles separately and then mix
them for delivery. The particle sizes and concentrations of each agent can be
independently controlled. In this study, PLGA-based drug particles were generated
using the twin-head ES. The drug release profiles were compared with that of particles
generated by one dual-capillary ES.
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8.2 Experiments and Methods
8.2.1 Materials
Poly(lactic-co-glycolic acid) (PLGA, molecular weight =5000-15,000, lactide :
glycolide = 50:50, Sigma-Aldrich, St. Louis, MO) was used as outer coating material.
Two tested drugs were budesonide and pioglitazone. Acetonitrile (anhydrous, 99.8%,
Sigma-Aldrich) were used to dissolve both drugs and PLGA.

8.2.2 Drug Preparation using THES
A schematic diagram of the experimental setup is shown in
Figure 8.1. Dual-capillary was used in each spray head. The inner capillary had an i.d.
of 0.008” and an o.d. of 0.03125”. The outer capillary was manufactured with an i.d. of
0.046”. The inner and outer solutions were introduced separately using two syringe
pumps (PHD 2000, Harvard Apparatus, MA). Filtered air was used as carrier gas.
Positive and negative high voltages were applied to each spray head separately by
connecting the stainless steel capillary piece with DC power supply (Bertan, Series 230,
Spellman High Voltage Electronics Corporation, NY). The spray condition was
monitored via an optical system including an illumination light source, a microscope
lens (Infinivar CFM-2/S™ Microscope Video Lenses), and a CCD camera (Model
XCD-SX910CR, SONY). The charge reduction chamber was designed to hold up to
four spot ionizers (Po210, Nuclespot P-2042, NRD LLC, NY). No neutralizer was
installed when the two spray heads were all in use, in which case coagulation between
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oppositely charged droplets served as charge neutralization process. The drug particles
exiting the chamber were collected on a HEPA filter (Lydall Filtration/Separation, Inc.,
Rochester, NH) for the subsequent test.
Syringe Pump

Syringe Pump

Positive H.V.

Negative H.V.

Compressed Air

Compressed Air

Filter Holder

Electrostatic Classifier

UCPC

(TSI 3080)

(TSI 3025A)

Figure 8.1 A schematic diagram of the experimental setup

8.2.3 Characterization
The diameters of particles were characterized using scanning mobility particle sizer
(SMPS). The morphology of particles was characterized by SEM (Nova NanoSEM
2300, FEI).
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8.2.4 In vitro Drug Release Profile Studies
Particles generated by the THES were collected on high efficiency glass fiber filter.
After collection, the filter was immersed in a sample vial with 0.5 ml Phosphate Buffer
Solution (PBS). The sample vial was continually shaken at room temperature. At a
desired time point, the buffer solution was extracted. Fresh PBS (0.5 ml) was then
added in the same sample vial for continue release. After the last time point, DMSO was
used to dissolve the remaining polymer and unreleased drug.
Drug concentration was measured by high efficiency liquid chromatography
(HPLC). The HP 1100 series HPLC system was used. The analyzing conditions were
the same as described in chapter 3.3.

8.2.5 Release Kinetics
A biexponential model was used to fit the release profile.

C (t )
t
t
= 1 − ( A1 exp( − ) + A2 exp( − )) ,
C0
k1
k2

(8.1)

where C(t)/C0 is the percentage of drug released at time t, A1 and A2 are the
parameters that reflect the portion of initial drug concentrations contributing to burst
release and sustained release, respectively. k1 and k2 are the apparent release rate
constants, from which the half-life of burst and sustained release can be calculated.
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8.3 Results and Discussion
8.3.1 Characterization of Particles Generated Using DualCapillary THES
Dual-capillary electrospray is capable of generating particles in core-shell structure
with high encapsulation efficiency (Lee et al. 2010; Loscertales et al. 2002; Mei and Chen
2007; Xie et al. 2008). The dual-capillary ES head contains two coaxially aligned
capillaries. The core material and the shell material can be separately introduced through
two liquid channels. The operational modes of dual-capillary ES and the effects of
liquid properties on the encapsulation process were studied by Mei et al. (Mei and Chen
2007; 2008). In order to achieve nearly monodisperse distribution of generated particles,
a cone-jet mode is preferred during operation. When the inner and outer liquids are
miscible or partially miscible, the stable cone-jet can be easily established. In this study,
to ensure a stable cone-jet mode operation, acetonitrile was used as the solvent for both
the inner and the outer materials to minimize the interfacial surface tension.
Two drugs were used as core materials. Budesonide is a synthetic glucocorticoid
steroid used frequently for the treatment of asthma. Pioglitazone is a synthetic PPARγ
ligands used clinically to treat type II diabetes. Each of them has been shown to have
inhibitory effects on lung tumorigenesis by either aerosol or oral delivery (Alyaqoub et
al. 2007; Nemenoff 2007; Wattenberg and Estensen 1997; Wattenberg et al. 2000;
Wattenberg et al. 1997). In our previous study using A/J mice, by combining
budesonide and pioglitazone, 90% inhibition was achieved on tumor load. However,
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budesonide and pioglitazone were administrated by different routes. Budesonide was
aerosolized using a custom-built atomizer, while pioglitazone was oral delivered by
gavage. A simple way to conduct the combination treatment would be to introduce both
drugs together in aerosolized form.
One spray head with dual-capillary was first used to generate drug/PLGA particles.
The experiment conditions and average particle diameters are summarized in Table 8.1.

Table 8.1 Cases summary and average particle diameters for one spray head experiments

Inner Solution

Outer Solution

(Drug/ACN)

S1

(PLGA/ACN)

Dp
(nm)

GSD

0.1% Budesonide, 1 µl/min

0.5%, 5 µl/min

330

1.19

S2

0.1% Budesonide, 1 µl/min

1%, 6.25 µl/min

438

1.21

S3

0.1% Pioglitazone, 1 µl/min

0.5%, 10 µl/min

270

1.20

0.5%, 15 µl/min

414

1.38

Case

S4

0.1% Budesonide & 0.1%
Pioglitazone, 1 µl/min

The particle size distributions were measured by SMPS. The morphology of
drug/PLGA particles was characterized by SEM. Figure 8.2 shows representative
particle size distributions (S1 and S3) and SEM image (case S2). The diameters of
drug/PLGA particles generated by dual-capillary ES were within a narrow range, with a
geometric standard deviation (GSD) around 1.2. The SEM image showed that the
particles were spherical in shape. The particle diameter is related to the solution
conductivity, liquid feed flow rate and the concentration. In this study, the particle
diameters were in sub-micrometer ranges.
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Figure 8.2 Representative particle size distributions (S1 and S3) and SEM image (case S2) of cases using
only one spray head

Twin-head ES was used to generate particles containing two drugs which were
fabricated separately using each spray head. Different combinations of drug/polymer
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ratios were compared for the release profiles. The cases using THES were summarized
in Table 8.2.
Table 8.2 Cases summary and average particle diameters for Twin-Head ES experiments

Case

Spray

Case in

Inner Solution

Outer Solution

Dp

Head

Table 1

(Drug/ACN)*

(PLGA/ACN)

(nm)

Positive

S1

0.1% Budesonide, 1 µl/min

0.5%, 5 µl/min

Negative

-

0.5% PLGA, 1 µl/min*

-

Positive

S1

0.1% Budesonide, 1 µl/min

0.5%, 5 µl/min

Negative

S2

0.1% Budesonide, 1 µl/min

1%, 6.25 µl/min

Positive

S1

0.1% Budesonide, 1 µl/min

0.5%, 5 µl/min

Negative

S3

0.1% Pioglitazone, 1 µl/min

0.5%, 10 µl/min

Positive

S2

0.1% Budesonide, 1 µl/min

1%, 6.25 µl/min

Negative

S3

0.1% Pioglitazone, 1 µl/min

0.5%, 10 µl/min

D1

340

D2

490

D3

398

D4

460

* Except for D1 case, where single capillary was used for spray and the solution was PLGA/ACN.

When the two identical spray heads were both used, droplets carrying either positive
or negative charges were generated by the two spray heads, respectively. After emitted
from the cone-jet, the droplets passed through the grounded orifice and entered the
coagulation chamber, where the two aerosols met. Due to the electrostatic attractive
forces, droplets with opposite charges collided with each other, which served as a charge
neutralization process. After coagulation, the charges carried on the resulted droplets
were highly reduced, while the droplet diameter increased because two droplets merged
together to form a larger one. The particle size distribution was broadened due to the
coagulation process, as shown in Figure 8.3(a). The SEM image showing the
morphology of the particles generated by THES is shown in Figure 8.3(b). Unlike the
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case with only one dual-capillary, by including coagulation between oppositely charged
particles, the particles were not perfectly spherical. The irregular shape was the result of
the solvent evaporating during the process of two spherical particles evolving into one
spherical particle.
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Figure 8.3 Representative size distribution of D3 and D4 and SEM images of D3 using twin-head
electrospray
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8.3.2 In vitro Release Profile Characterization
The release profiles of budesonide/PLGA particles generated by one dual-capillary
electrospray are shown in Figure 8.4. The concentration and feed flow rate of inner
solution of budesonide were kept as 0.1% (v/v) and 1 µl/min. By varying the
concentration and feed flow rate of outer PLGA solution, the release rates were
changed. In general, the release profile contained a fast burst release which continued
with sustained release at a slower rate. The release rate decreased with the increase in the
amount of polymer. For S1, in which the ratio of feed flow rate between the inner and
out solution was 1:5, over 26% of the total drug released within the first hour. By
doubling the polymer concentration and increasing the feed flow rate, the release rate
decreased in S2. The first hour release was 6%. S4 used solution contained both
budesonide and pioglitazone as inner solution, and PLGA solution at a feed flow rate
of 15 µl/min as outer solution. The release profile was similar to S2. In both S2 and S4,
one dual-capillary ES was utilized, so the structures of generated particles were similar.
The total amount of polymer in both cases was close. As a result, the release profiles
were overlapped with each other. 50% release took place after 5 hrs for S1, 59 hrs for
both S2 and S4.

151

100

Release Percentage (%)

80

60

40

S1
S2
S4

20

0
0

50

100

150

200

250

300

Time (h)

Figure 8.4 Release profilesof budesonide/PLGA particles generated by one dual-capillary electrospray.
Bar, SD.

Table 8.3 summarized the model parameters obtained by fitting the experimental
data of one dual-capillary ES cases with the biexponential model. The release profiled
could be fitted very well using the biexponential model. As shown in Table 8.3, the
burst release accounted for 57% for S1, 15% for S2, and 24% for S4. The half-life of
burst release was 3.1 hr for S1, 5.7 hr for S2, and 7.2 hr for S4. The burst release was
suppressed by increasing the amount of PLGA. Also, more PLGA decreased the
sustained release rate, which was characterized by the half-life (t2(1/2)).
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Table 8.3 Release kinetics for budesonide/PLGA particles generated by one spray head in THES. (Data
shown in Mean±SD)

Cases

S1

S2

S4

A1

0.56965±0.03397

0.15163±0.00996

0.23713±0.02181

k1

4.40459±0.54717

8.17132±1.34242

10.3339±1.97996

A2

0.31444±0.03369

0.81680±0.00976

0.76077±0.02269

k2

72.81541±11.08148

121.86882±2.56211

136.01662±4.81455

t1(1/2)

3.05238±0.37919

5.66272±0.93030

7.16139±1.37211

t2(1/2)

50.46108±7.67947

84.45509±1.77554

94.25952±3.33648

R2

0.99412

0.99935

0.99852

By using THES, two spray heads were operated with high voltage of different
polarities simultaneously. In the experimental conditions, the polarity did not affect the
spray condition. Thus, the solutions for either positive or negative spray were
interchangeable. Figure 8.5 shows the comparison of the release profile between THES
cases and one dual-capillary ES cases. Table 8.4 gives the parameters in the
biexponential release kinetic model. In D1, one spray head was operated in exactly the
same condition as S1, while the other spray head sprayed PLGA with feed flow rate of
1 µl/min. As shown in Figure 8.5 (a), the release rate was slightly decreased compared
to S1. But the release was still faster than S2. The first hour release was 20% for D1.
From the kinetic parameters shown in Table 8.4, we can see that the portion accounted
for burst release (A1) was highly decreased in D1, which might be because the S1
particles were partially coated by the polymer generated by the other spray head after
they collided. In case D2, both S1 and S2 were sprayed separately using two identical
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spray heads at the same time. S1 and S2 both contained budesonide/PLGA, but they
released at different rates. The combination of these two cases showed a release rate in
between (Figure 8.5 (b)), as well as the kinetic parameters (Table 8.4). Particles
containing both budesonide and pioglitazone can be generated using THES, with
budesonide introduced to one spray head and pioglitazone introduced to the other one.
The cases of D3 and D4 were prepared in such ways. D3 included cases S1 and S3,
while D4 included cases S2 and S3. Since D3 contained S1, and the total amount of
polymer in D3 was the same as S4, the release rate of D3 was compared with that of S1
and S4, as shown in Figure 8.5 (c). By spraying S1 and S3 at the same time, the polymer
contained in each droplet after coagulation was much greater than cases using only one
ES. As a result, the overall release rate of D3 was close to that of S4, which was much
decreased than that of S1. However, the initial burst release was still fast, indicating that
the structure of the particles after coagulation in D3 was not the same as the core-shall
structure generated in S4. Similarly, in D4, the total amount of polymer was almost
doubled compared with S2, which greatly decreased the release of budesonide, as
shown in Figure 8.5 (d). The portion for burst release (A1) was reduced to 11%, and the
half-life of sustained release (t2(1/2)) increased to 227 hrs.
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Figure 8.5 In vitro release profiles of budesonide/PLGA particles generated by dual-capillary THES. (a)
D1; (b) D2; (c) D3; (d) D4. Bar, SD.

156

Table 8.4 Release kinetics for budesonide/PLGA particles generated by THES. (Data shown in Mean ±
SD)

Cases

D1

D2

D3

D4

A1

0.25245±0.01372

0.25927±0.01365

0.24961±0.02001

0.10521±0.02119

k1

3.66169±0.54585

3.08294±0.43701

2.76235±0.66191

5.58165±3.23055

A2

0.63189±0.0137

0.72006±0.0113

0.64816±0.01633

0.8896±0.01803

k2

63.16622±2.21646

98.25345±2.60958

165.91127±8.61792

327.42528±18.29548

t1(1/2)

2.53755±0.37827

2.13648±0.30285

1.91431±0.45870

3.86808±2.23877

t2(1/2) 43.77419±1.53601

68.08964±1.80844

114.97651±5.97222

226.90572±12.67877

0.99872

0.99555

0.9868

R2

0.99840

The in vitro release profiles of pioglitazone are shown in Figure 8.6. Table 8.5
summarized the corresponding release kinetics based on the biexponential model. When
only one dual-capillary was used (S3), pioglitazone released rapidly, especially in the first
few hours. The burst release accounted for 35% (A1) of total concentrations. Similar to
budesonide cases, the release rate was decreased when THES was used. D3, which
sprayed S1 and S3 separately, had the same amount of PLGA in the final particles as S4.
The release rate of D3 was slower than S3, due to the increase of the mass of polymer.
However, D3 released faster than S4, indicating that unlike S4, pioglitazone was not in
the center of the particles generated in D3. In fact, the release rate of D4, which had
more polymer than S4, was comparable with that of S4. The parameters of release
kinetics for D4 and S4 were close to each other. Although particles of D4 were larger
than S4, the thickness of the polymer layer surrounding pioglitazone was similar to that
of particles of S4, indicating that the mixing in the coagulated particles were incomplete.
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Figure 8.6 In vitro release profile of pioglitazone/PLGA particles generated by THES. Bar, SD.
Table 8.5 Release kinetics for pioglitazone/PLGA particles generated by THES (Data shown in Mean ±
SD)

Cases

S3

S4

D3

D4

A1

0.35328±0.0338

0.18841±0.01297

0.20791±0.01128

0.21508±0.00582

k1

6.51925±1.57474

5.48643±1.05842

24.61033±2.53679

14.69661±0.97091

A2

0.53359±0.03136

0.75353±0.01006

0.77033±0.01149

0.78087±0.00563

k2

172.2906±16.9813

t1(1/2)

4.51783±1.09129

379.23512±17.00545 739.34843±41.47648 996.72317±38.54218
3.80210±0.73349

17.05496±1.75800

10.18475±0.67284

t2(1/2) 119.39739±11.76804 262.80994±11.78478 512.36846±28.74320 690.72916±26.70973
R2

0.99061

0.99543

0.99772

0.99867

In the coagulation chamber, the coagulation between droplets containing either
budesonide/PLGA or pioglitazone/PLGA (or only PLGA as in D1) was increased due
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to an electrical attraction between charges with opposite polarities. As shown in the
SEM image (Figure 8.3 (b)), the particles after coagulation were not spherical. A
reasonable guess would be that by the time coagulation happened, the solvent had not
been completely evaporated from the droplet. As a result, after two droplets collided,
the two solutions mixed due to diffusion until all the solvents were evaporated and the
particles turned into the solid phase. This hypothesis was supported by the release
profile. For one dual-capillary spray cases, the release rate decreased with the increase in
polymer mass concentration. In twin-head ES cases, if the drug/polymer remained in
the same structure as one spray head cases, the release profile would not be affected. If
no coagulation took place, or the particles separated after collision, or the particles were
in solid state, the inner structure of each particle would still be the same. However, for
all the THES cases, the release was slower than the corresponding one spray head case.
The decrease in release rate was associated with the change in particle structure, which
was the increase in the thickness of the polymer layer.
The release mechanisms in polymer-based controlled delivery system are rather
complicated. Depending on the types of drug and polymer, one or more mechanisms
might be involved in the controlled release system, such as diffusion, dissolution,
swelling, hydrolysis, erosion, osmosis (Siepmann and Siepmann 2008; Uhrich et al. 1999).
Mathematical modeling of drug delivery is used to explain the release mechanism and to
predict the release profile. Numerous models, including mechanistic realistic models and
empirical/semi-empirical models have been described in the literature (Arifin et al. 2006;
Narasimhan 2001; Siepmann and Gopferich 2001). In this study, we have tried to fit the
drug release profiles with several well-defined empirical/semi-empirical models.
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However, since assumptions have been made for all the models, and each model was
designed for their special controlled release system, there was no single model that
could explain all the release data. More characterizations will facilitate the mechanism
modeling.

8.3.3 Potential Application of THES as ES Inhaler
As discussed in section 7.3.6, the penetration of the coagulated particles were 44%
for the 90 degree chamber and over 60% for the 180 degree chamber, which were over
75% of the penetration achieved by using radioactive materials. There were strict
regulations about using radioactive materials. In the THES system, no neutralizers were
necessary and the particle transmission efficiency still remained at a high level. The
particles generated by THES were airborne after exiting the system. They can be
directly used for pulmonary drug delivery studies without further processes.
The neutralization process is the key issue that obstructs the previous electrospray
inhaler designed by Battelle Memorial Institute from success. By controlling the
coagulation process, highly charged particles generated by twin-head electrospray system
can be neutralized without using extra neutralizer.
For single drug delivery, one spray head can be used to generate drug particles with
desired particle size in order to reach a high deposition ratio in the lungs. The drug can
be coated by polymer to obtain a predesigned release rate if necessary. The other spray
head serves as a neutralizer, which can spray either highly volatile organic solvent, or
drug solution, or even polymer solution. The highly volatile solvent neutralizes drug
particles without changing the chemical composition or the particle size. If a drug
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solution is used in the second spray head, the final aggregates contain primary drug
particles formed by both spray heads, which will increase the drug mass output. To
spray polymer solution in the second spray head will further decrease the release rate.
The collisions between oppositely charged particles neutralize the charges, so that
neutral drug aggregates are ready for pulmonary delivery.
Besides the neutralization process, another issue that needs to be considered in
order to make the electrospray inhaler easy and safe to use was the mass production rate.
A certain dose of the drugs is required in order to show effectiveness. One drawback of
electrospray is its relatively low throughput. The liquid feeding flow rate cannot be
increased without limitation. Besides optimizing the design of the electrospray system
to get high particle transmission efficiency, another possible solution is to use multiple
spray nozzles. The multiplexed electrospray has already been well studied (Deng and
Gomez 2007; Deng et al. 2006; Deng et al. 2009). There are already two electrospray
heads in our twin-head electrospray system; to add more spray nozzles is feasible for the
electrospray inhaler.

8.4 Summary
The twin-head electrospray system was used to generate drug-loaded PLGA
particles. The particle size distribution, morphology, and in vitro release profile were
characterized. Dual-capillary ES could produce drug/polymer particles with various
diameters. By using both spray heads in the THES system, the release rate could be
further decreased when compared with the release of particles generated by each spray
head. The initial burst release was also reduced after coagulation. The decrease in release
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rate was associated with the increase in the amount of polymer. The particles generated
by dual-capillary ES were spherical in shape. After coagulation, the coagulated particles
were irregular. The change in shape as well as in the release profile indicated that when
the droplets collided due to electrical attraction, the solvent was not completely
evaporated. After collision, the two droplets merged while the solvent continued
evaporating. The non-spherical shape suggested that the two droplets were not well
mixed when the solvent was completely vaporized. The non-solid state collision ensures
that the two droplets became one after colliding with each other. The change in release
profiles provides more evidence for the coagulation process that happened in the THES
system. The THES also provides the possibility of developing new electrospray inhalers
for animal studies as well as human use.
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Chapter 9
Dissertation Accomplishments and
Recommendations for Future Work
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9.1 Summary of Accomplishments
In this dissertation, two spray techniques were studied. First, an animal exposure
system using spray drying technique was used for the investigation of chemopreventive
agents for their inhibitory effects on lung tumorigenesis. Second, a twin-head
electrospray system, which could be used as a drug delivery system in both the animal
studies for lung cancer chemoprevention and potentially for humans, was designed and
evaluated. The accomplishments of each part of the study are summarized as follows:

9.1.1 Aerosol Delivery and Evaluation of Chemopreventive
Agents for the Inhibition of Lung Tumorigenesis
An aerosol delivery system, containing a custom-build Collison-type atomizer,
diffusion dryers and/or scrubbers, and a nose-only 12-mice exposure chamber, was
used to deliver the chemopreventive agents directly to the lung of mice. Six single
agents and three groups of combination treatment were evaluated using female A/J
mice and postinitiation protocol.
The six single agents, Polyphenon E, Polyphenon E without EGCG, resveratrol,
gefitinib, erlotinib, and budesonide, were all administrated via an aerosol route. This
study showed that Polyphenon E was an effective chemopreventive agent for inducing
tumor regression and inhibiting tumor growth, while Polyphenon E without EGCG was
ineffective. EGCG is thought to be the most active component in Polyphenon E, but
the results of this study proved that EGCG has to be with other tea catechins to show
chemopreventive activity on lung tumorigenesis in aerosolized form. Resveratrol, which
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showed no effects on lung tumorigenesis previously when it was given in diet, inhibit
tumor growth significantly. HPLC analysis confirmed the existence of resveratrol in the
lung, indicating that aerosol delivery could highly improve the bioavailability of
resveratrol in the lung. Two EGFR inhibitors, gefitinib and erlotinib, inhibited the
growth of tumors initiated by either B(a)P or VC. No skin toxicity, which was
commonly associated with the effectiveness in both animal study and human clinical
trials, was observed throughout the treatment. Budesonide inhibited tumor multiplicity
and tumor load. The inhibitory effects increased with the dose. However, higher dosage
causes severe decrease in body weight. Lower dosages are recommended for future
testing.
Through single agent evaluation experiments, the delivery by aerosol of
chemopreventive agents was demonstrated to be a novel method for providing the
powerful efficacies in chemoprevention of lung tumorigenesis. Aerosol delivery can
decrease the dose, minimize the toxicity, and improve the bioavailability in the lung. The
inhalation system used in this study is able to provide aerosol with stable size
distribution which was suitable for a chemoprevention study in mice as well as in men.
The aerosol delivery is an effective approach of chemoprevention, which could be
considered for further studies in animal models as well as clinical trials.
The combination effects of aerosolized budesonide with oral Polyphenon E, indole3-carbinol, or pioglitazone were investigated using female A/J mice. Aerosolized
budesonide inhibited lung adenoma formation. Compared to the solvent control group,
budesonide decreased the tumor multiplicity and the tumor load by 56.7% and 78.4%,
respectively. Furthermore, aerosol delivery can achieve higher concentration in the lung
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with low chemopreventive agent dose compared to other administration routes. Used as
a single agent, Polyphenon E, I3C and pioglitazone all showed significant inhibition on
the tumor load. The decrease in the tumor load was 82.9% by Polyphenon E, 83.2% by
I3C, and 63.3% by pioglitazone. No effects on the tumor multiplicity were achieved. By
combining aerosolized budesonide with Polyphenon E, indole-3-carbinol or
pioglitazone, respectively, the tumor load of test mice could be significantly reduced.
Budesonide with Polyphenon E decreased the tumor load by 88.8%. For budesonide
with I3C, the decrease in the tumor load was 84.9%. Budesonide and pioglitazone
showed the most decrease on the tumor load among the three combination treatment
cases. The decrease in tumor load was 89.6%. The three agents used for combination
treatment with budesonide alone did not decrease the tumor number. As a result, the
combination groups all showed similar inhibitory effects on tumor multiplicity as
budesonide alone case. Among all three combination groups, pioglitazone combined
with budesonide showed the greatest inhibitions on tumor load, which makes them a
promising candidate for further investigation. Our result shows that the combination of
agents targeting different pathways could be a promising approach in lung cancer
chemoprevention.

9.1.2 Design and Evaluation of a Twin-head Electrospray
System
A twin-head electrospray system was designed with two configurations of the
coagulation chamber. The performance was evaluated under different operational
conditions. The spray head operated in the cone-jet mode could generate monodisperse
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aerosols. By using two or more neutralizers, the charge-enhanced coagulations between
oppositely charged particles were negligible. When no neutralizers were included at the
mixing region of the two aerosol flows, coagulation happened. The coagulation process
was confirmed by the size distribution, fluorescence microscope, and chemical
composition analysis using HPLC.
The size change due to coagulation was characterized for particle size ranging from
10 nm to 710 nm, including both primary particles and satellites. The peak diameter of
particles after coagulation was about 1.3 times larger than the size before the
coagulation, indicating that the large particles were formed due to the collision of two
oppositely charged initial particles. The initial particle size and the charge level did not
affect the size distributions after coagulation. By using the 180 degree chamber, similar
size distributions of coagulated particles were observed. The number of charges on
particles was highly reduced due to the coagulation. Only a small portion of coagulated
particles are neutral. At least two-thirds of the particles remained carrying charges after
coagulation.
The particle transmission efficiency was characterized for both spray chambers. By
using two neutralizers, the transmission efficiency was 52.3% for the 90 degree chamber
and 79.0% for the 180 degree chamber. Compared with the cases with two neutralizers,
the transmission efficiency of the experiments without neutralizers was slightly smaller:
44.2% for the 90 degree chamber and over 60.0% for the 180 degree chamber. The
design of twin-head electrospray, which utilized the coagulation between oppositely
charged particles as the charge reduction method, could achieve almost equivalent
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particle transmission efficiency with that achieved by using radioactive sources to
neutralize the charge.
The twin-head electrospray system was used to generate drug-loaded PLGA
particles. The particle size distribution, morphology, and in vitro release profile were
characterized. Dual-capillary ES could produce drug/polymer particles with various
diameters. By using both spray heads in the THES system, the release rate could be
further decreased when compared with the release of particles generated by each spray
head. The decrease in release rate was associated with the increase in the amount of
polymer. The particles generated by dual-capillary ES were spherical. After coagulation,
the coagulated particles were irregular in shape. The change in shape as well as in the
release profile indicated that when the droplets collided due to electrical attraction, the
solvent was not completely evaporated. After collision, the two droplets merged while
the solvent continued evaporating. The non-spherical shape suggested that the two
particles were not well mixed when the solvent was completely vaporized. The non-solid
state collision ensures that the two droplets became one after colliding with each other.
The change in release profiles provides more evidence for the coagulation process that
happened in the THES system. The THES also provides the possibility of developing
new electrospray inhalers for animal studies as well as human use.

9.2 Recommendations for Future Research
The animal exposure system used in this study was proved to be effective in the
aerosol delivery for lung cancer chemoprevention. Besides investigating more agents
using aerosol delivery, a more detailed study regarding particle deposition in the lung of
168

mice can provide useful information for the design and improvement of the aerosol
generation system. The geometry of the airway of mice is much smaller than human. A
lot of research has been done regarding the deposition efficiency of particles with
various sizes in the lung of human. Limited information could be found about the
deposition pattern in the lung of mice. Since the animal study is the necessary step for
drug screening, knowing more about the depositions in mice can facilitate the aerosol
delivery study.
Besides particle size, other properties of particles, such as the charge level, the shape
and morphology, may also affect the deposition and absorption of the drugs in the lung.
The deposition efficiency of the current delivery system can be highly improved if
more information about the particle deposition is available. The characterization may
also serve as a reference for human studies.
In this study, the combination treatment for lung cancer chemoprevention used
different administration methods for the two combined drugs. Because of the
advantages of aerosol delivery, the drugs for the combination study can all be
introduced through an aerosol route.
In the study of the THES system, the characterizations were mainly focused on the
size distribution before and after coagulation. Beside the size distribution, the particle
charge distribution is also important for applications. The initial charge distribution of
ES generated particles was very difficult to be directly characterized due to the
extremely high charge level. The charge distribution of coagulated particles that exited
from the THES system could be characterized using electrical aerosol analyzer (EAA).
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The twin-head electrospray was initially designed for animal studies in lung cancer
chemoprevention. However, due to limited time, this experiment has not been carried
out. The THES can generate two drug particles separately without interference, which is
suitable for the combination treatment. Also, the capability of generating drug/polymer
particles for controlled release that can directly used for inhalation provides more
options for future animal exposure studies.
As mentioned in chapter 8, the twin-head ES can potentially be used as an ES
inhaler. The inhaler can be easily translated from the design of THES. The previously
designed ES inhaler which failed the clinical trial already proved the possibility of a
portable ES inhaler. Since the main drawback of their design has been solved by using
the twin-head ES, the success in this new ES inhaler is very likely to happen.
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Abstract
A new single capillary electrospray aerosol generator has been developed for
monodisperse particle production with maximal transmission efficiency. The new
generator consists of both a spray chamber in a point-to-orifice-plate configuration and
a charge reduction chamber that can hold up to four Nuclespot ionizers (Model P-2042,
NRD Inc.). The two chambers are partitioned by an orifice plate. To optimize the
particle transmission efficiency of the prototype, a systematic study was performed on
the generator by varying the system setup and operation. Two key dimensions of the
generator setup, the orifice diameter and the distance from the capillary tip to the orifice
plate, were varied. Fluorescence analysis was applied to characterize the loss of ESgenerated particles at different locations of the prototype. It was found that particle loss
in the generator could be reduced by either increasing the orifice diameter or decreasing
the distance between the capillary tip and the orifice plate. Increasing either the total
radioactivity of the ionizers or the flowrate of the particle carrier gas also further
decreased the particle loss in the system. The maximum particle transmission efficiency
of 88.0% was obtained with the spray chamber fully opened to the charge reduction
chamber, the capillary tip at the same level as the orifice plate, and four bipolar ionizers
installed.

Keywords: Electrospray generator, particle transmission efficiency, particle loss,
particle discharge.
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1. Introduction
Electrohydrodynamic spraying (i.e., electrospray, ES) uses electric forces to atomize
liquids. In ES, the liquid flowing out of a capillary nozzle is forced into fine droplets
when the local liquid surface tension is overcome by the electric forces at the surface of
the liquid. The basic forms of ES include single capillary ES, dual-capillary ES, and trinozzle ES (Chen et al. 1995; Lee et al. 2011; Mei and Chen 2007). The operational mode
of single capillary ES has been well investigated and summarized (Cloupeau and
Prunetfoch 1994; de la Mora 2007; Jaworek and Krupa 1999; Marginean et al. 2007).
Among all the operational modes, the so-called cone-jet mode, capable of generating
monodisperse particles in diameters ranging from nanometers to micrometers, has
attracted much attention in particle research and applications. Unlike mechanical spray
techniques, ES can generate particles within a narrow size range, and the particle size
can be varied by changing the liquid conductivity, liquid flowrate, and solute
concentration without degrading the particles’ chemical or biological properties (Chen
and Pui 1997; Ganan-Calvo 1997; Hartman et al. 2000). Examples of ES applications
include drug delivery, nanoparticle material synthesis, thin film deposition, and particle
encapsulation (Chen et al. 1995; Ciach 2007; Jaworek 2007; Jaworek and Sobczyk 2008;
Mei and Chen 2007; Peltonen et al. 2010). However, the low particle transmission
efficiency with existing ES systems has not been fully addressed. Based on the
experimental evaluation previously done by one of the authors a commercial
electrospray aerosol generator system typically has only 30-40% particle transmission
efficiency. This becomes significant for applications in which the mass concentration of

173

particles is critical, such as targeted medicine delivery, particle material synthesis and
recovery, and nanoparticle toxicity studies.
The transport behavior of ES-generated droplets emitted from the jet break-up has
been investigated (Ganan-Calvo et al. 1994; Gomez and Tang 1994; Hartman et al.
1999). Most studies on particle transport in ES processes, however, have focused on
droplet behavior in the spray plume. In the radial direction of the plume, the spray is at
first very narrow. Because of the mutual repulsion of highly charged droplets, it then
spreads significantly as droplets move towards the counter electrode. More, it has been
observed that particles of smaller sizes move toward the edge of the spray due to their
high electrical mobility when compared with particles of large sizes (Ganan-Calvo et al.
1994). In the axial direction of the plume, the velocity of ES-generated particles is
mainly attributed to the electric field strength between the capillary and counter
electrode plate. It is therefore easy for highly-charged droplets to be deposited on the
counter electrode. The above spray behavior is advantageous for thin film preparation
via electrospray. However, for aerosol applications, ES-generated particles must remain
airborne prior to their use. Therefore, the electrical charge level on ES-generated
particles needs to be reduced for further transportation. In general the charge level of
ES-produced particles can be reduced by passing them through an environment where
bipolar ions are produced via corona discharge, soft X-ray, or radioactive materials
(Chen et al. 1995; Ebeling et al. 2000; Hogan et al. 2004). However, beyond these
generalizations, information about the particle transmission efficiency of electrospray
systems is very limited. In fact, most documented ES systems are not optimized to
achieve high particle transmission efficiency. Further, to the authors’ knowledge, there

174

has been no thorough investigation into the particle loss in an ES system via variation
of the system setup and operational parameters.
In this study we developed a new single capillary electrospray aerosol system to
achieve high particle transmission efficiency. The performance of this new electrospray
system, especially the particle transmission efficiency, was optimized via variations of
the system design, operational flowrate of carrier gas, and strength of radioactive
material used. We also modeled the electric field in various system configurations to
assist in the interpretation of experimental observations. The modeling results are
included in the supplemental information.

2. Experimental Setup and Methods
The newly designed single-capillary ES aerosol system in this study consisted of
both spray and particle charge reduction chambers. A point-to-orifice-plate arrangement
was used in the spray chamber, which was made of transparent plexiglass. A stainless
steel capillary with an I.D. of 0.012" and O.D. of 1/32" was fixed on a holding plate
that was installed at the top of the spray chamber, with the capillary in line with the
center of the orifice plate. The distance between the capillary tip and the orifice plate
could be adjusted from 0 to 1/4" by inserting 1/32" thick spacers. Plates with orifices
of three diameters (1/4", 3/4", and 5/4" D) were tested in the study. All of the orifice
plates were 3/16” thick. The transparent plexiglass spray chamber enabled observation
of the spray condition via an optical system including an illumination light source, a
microscope lens (Infinivar CFM-2/S™ Microscope Video Lenses, Edmund Optics Inc.,
Barrington, NJ), and a CCD camera (Model XCD-SX910CR, SONY). The charge
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reduction chamber was designed to hold up to four spot ionizers (Po210, Nuclespot P2042, NRD LLC, Grand Island, NY). A cylindrical opening with a 5/4” diameter was
the working zone in the charge reduction chamber. The axial distance between the
upper edge of the ionizer and the lower surface of the orifice plate was 5/16”. The
above distance was chosen to ensure that high energy  particles emitted from Po210
sources did not reach the tip of the spray capillary. As a result, the bipolar ions in the
spray chamber neutralized the particles: no influences on the spray were observed.
During operation, a positive high voltage was applied at the capillary tube via a high
voltage DC power supply (Bertan, Series 230, Spellman High Voltage Electronics
Corporation, Valhalla, NY). The orifice plate and charge reduction chamber were
electrically grounded. The spray solution was introduced into the capillary tube by a
syringe pump (PHD 2000, Harvard Apparatus, Holliston, MA). Filtered air was
introduced into the spray chamber as particle carrier gas. The carrier gas flowrate was
controlled by a needle valve and monitored by a laminar flow meter. Note that an
optional flow channel was designed in the system to introduce sheath gas flow around
the capillary tip when spraying solutions with high surface tension, such as aqueous
solutions. This option, however, was not needed for this study.
Figure 1 is a schematic diagram of the experimental setup. The ES system was
operated in a stable cone-jet mode to generate monodisperse particles. The liquid feed
flow rate was fixed at 1 µl/min, and the applied positive voltage was around 4 kV
relative to the electrically grounded orifice plate. Two flowrates of particle carrier air
(1.5 and 6.0 lpm) were tested. At the exit of the charge reduction chamber, a 47 mm
filter holder (Millipore, Billerica, MA) with high efficiency particulate air (HEPA) filter
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media (Lydall Filtration/Seperation, Inc., Rochester, NH) collected all the particles
exiting from the ES system.

Figure 1 Schematic diagram of experimental setup to characterize the transmission loss of particles
generated by the single-capillary ES system.

Fluorescence analysis was used to characterize the particle loss at various locations
of the ES system (Chen and Pui, 1995). Uranine was the fluorescent tracer for the
quantitative analysis of deposited particles. The electrospray solution was prepared by
dissolving 0.1% (v/v) sucrose and 1 g/l uranine in a 2-propanol/water mixture. Each
experimental run lasted for 60 min.
After each run, particles deposited at various locations in the ES system were
washed off by an aqueous solution of 0.001 N ammonium hydroxide. The uranine
deposited on the orifice plate ( M Plate ) was recovered by wiping the surface with cotton
swabs wetted in the wash solution. The uranine on the cotton swabs was then dissolved
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in 25 ml of wash solution. The uranine deposited in the charge reduction chamber
( MChamber ) was recovered in the same way. The mass of the uranine collected on the
filter was measured by immersing the entire filter medium in 25 ml of the wash solution.
The uranine deposited on the wall of the tubing connecting the ES system with the
HEPA filter was also recovered by cotton swabs, which were then immersed in the same
wash solution as the filter. M Filter thus included the uranine that survived passage
through the ES system. The concentration of uranine in the various wash solutions was
measured by a calibrated fluorometer (GloMax®-Multi Jr Single Tube Multimode
Reader, Promega Corporation, CA). For each experimental run, we further checked the
mass conservation of uranine by comparing the amount of uranine recovered from
various locations in the generator with the total amount of uranine sprayed. In general
the difference between the sprayed and recovered amounts was within 5% of the total
sprayed.
The transmission efficiency of ES-produced particles was then calculated by the
following equation:
η=

M Plate

M Filter
.
+ M Chamber + M Filter

(1)

3. Results and Discussion
ES that operates in the cone-jet mode can generate monodisperse particles with
diameters varying from nanometers to micrometers. Because particles produced by ES
are highly charged, significant particle loss in the system is expected, owing to the
presence of the strong DC electrical field for the spray and the mutual repulsion among
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highly charged particles. Reducing the electric charge of ES-generated particles will help
keep them airborne. The transmission efficiency of the studied ES aerosol generator
was influenced by factors including the system setup configuration, particle carrier gas
flowrate, and the strength of the radioactive sources. In this study, the particle
transmission efficiency was characterized under these factors.

3.1 Effects of Orifice Diameter and Capillary-to-Plate Distance
The orifice ratio, defined as the ratio of the orifice diameter to the diameter of the
charge reduction chamber, was used to characterize the effects of orifice diameter on
the transmission efficiency of the ES generator. Three plates were tested, with orifice
ratios of 1:5 (plate #1; 1/4" D), 3:5 (plate #2; 3/4" D), and 1:1 (plate #3; 5/4" D). The
transmission efficiency was characterized at a carrier gas flowrate of 6.0 lpm, with four
ionizers installed in the charge reduction chamber. No spacer was used for this part of
the experiment, so the spray capillary tip was at the same level as the upper surface of
the orifice plate. Figure 2 shows the transmission efficiencies as a function of the orifice
ratios.
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Figure 2 Transmission efficiency and particle loss on the orifice plate for different orifices.

Under the given experimental conditions, approximately 45.8% of particles
generated by the single capillary ES penetrated through the system when plate #1 was
installed. The transmission efficiency increased with larger orifices. Compared to the
case with plate #1, the transmission efficiency of the aerosol generator was almost
doubled (i.e., 86.2%) by using plate #3. Also shown in Figure 2 is the percentage of
particles deposited on the orifice plate. With increased orifice diameters, the particle loss
on the plate decreased from 53.3% for plate #1 to 3.7% for plate #3.
In addition to the orifice size, another dimension in the system setup was the
distance between the tip of the capillary and the upper surface of the orifice plate. In
our system the distance could be adjusted by the spacers. The experimental results for
this part of the study are shown in Figure 3. Four ionizers were installed in the charge
reduction chamber of the ES generator for these experiments. Recall that with no
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spacer, plate #1 (1/4" D) had a transmission efficiency of 45.8% at a carrier gas
flowrate of 6.0 lpm. When a 1/4" spacer was installed, the efficiency at the same
flowrate dropped to 11.0%. For plate #3 (5/4" D), at a gas flowrate of 1.5 lpm, spacers
of 1/8" and 1/4" thicknesses resulted in transmission efficiencies of 84.9% and 70.1%,
respectively. When no spacer was installed, the transmission efficiency for plate #3 was
88.0%. The particle transmission efficiency of the studied ES generator was again
decreased by larger distances between the capillary tip and orifice plate.

Figure 3 Effect of the spacers and orifice plate on transmission efficiency and particle loss on the
orifice plate.

For an ES setup in the point-to-orifice-plate configuration, the electrical field is
present in both the spray and charge reduction chambers. The movement of ESgenerated droplets results from the flow and electrical fields, the charges on particles,
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and the gravity of large particles. In general, because of the DC electrical field, particles
generated by ES are highly charged with the same polarity. When the electrical field is
sufficiently strong, charged droplets are most likely moving in the field direction. When
no spacer is used (i.e., the tip of the capillary is in the plane of the orifice plate), the
steepest decrease in electrical potential is in the radial direction, from the capillary tip to
the edge of the orifice. The gradient of electrical potential decreases with an increase of
the orifice diameter. The percentage of the particles lost on the orifice plate thus
decreased as the orifice diameter varied from 1/4" to 5/4".
When a spacer was used, the capillary tip was located above the orifice plate. Highly
charged droplets generated by ES had to first travel through the spray chamber, pass the
orifice plate, and enter the charge reduction chamber, where the particle charge level
could be reduced by exposing them to bipolar ions produced by the radioactive sources
(Po210). For the case of the 1/4" D orifice plate, the larger the distance between the
capillary tip and orifice plate, the longer the distance droplets had to travel.
Consequently, more droplets were likely deposited on the orifice plate. With the 5/4" D
orifice plate, the gradient of the electrical potential was much less than for the case with
the 1/4" D orifice plate. Therefore, the movement of charged droplets in the radial
direction was much slower, giving more time for charge reduction. The result was a
reduction of particle deposition on the orifice plate. In fact, with 5/4" D orifice plate,
most of the particle loss was in the charge reduction chamber.

3.2 Effect of Radioactive Source Strength
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Particles generated by ES are highly charged, especially when spraying liquids of
high electrical conductivity. ES-produced particles thus tend to follow the electrical field
and deposit on the counter electrode (i.e., orifice plate). For applications in which the
collection or deposition of particles is essential, the particle collection efficiency can be
increased by grounding or applying minor voltage of reverse polarity on the collector,
consequently decreasing the particle loss. However, some applications, such as aerosol
drug delivery, require particles to remain airborne. In such applications the above
methodology will not improve the particle transmission efficiency of the studied
generator. To reduce the particle loss due to the electrostatic force, charges on ESgenerated particles must be reduced. Several charge reduction techniques, such as
corona discharge, radioactive sources, and soft X-ray irradiation, could be applied in ES
systems. Using a radioactive source is an effective and reliable way to electrically
neutralize charged particles (Liu and Pui 1974). In this study,

210

Po α ionization sources

(Model P-2042; NRD Inc.) were used in the charge reduction chamber, which could
simultaneously hold up to four ionizers. The bipolar ion concentration in the chamber,
N0, which increases with the radioactive strength, can be estimated as follows (Vivas et
al. 2008):

N0 =

A0 E
,
α r VW

(2)

where A0 is the activity of the radioactive source, E is the energy of the α particles,
αr is the ion recombination coefficient (1.6 × 10-12 m3s-1), W is the mean ionization
potential of air (35 eV), and V is the volume of the charge reduction chamber. The
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original activity of the Nuclespot ionizers was 5.0 mCi. The actually activity can thus be
calculated based on the half-life of

1
A 0 ( t ) = 5.0 ×  
2

210

Po, which is 138 days:

t / t1/ 2

mCi .

(3)

In this part of study, the effect of the ion concentration on the particle transmission
efficiency of ES-produced particles was studied by varying the number of sources
installed in the charge reduction chamber. Figure 4 shows the transmission efficiency of
the generator as a function of ion concentration at a carrier gas flowrate of 6.0 lpm.
The data for the cases with Plate #1 (1/4" D) and #3 (5/4" D) are compared. In both
cases, the transmission efficiency increased with an increase in bipolar ion concentration.
When no ionizer was installed, ES-produced particles were more likely to follow the
electrical field and be deposited on the grounded surfaces (i.e., the surfaces of the
orifice plate and the inner surface of the charge reduction chamber). As a result, the
measured particle transmission efficiency was less than 5% for both orifice plate cases.
With only one ionizer in the prototype, the percentage of ES-produced particles that
exited the system were 37.4% for the 5/4" D orifice and 13.3% for the 1/4" D orifice,
respectively. The particle transmission efficiency kept increasing with an increase in
bipolar ion concentration. When more ionizers were used, the bipolar ion density in the
charge reduction zone was increased, thus increasing the chance to reduce the charges
on ES-produced particles. As shown in Figure 4, the particle transmission efficiency was
doubled when the ion concentration increased from about 4.9 × 108 #/cm3 to over 5.9
× 108 #/cm3. However, as the ion concentrations increased from 5.9 × 108 #/cm3 to 7.1
× 108 #/cm3, the particle transmission efficiency increased by less than 10%. The
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average charges associated with ES-produced particles are directly related to the spray
current, which remained constant in our study (the sprayed solutions had the same
electrical conductivity). Thus, for a certain average charge level, there existed a
minimum ion concentration required to effectively reduce charges on most ESproduced particles. For the given experimental conditions, to reach over 80% of the
highest transmission efficiency, the ion concentration was larger than 5.9 × 108 #/cm3,
corresponding to more than two ionizers used in the prototype. The half-life of Po210 is
about 138 days. Using at least three ionizers with a total radioactivity larger than 4 mCi
is thus recommended for the studied ES generator.

Figure 4 Transmission efficiency as a function of bipolar ion concentration. The flow rate of carrier
gas was 6 lpm. No spacer was used.

Similarly, Figure 5 shows the transmission efficiency of ES-produced particles as a
function of ion concentration for the cases of (a) the 1/4" D orifice plate with spacers
and (b) the 5/4" D orifice plate with spacers. For all spacer cases, the transmission
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efficiency increased with an increase in bipolar ion concentration. Moreover, the
increases in the transmission efficiencies for the cases when the ion concentration was
larger than 6 × 108 #/cm3 were all within 5%. For cases with both 1/4" D and 5/4" D
orifice plates, at a given ion concentration, the use of a spacer increased the particle loss,
which is in agreement with the modeling result. Note that the particle transmission
efficiency did not vary much for the cases using a 5/4" D orifice plate (with/without
spacers installed). In contrast, a significant difference in the efficiency was observed for
the cases using a 1/4" D orifice plate (with/without spacers).

(a)
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(b)
Figure 5 Transmission efficiency as a function of bipolar ion concentration: (a) using ¼” orifice
plate together with spacers and (b) using 5/4” orifice plate together with spacers.

3.3 Effect of Carrier Gas Flowrate
In addition to the bipolar ion concentration, the other factor affecting the charge
reduction process is the particle residence time in the charge reduction chamber. The
residence time is controlled by the flowrate of particle carrier gas. We used particle
carrier gas flowrates of 1.5 lpm and 6.0 lpm, corresponding to residence times of 1.6 s
and 0.4 s, respectively. The Reynolds numbers in the ES system were 67 and 267 for 1.5
lpm and 6.0 lpm flow, respectively, indicating that the flow was mostly laminar in the
system. Fig. 6a shows the transmission efficiency as a function of bipolar ion
concentration for the ES generator with the 1/4" D orifice plate and without a spacer.
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Fig. 6b is for the system with the 1/4" D orifice plate and a spacer of 1/4” thickness,
and Fig. 6c is for the 5/4” D orifice plate without a spacer.

(a)

(b)
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(c)
Figure 6 Effects of carrier gas flowrate on transmission efficiency as a function of bipolar ion
concentration. (a) 1/4" D orifice plate, no spacer; (b) 1/4" D orifice plate, 1/4" spacer; (c) 5/4" D
orifice plate, no spacer.

For the 1/4" D orifice plate, the transmission efficiency at a carrier gas flowrate of
6.0 lpm was much improved over that at 1.5 lpm. The transmission efficiency for the
generator with the 1/4" D orifice plate, operated at the 1.5 lpm air flowrate, was less
than 15%, even with four ionizers installed. However, as indicated in Fig. 6c, the
improvement between the cases with the 1/4" D orifice plate was not observed with the
5/4" D orifice plate.
With the 1/4" D orifice plate installed in the studied ES generator, the spray and
charge reduction chambers were separated. Charges on ES-generated particles could not
be efficiently reduced before they entered the charge reduction chamber. The major
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particle loss for the generator with the 1/4" D orifice plate was thus attributed to
particle deposition on the orifice plate. By operating the ES system at a high flowrate,
the gas flow velocity was increased and the particle residence time was decreased,
leading to less deposition of charged droplets on the orifice plate.
The bore of the spray and charge reduction chambers are each cylinders with an
inner diameter of 5/4". When the 5/4" D orifice plate was installed in the system, the
two chambers were effectively merged into one. The distance between the capillary tip
and the chamber wall was at least 5/8”. Under the given ion concentration, the long
travel distance increased the chance for particles to be charge-reduced prior to their
deposition on the orifice plate. At the same time, their residence time was decreased
when the flowrate of carrier gas was increased. The chance for ion-particle interaction
was decreased, leading to an increase in particle loss due to ineffective charge reduction.
The overall particle transmission efficiency of the studied system was the result of the
two competitive factors described above. Fig. 6c shows that the particle transmission
efficiencies at two carrier gas flowrates were nearly the same for the system with the
5/4" D orifice plate, indicating that the carrier gas flowrate did not significantly affect
the particle transmission. It is possible that the effect of residence time decrease on the
transmission efficiency was offset by that of the long particle travel distance in the
system prior to their deposition.
Note that we tried to plot the transmission efficiency as a function of the Nit value
since the product of the ion concentration Ni and residence time t is normally used as
the key parameter in neutralization/charging theories. However, no simple correlation
could be found in all the studied cases, indicating that other factors, for example, spatial
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distribution of ions and chamber geometry, play roles in the loss of ES-generated
particles.

3.4 Effect of Particle Loss on the Size Distribution of ES-generated
Particles
As shown in the previous section, the particle loss in the studied ES system depends
on the system setup and operation. We wanted to check whether or not the particle loss
affected the size distribution of particles generated. We thus characterized the size
distribution of particles using a scanning mobility particle sizer (SMPS, Model 3080, TSI
Inc., St Paul, MN) for various system setups and operating conditions. All the data
obtained in this part of the experiment were obtained from systems with four bipolar
ionizers installed.
Two typical size distributions are shown in Figure 7. Fig. 7a is the size distribution
for the case with low particle transmission efficiency (4.0%): the system was operated
with the 1/4" orifice plate and 1/4" spacer installed (1.5 lpm flowrate). Fig. 7b gives the
size distribution of particles generated from the system with high particle transmission
efficiency (86.2%), with the 5/4" D orifice plate and no spacer installed (6.0 lpm
flowrate).
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Figure 7 Particle size distribution generated by the designed ES system: (a) 1/4" D orifice plate, 1/4"
spacer, 1.5 lpm; (b) 5/4" D orifice plate, no spacer, 6 lpm.

The geometric mean diameters and geometric standard deviations for the size
distributions in Fig. 7 were 145.9 nm and 1.20 for Fig. 7a, and 153.7 nm and 1.20 for Fig.
7b. The primary particle size distributions are similar in shape for all the tested cases. In
general, the monodispersity of generated particles remained good, confirming that the
distribution of primary particles was not affected in our system optimization for
maximal particle transmission efficiency. The major difference between the distributions
was that the case of high particle transmission efficiency (Fig. 7b) had more particles
with smaller diameters than the low efficiency case (Fig. 7a). It is known that particles
generated in ES move with different velocities in the radial direction of the spray. Due
to their high electrical mobility,more smaller particles moved toward the edge of the
spray than large particles (Ganan-Calvo et al. 1994). As a result, the loss of smaller
particles increased significantly when the orifice diameter was decreased. As shown in
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Fig. 7, more particles with smaller diameters passed through the ES system with the
5/4”D orifice, while the primary particle size distribution remained similar in shape.

4. Conclusion
A prototype single-capillary electrospray aerosol generator in point-to-orifice-plate
configuration was constructed and optimized to achieve high transmission efficiency of
produced particles. A systematic study was performed by varying the system setup and
flowrate operation. Two key dimensions were varied, the orifice diameter of the counter
electrode plate and the distance between the capillary tip and the plate. Fluorescence
analysis was used to quantify the particle loss at different locations of the prototype
under various setups and operating conditions. Numerical modeling of the electrical
field at different system setups was also performed to assist in interpreting the
experimental observations. It was found that the particle loss could be significantly
reduced by increasing the orifice diameter and/or decreasing the distance between the
capillary tip and orifice plate. The particle transmission efficiency of the studied ES
system could be further improved by increasing either the ionizing radioactivity or the
flowrate of carrier gas. It was concluded that three radioactive ionizers with a total
radioactivity larger than 4 mCi would be sufficient for the prototype. The flowrate of
particle carrier gas more significantly influenced the system with the 1/4" D orifice
plate than that with the 5/4" D orifice plate, possibly because of the balance between
the charge reduction process and particle transportation in the prototype. The quality of
particles generated by the prototype ES system was also examined by SMPS, and
measured primary particle peaks were not affected by particle loss. Thus, the prototype
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generated particles with good monodispersity while achieving high particle transmission
efficiency. The highest particle transmission efficiency, 88.0%, was achieved with the
spray chamber fully open to the charge reduction chamber, the capillary tip at the same
level as the orifice plate, and four bipolar ionizers installed. The knowledge obtained in
this study provides general guidance for the system setup of single-capillary electrospray
to achieve high transmission efficiency. It may also provide basic guidelines for the
system setup in multiplexing ES.
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